
<html lang="en"     class="pb-page"  data-request-id="1e6934c3-f131-4326-a626-8db5a44e6952"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";issue:issue:10.1021/jmcmar.2014.57.issue-4;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;article:article:10.1021/jm401358b"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Structure-Based Optimization of Tyrosine Kinase Inhibitor CLM3. Design, Synthesis, Functional Evaluation, and Molecular Modeling Studies." /></meta><meta name="dc.Creator" content="Stefania  Sartini" /></meta><meta name="dc.Creator" content="Vito  Coviello" /></meta><meta name="dc.Creator" content="Agostino  Bruno" /></meta><meta name="dc.Creator" content="Valeria  La Pietra" /></meta><meta name="dc.Creator" content="Luciana  Marinelli" /></meta><meta name="dc.Creator" content="Francesca  Simorini" /></meta><meta name="dc.Creator" content="Sabrina  Taliani" /></meta><meta name="dc.Creator" content="Silvia  Salerno" /></meta><meta name="dc.Creator" content="Anna Maria  Marini" /></meta><meta name="dc.Creator" content="Anna  Fioravanti" /></meta><meta name="dc.Creator" content="Paola  Orlandi" /></meta><meta name="dc.Creator" content="Alessandro  Antonelli" /></meta><meta name="dc.Creator" content="Federico  Da Settimo" /></meta><meta name="dc.Creator" content="Ettore  Novellino" /></meta><meta name="dc.Creator" content="Guido  Bocci" /></meta><meta name="dc.Creator" content="Concettina  La Motta" /></meta><meta name="dc.Description" content="Recent advances in the knowledge of thyroid carcinomas development identified receptor tyrosine kinases, like VEGFR2 and RET, as viable and promising targets. Accordingly, their inhibition is emerg..." /></meta><meta name="Description" content="Recent advances in the knowledge of thyroid carcinomas development identified receptor tyrosine kinases, like VEGFR2 and RET, as viable and promising targets. Accordingly, their inhibition is emerg..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="February 5, 2014" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm401358b" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2014 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm401358b" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm401358b" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm401358b" /></link>
        
    
    

<title>Structure-Based Optimization of Tyrosine Kinase Inhibitor CLM3. Design, Synthesis, Functional Evaluation, and Molecular Modeling Studies. | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm401358b" /></meta><meta property="og:title" content="Structure-Based Optimization of Tyrosine Kinase Inhibitor CLM3. Design, Synthesis, Functional Evaluation, and Molecular Modeling Studies." /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401358b/production/images/large/jm-2013-01358b_0008.jpeg" /></meta><meta property="og:description" content="Recent advances in the knowledge of thyroid carcinomas development identified receptor tyrosine kinases, like VEGFR2 and RET, as viable and promising targets. Accordingly, their inhibition is emerging as the major therapeutic strategy to treat these pathologies. In this study we describe the synthesis and the functional evaluation of three different series of 4-substituted pyrazolo[3,4-d]pyrimidine derivatives, 8a–g, 9a–g, and 10a–g, designed exploiting a structure-based optimization of the previously developed inhibitor CLM3. Compared to the lead, the novel compounds markedly improved both their inhibitory profile against the target proteins, VEGFR2 and RET, and their antiproliferative efficacy against the medullary thyroid cancer cell line TT. Significantly, compounds 8b, 9c, and 10c proved to block the kinase activity of the mutant RETV804L, which still lacks effective inhibitors." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm401358b"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm401358b">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm401358b&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm401358b&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm401358b&amp;href=/doi/10.1021/jm401358b" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2014</span><span class="cit-fg-volume">, 57</span><span class="cit-fg-issue">, 4</span><span class="cit-fg-pageRange">, 1225-1235</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/57/4" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm401552y" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/jm401780b" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Structure-Based Optimization of Tyrosine Kinase Inhibitor <b>CLM3</b>. Design, Synthesis, Functional Evaluation, and Molecular Modeling Studies.</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Stefania++Sartini">Stefania Sartini</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Vito++Coviello">Vito Coviello</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Agostino++Bruno">Agostino Bruno</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Valeria++La+Pietra">Valeria La Pietra</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Luciana++Marinelli">Luciana Marinelli</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Francesca++Simorini">Francesca Simorini</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sabrina++Taliani">Sabrina Taliani</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Silvia++Salerno">Silvia Salerno</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Anna+Maria++Marini">Anna Maria Marini</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Anna++Fioravanti">Anna Fioravanti</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Paola++Orlandi">Paola Orlandi</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Alessandro++Antonelli">Alessandro Antonelli</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Federico++Da+Settimo">Federico Da Settimo</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ettore++Novellino">Ettore Novellino</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Guido++Bocci">Guido Bocci</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Concettina++La+Motta">Concettina La Motta</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">Dipartimento di Farmacia, Università di Pisa, Via Bonanno 6, 56126 Pisa, Italy</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">Dipartimento di Farmacia, Università di Napoli “Federico II”, Via D. Montesano, 49, 80131 Napoli, Italy</span></div><div class="aff-info" id="aff3"><span class="aff-symbol">§</span> <span class="aff-text">Dipartimento di Medicina Clinica e Sperimentale, Università di Pisa, Via Roma 55, 56126 Pisa, Italy</span></div><div class="aff-info" id="aff4"><span class="aff-symbol">∥</span> <span class="aff-text">Istituto Toscano Tumori, Via T. Alderotti 26N, 50139 Firenze, Italy</span></div><div class="corresp-info"><strong>*</strong>Phone: (+)39 050 2219593. Fax: (+)39 050 2219605. E-mail: <a href="/cdn-cgi/l/email-protection#4c2f23222f29383825222d62202d212338382d0c2a2d3e21623922253c25622538"><span class="__cf_email__" data-cfemail="dbb8b4b5b8beafafb2b5baf5b7bab6b4afafba9bbdbaa9b6f5aeb5b2abb2f5b2af">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm401358b&amp;href=/doi/10.1021%2Fjm401358b" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2014</span></span><span class="cit-volume">, 57</span><span class="cit-issue">, 4</span><span class="cit-pageRange">, 1225–1235</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">January 21, 2014</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>2 August 2013</li><li><span class="item_label"><b>Published</b> online</span>5 February 2014</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 27 February 2014</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm401358b" title="DOI URL">https://doi.org/10.1021/jm401358b</a></div><div class="article_header-article-copyright"><strong>Copyright © 2014 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D1225%26pageCount%3D11%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DStefania%2BSartini%252C%2BVito%2BCoviello%252C%2BAgostino%2BBruno%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D57%26issueNum%3D4%26contentID%3Djm401358b%26title%3DStructure-Based%2BOptimization%2Bof%2BTyrosine%2BKinase%2BInhibitor%2BCLM3.%2BDesign%252C%2BSynthesis%252C%2BFunctional%2BEvaluation%252C%2Band%2BMolecular%2BModeling%2BStudies.%26numPages%3D11%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D1235%26publicationDate%3DFebruary%2B2014">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm401358b"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1584</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">15</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm401358b" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Structure-Based Optimization of Tyrosine Kinase Inhibitor CLM3. Design, Synthesis, Functional Evaluation, and Molecular Modeling Studies.&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Stefania&quot;,&quot;last_name&quot;:&quot;Sartini&quot;},{&quot;first_name&quot;:&quot;Vito&quot;,&quot;last_name&quot;:&quot;Coviello&quot;},{&quot;first_name&quot;:&quot;Agostino&quot;,&quot;last_name&quot;:&quot;Bruno&quot;},{&quot;first_name&quot;:&quot;Valeria&quot;,&quot;last_name&quot;:&quot;La Pietra&quot;},{&quot;first_name&quot;:&quot;Luciana&quot;,&quot;last_name&quot;:&quot;Marinelli&quot;},{&quot;first_name&quot;:&quot;Francesca&quot;,&quot;last_name&quot;:&quot;Simorini&quot;},{&quot;first_name&quot;:&quot;Sabrina&quot;,&quot;last_name&quot;:&quot;Taliani&quot;},{&quot;first_name&quot;:&quot;Silvia&quot;,&quot;last_name&quot;:&quot;Salerno&quot;},{&quot;first_name&quot;:&quot;Anna&quot;,&quot;last_name&quot;:&quot;Maria Marini&quot;},{&quot;first_name&quot;:&quot;Anna&quot;,&quot;last_name&quot;:&quot;Fioravanti&quot;},{&quot;first_name&quot;:&quot;Paola&quot;,&quot;last_name&quot;:&quot;Orlandi&quot;},{&quot;first_name&quot;:&quot;Alessandro&quot;,&quot;last_name&quot;:&quot;Antonelli&quot;},{&quot;first_name&quot;:&quot;Federico&quot;,&quot;last_name&quot;:&quot;Da Settimo&quot;},{&quot;first_name&quot;:&quot;Ettore&quot;,&quot;last_name&quot;:&quot;Novellino&quot;},{&quot;first_name&quot;:&quot;Guido&quot;,&quot;last_name&quot;:&quot;Bocci&quot;},{&quot;first_name&quot;:&quot;Concettina&quot;,&quot;last_name&quot;:&quot;La Motta&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2014&quot;,&quot;month&quot;:&quot;02&quot;,&quot;day&quot;:&quot;05&quot;,&quot;issue&quot;:&quot;4&quot;,&quot;volume&quot;:&quot;57&quot;,&quot;pages&quot;:&quot;1225-1235&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm401358b&quot;},&quot;abstract&quot;:&quot;Recent advances in the knowledge of thyroid carcinomas development identified receptor tyrosine kinases, like VEGFR2 and RET, as viable and promising targets. Accordingly, their inhibition is emerging as the major therapeutic strategy to treat these pathologies. In this study we describe the synthesis and the functional evaluation of three different series of 4-substituted pyrazolo[3,4-d]pyrimidine derivatives, 8a–g, 9a–g, and 10a–g, designed exploiting a structure-based optimization of the previously developed inhibitor CLM3. Compared to the lead, the novel compounds markedly improved both their inhibitory profile against the target proteins, VEGFR2 and RET, and their antiproliferative efficacy against the medullary thyroid cancer cell line TT. Significantly, compounds 8b, 9c, and 10c proved to block the kinase activity of the mutant RETV804L, which still lacks effective inhibitors.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm401358b&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm401358b" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm401358b&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm401358b" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm401358b&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm401358b" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm401358b&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm401358b&amp;href=/doi/10.1021/jm401358b" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm401358b" /></input><a href="/doi/pdf/10.1021/jm401358b" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm401358b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm401358b%26sid%3Dliteratum%253Aachs%26pmid%3D24447248%26genre%3Darticle%26aulast%3DSartini%26date%3D2014%26atitle%3DStructure-Based%2BOptimization%2Bof%2BTyrosine%2BKinase%2BInhibitor%2BCLM3.%2BDesign%252C%2BSynthesis%252C%2BFunctional%2BEvaluation%252C%2Band%2BMolecular%2BModeling%2BStudies.%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D57%26issue%3D4%26spage%3D1225%26epage%3D1235%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291788" title="Reaction products">Reaction products</a>,</li><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=291864" title="Fluorescence resonance energy transfer">Fluorescence resonance energy transfer</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/57/4" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jmcmar.2014.57.issue-4/production/jmcmar.2014.57.issue-4.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401358b/production/images/medium/jm-2013-01358b_0008.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401358b/production/images/large/jm-2013-01358b_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401358b&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Recent advances in the knowledge of thyroid carcinomas development identified receptor tyrosine kinases, like VEGFR2 and RET, as viable and promising targets. Accordingly, their inhibition is emerging as the major therapeutic strategy to treat these pathologies. In this study we describe the synthesis and the functional evaluation of three different series of 4-substituted pyrazolo[3,4-<i>d</i>]pyrimidine derivatives, <b>8a</b>–<b>g</b>, <b>9a</b>–<b>g</b>, and <b>10a</b>–<b>g</b>, designed exploiting a structure-based optimization of the previously developed inhibitor <b>CLM3</b>. Compared to the lead, the novel compounds markedly improved both their inhibitory profile against the target proteins, VEGFR2 and RET, and their antiproliferative efficacy against the medullary thyroid cancer cell line TT. Significantly, compounds <b>8b</b>, <b>9c</b>, and <b>10c</b> proved to block the kinase activity of the mutant RET<sup>V804L</sup>, which still lacks effective inhibitors.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_21660" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_21660" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Thyroid carcinomas (TCs) are the most common endocrine tumors, accounting for up to 1% of all human malignancies. Their worldwide incidence rate has been increasing sharply since the mid-1990s, thus becoming the fastest increasing type of cancer in both men and women in Western countries. According to American Cancer Society forecasts, in 2013 there will be about 60 000 novel cases of TCs diagnosed in U.S., with three to four cases occurring in women, and almost 2000 deaths due to TCs in both sexes, thus indicating a marked acceleration in the incidence rate of the past decade of 5.5% and 6.6% per year in men and women, respectively.<a onclick="showRef(event, 'ref1 ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3">(1-3)</a></div><div class="NLM_p">To date, the treatment of choice for different forms of TCs relies in their complete surgical resection, possibly associated with external radiation therapy. However, disease can persist or recur with local and distant metastases, and in these cases, outcomes are poor, with 5-year survival rates lower than 50%, often associated with a marked resistance to cytotoxic chemotherapy.</div><div class="NLM_p">Indeed, endocrine cancers are generally resistance to DNA-damaging chemotherapies or radiotherapy, normally exploited to lead cancer cells to apoptosis.<a onclick="showRef(event, 'ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref4 ref5">(4, 5)</a> Accordingly, novel therapeutic strategies are urgently needed. Recent advances in the knowledge of pathogenic mechanisms leading to TCs clearly demonstrate that oncogenic tyrosine kinases sustain their development and/or progression, thus identifying these proteins as new and promising targets. “Gain of function” mutations and/or rearrangement of tyrosine kinase receptors like EGFR and RET, as well as signaling molecules acting downstream through BRAF, RAS/RAF/ERK, and RAS/PI3K/AKT pathways, can trigger cell transformations in TCs, thus providing mitogenic and survival signals. Mutations of the tyrosine kinase receptor RET have been identified in about 98% of inherited medullary thyroid carcinoma (MTC) cases at the germ-line level and in 30–50% of the sporadic cases at the somatic level. RET rearrangement is also the most common genetic abnormality in papillary thyroid carcinoma (PTC) induced by radiation. EGFR and its ligands are implicated in TCs, having been found in all types of TCs. Moreover, TCs often exhibit markedly increased vascularisation and elevated VEGF expression. Indeed, VEGF receptors have been found on TC cell lines and tumor endothelial cells, and increased VEGF levels have been determined in the serum/plasma of thyroid cancer patients. These outcomes correlate positively with high tumorigenic potential, thus clearly highlighting angiogenesis as an important factor in tumor growth and metastasis. Protein kinases therefore represent a sound target for the molecular therapy of people affected by TCs, and their inhibition is now accepted as an effective therapeutic strategy.<a onclick="showRef(event, 'ref6 ref7 ref8 ref9 ref10 ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref6 ref7 ref8 ref9 ref10 ref11 ref12">(6-12)</a></div><div class="NLM_p">Different approaches have been considered to block the kinase activity of the mentioned proteins, the most pursued one being the use of small molecules able to compete with the ATP site of their catalytic domain. These include compounds already approved throughout the world for the treatment of other types of tumors, like sorafenib<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> and sunitinib<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> (Chart <a class="ref internalNav" href="#cht1" aria-label="1">1</a>), and novel derivatives such as ponatinib,<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> nintedanib,<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> axitinib,<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> and pazopanib<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> (Chart <a class="ref internalNav" href="#cht1" aria-label="1">1</a>), either proposed or already enrolled in phases II and III clinical trials for TCs. However, to date, the only commercially available tyrosine kinase inhibitors approved by FDA for the treatment of symptomatic or progressive advanced and metastatic MTC are the quinazolin-4-amino derivative vandetanib<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> and the quinoline derivative cabozantinib<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> (Chart <a class="ref internalNav" href="#cht1" aria-label="1">1</a>). Similar to the previously mentioned derivatives, they both are multitarget compounds, being able to combine a potent antiangiogenic activity, mainly due to VEGFR2 inhibition, with inhibitory properties against additional protein kinases. Accordingly, affecting simultaneously different mitogenic pathway in both cancer cells and vasculature, they are able to control both tumor growth and metastasis. However, their significant efficacy is often associated with serious toxicities, including osteonecrosis, fatal hemorrhages, hypertension, QTc prolongation, and respiratory failures.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Moreover, as regard to vandetanib, acquired resistance has been indicated, mainly driven by point mutations of the target proteins, which strongly limits its exploitation as a plain and widespread therapeutic agent against TCs.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Accordingly, the search of novel tyrosine kinase inhibitors is highly welcome, as novel clinically effective and safe compounds to treat TCs are strongly required.</div><figure id="cht1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Chart 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401358b/production/images/medium/jm-2013-01358b_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401358b/production/images/large/jm-2013-01358b_0010.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 1. Tyrosine Kinase Inhibitors</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401358b/production/images/large/jm-2013-01358b_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401358b&amp;id=cht1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Our research group has been involved in the development of novel tyrosine kinase inhibitors for many years, to achieve novel drug candidates for the treatment of TCs. Focusing on the pyrazolo[3,4-<i>d</i>]pyrimidine heterocyclic core, a privileged scaffold in the tyrosine kinase inhibitors field,<a onclick="showRef(event, 'ref23 ref24 ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref23 ref24 ref25 ref26">(23-26)</a> we recently disclosed a new derivative, (<i>R</i>)-1-phenethyl-<i>N</i>-(1-phenylethyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-amine, namely, <b>CLM3</b> (Chart <a class="ref internalNav" href="#cht1" aria-label="1">1</a>), which proved to combine an excellent antiangiogenic efficacy with a less marked inhibitory activity against human thyroid cancer cell lines, both demonstrated through time- and concentration-dependent antiproliferative and proapoptotic activities on specific cell lines.<a onclick="showRef(event, 'ref27 ref28'); return false;" href="javascript:void(0);" class="ref ref27 ref28">(27, 28)</a> Actually, the microvascular endothelial cell line HMVEC-d was remarkably sensitive to low concentrations of <b>CLM3</b> (IC<sub>50</sub> = 0.40 ± 0.22 nM after 72 h of exposure), whereas thyroid cancer cell lines as the undifferentiated 8305C (IC<sub>50</sub> = 9.20 ± 5.06 μM after 72 h of exposure), expressing endogenous RET, and the medullary TT (IC<sub>50</sub> = 26.93 ± 7.60 μM), expressing the mutated protein, required higher concentrations to be inhibited in their growth. Tested on papillary dedifferentiated thyroid cancer cell line (DePTC), obtained at reoperation from patients with recurrence of the tumor, <b>CLM3</b> proved to inhibit significantly its proliferation, increasing the percentage of apoptotic cells and inhibiting their migration in a dose-dependent manner. Moreover, when administered to CD nu/nu mice xenotransplanted with the same DePTC cell line, CLM3 proved to inhibit both tumor growth and weight, without showing any appreciable toxicity.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a></div><div class="NLM_p">Taken together, these results were extremely encouraging, as they affirmed <b>CLM3</b> as a sound and viable lead candidate, deserving of further development. Accordingly, guided by preliminary docking studies performed on the target kinases, we embarked in rational optimization of <b>CLM3</b>, with the purpose of obtaining novel and effective dual VEGFR2/RET inhibitors.</div><div class="NLM_p last">In this work we present the synthesis of new derivatives of <b>CLM3</b>, whose benzylamino substituent at position 4 of the heterocyclic core was suitably lengthened through the insertion of arylamido (<b>8a</b>–<b>g</b>, Chart <a class="ref internalNav" href="#cht1" aria-label="1">1</a>), arylureido (<b>9a</b>–<b>g</b>, Chart <a class="ref internalNav" href="#cht1" aria-label="1">1</a>), and arylsulfonyl (<b>10a</b>–<b>g</b>, Chart <a class="ref internalNav" href="#cht1" aria-label="1">1</a>) groups. These were chosen to plainly comply with pharmacophore requirements of the ATP binding sites of both VEGFR2 and RET, highlighted by the aforementioned docking studies. All of the synthesized compounds were evaluated for their inhibitory properties against the target tyrosine kinases and for their antiproliferative activity toward both endothelial and human thyroid cancer cell lines.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_34086" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_34086" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The target inhibitors <b>8a</b>–<b>g</b>, <b>9a</b>–<b>g</b>, and <b>10a</b>–<b>g</b> were synthesized as illustrated in Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>. Reaction of phenethylhydrazine, <b>1</b>,<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> with the commercially available 2-(ethoxymethylene)malononitrile, <b>2</b>, gave the pyrazole derivative, <b>3</b>, whose cyclization with boiling formic acid provided the 1-phenethyl-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4(5<i>H</i>)-one, <b>4</b>. Treatment of <b>4</b> with phosphoryl trichloride in DMF afforded the corresponding 4-chloro derivative, <b>5</b>, which led to the intermediate <b>6</b> by reaction with (3-nitrophenyl)methanamine, in the presence of triethylamine. Catalytic hydrogenation of <b>6</b> carried out with 10% Pd on carbon at room temperature and atmospheric pressure gave the key amino derivative <b>7</b>, which was then treated with the suitable reactants to give the target inhibitors. In particular, reaction with the appropriate aroyl chloride in the presence of triethylamine led to compounds <b>8a</b>–<b>g</b>, treatment with the suitable isocyanate provided the urea derivatives <b>9a</b>–<b>g</b>, and addition of substituted sulfonyl chlorides afforded the sulfonamido inhibitors <b>10a</b>–<b>g</b>.</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401358b/production/images/medium/jm-2013-01358b_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401358b/production/images/large/jm-2013-01358b_0006.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Pyrazolo[3,4-<i>d</i>]pyrimidine Derivatives <b>8a</b>–<b>g</b>, <b>9a</b>–<b>g</b>, and <b>10a</b>–<b>g</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401358b/production/images/large/jm-2013-01358b_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401358b&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i5">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_15374" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_15374" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> Structure-Based Lead Optimization</h3><div class="NLM_p">We started our optimization campaign testing <b>CLM3</b> in vitro on the human recombinant target proteins, VEGFR2 and RET, to confirm its ability to compete with the ATP site of the tyrosine kinases. When an IC<sub>50</sub> value of 52.5 μM against VEGFR2 was obtained and the ability of <b>CLM3</b> to halve the kinase activity of RET was verified (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>), we then clarified its mode of binding to both of the target proteins, exploiting preliminary docking calculations. In the case of VEGFR2, Glide software<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> positioned <b>CLM3</b> into the X-ray structure of the protein (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4AG8">4AG8</a><a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a>) so that the N2 of the pyrazolopyrimidine ring can establish an H-bond with the C919 backbone, the phenylethanamine moiety is surrounded by V848, K868, A866, L889, L1035, and V916 side chains, while the phenylethyl group forms hydrophobic contact with L840 and F918 residues. As highlighted in Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>, the short substitution pattern on position 4 of the heterocyclic core prevents <b>CLM3</b> from reaching the VEGFR2 regulatory domain pocket (RDP), represented by the cleft enclosed by the juxtamembrane domain of the receptor refolding into the catalytic site. Accordingly, interactions with key E885 and D1046 residues, often hooked by known VEGFR2 inhibitors from the literature, like sorafenib,<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> are precluded, and this observation can be instrumental to improve <b>CLM3</b> binding toward VEGFR2.</div><figure id="fig1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401358b/production/images/medium/jm-2013-01358b_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401358b/production/images/large/jm-2013-01358b_0001.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Putative binding pose of <b>CLM3</b> (gold sticks) in the active site of VEGFR-2 shown as blue cartoon and cyan sticks. H-bonds are represented as black dashed lines and part of the backbone is in transparent ribbon, for clarity reason.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401358b/production/images/large/jm-2013-01358b_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401358b&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Tyrosine Kinases Inhibitory activity of Derivatives <b>8a</b>–<b>g</b>, <b>9a</b>–<b>g</b>, and <b>10a</b>–<b>g</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401358b/production/images/medium/jm-2013-01358b_0007.gif" alt="" id="fx1" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">IC<sub>50</sub>,<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a> μM</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">X</th><th class="colsep0 rowsep0" align="center">R</th><th class="colsep0 rowsep0" align="center">VEGFR2</th><th class="colsep0 rowsep0" align="center">RET</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8a</b></td><td class="colsep0 rowsep0" align="left">CO</td><td class="colsep0 rowsep0" align="left">C<sub>6</sub>H<sub>5</sub></td><td class="colsep0 rowsep0" align="left">8.57</td><td class="colsep0 rowsep0" align="left">22.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8b</b></td><td class="colsep0 rowsep0" align="left">CO</td><td class="colsep0 rowsep0" align="left">C<sub>6</sub>H<sub>4</sub>-4-Br</td><td class="colsep0 rowsep0" align="left">3.48</td><td class="colsep0 rowsep0" align="left">4.26</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8c</b></td><td class="colsep0 rowsep0" align="left">CO</td><td class="colsep0 rowsep0" align="left">C<sub>6</sub>H<sub>4</sub>-4-F</td><td class="colsep0 rowsep0" align="left">5.37</td><td class="colsep0 rowsep0" align="left">9.64</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8d</b></td><td class="colsep0 rowsep0" align="left">CO</td><td class="colsep0 rowsep0" align="left">C<sub>6</sub>H<sub>4</sub>-4-NO<sub>2</sub></td><td class="colsep0 rowsep0" align="left">3.29</td><td class="colsep0 rowsep0" align="left">17.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8e</b></td><td class="colsep0 rowsep0" align="left">CO</td><td class="colsep0 rowsep0" align="left">C<sub>6</sub>H<sub>4</sub>-4-OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">2.66</td><td class="colsep0 rowsep0" align="left">24.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8f</b></td><td class="colsep0 rowsep0" align="left">CO</td><td class="colsep0 rowsep0" align="left">C<sub>6</sub>H<sub>3</sub>-3,4-diOCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">2.03</td><td class="colsep0 rowsep0" align="left">28.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8g</b></td><td class="colsep0 rowsep0" align="left">CO</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub>C<sub>6</sub>H<sub>5</sub></td><td class="colsep0 rowsep0" align="left">6.45</td><td class="colsep0 rowsep0" align="left">22.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9a</b></td><td class="colsep0 rowsep0" align="left">CONH</td><td class="colsep0 rowsep0" align="left">C<sub>6</sub>H<sub>5</sub></td><td class="colsep0 rowsep0" align="left">2.16</td><td class="colsep0 rowsep0" align="left">7.04</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9b</b></td><td class="colsep0 rowsep0" align="left">CONH</td><td class="colsep0 rowsep0" align="left">C<sub>6</sub>H<sub>4</sub>-4-Br</td><td class="colsep0 rowsep0" align="left">3.40</td><td class="colsep0 rowsep0" align="left">9.07</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9c</b></td><td class="colsep0 rowsep0" align="left">CONH</td><td class="colsep0 rowsep0" align="left">C<sub>6</sub>H<sub>4</sub>-4-F</td><td class="colsep0 rowsep0" align="left">3.17</td><td class="colsep0 rowsep0" align="left">4.80</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9d</b></td><td class="colsep0 rowsep0" align="left">CONH</td><td class="colsep0 rowsep0" align="left">C<sub>6</sub>H<sub>4</sub>-4-NO<sub>2</sub></td><td class="colsep0 rowsep0" align="left">1.09</td><td class="colsep0 rowsep0" align="left">37<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9e</b></td><td class="colsep0 rowsep0" align="left">CONH</td><td class="colsep0 rowsep0" align="left">C<sub>6</sub>H<sub>4</sub>-4-OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">1.09</td><td class="colsep0 rowsep0" align="left">9.26</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9f</b></td><td class="colsep0 rowsep0" align="left">CONH</td><td class="colsep0 rowsep0" align="left">C<sub>6</sub>H<sub>3</sub>-3,4-diOCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">3.27</td><td class="colsep0 rowsep0" align="left">15.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9g</b></td><td class="colsep0 rowsep0" align="left">CONH</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub>C<sub>6</sub>H<sub>5</sub></td><td class="colsep0 rowsep0" align="left">6.74</td><td class="colsep0 rowsep0" align="left">10.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10a</b></td><td class="colsep0 rowsep0" align="left">SO<sub>2</sub></td><td class="colsep0 rowsep0" align="left">C<sub>6</sub>H<sub>5</sub></td><td class="colsep0 rowsep0" align="left">4.96</td><td class="colsep0 rowsep0" align="left">7.90</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10b</b></td><td class="colsep0 rowsep0" align="left">SO<sub>2</sub></td><td class="colsep0 rowsep0" align="left">C<sub>6</sub>H<sub>4</sub>-4-Br</td><td class="colsep0 rowsep0" align="left">4.89</td><td class="colsep0 rowsep0" align="left">12.85</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10c</b></td><td class="colsep0 rowsep0" align="left">SO<sub>2</sub></td><td class="colsep0 rowsep0" align="left">C<sub>6</sub>H<sub>4</sub>-4-F</td><td class="colsep0 rowsep0" align="left">2.89</td><td class="colsep0 rowsep0" align="left">4.83</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10d</b></td><td class="colsep0 rowsep0" align="left">SO<sub>2</sub></td><td class="colsep0 rowsep0" align="left">C<sub>6</sub>H<sub>4</sub>-4-NO<sub>2</sub></td><td class="colsep0 rowsep0" align="left">1.03</td><td class="colsep0 rowsep0" align="left">57<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10e</b></td><td class="colsep0 rowsep0" align="left">SO<sub>2</sub></td><td class="colsep0 rowsep0" align="left">C<sub>6</sub>H<sub>4</sub>-4-OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">3.87</td><td class="colsep0 rowsep0" align="left">57.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10f</b></td><td class="colsep0 rowsep0" align="left">SO<sub>2</sub></td><td class="colsep0 rowsep0" align="left">C<sub>6</sub>H<sub>3</sub>-3,4-diOCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">7.21</td><td class="colsep0 rowsep0" align="left">8<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10g</b></td><td class="colsep0 rowsep0" align="left">SO<sub>2</sub></td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub>C<sub>6</sub>H<sub>5</sub></td><td class="colsep0 rowsep0" align="left">2.23</td><td class="colsep0 rowsep0" align="left">58.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>CLM3</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">52.5</td><td class="colsep0 rowsep0" align="left">48<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>a</sup><p class="last">IC<sub>50</sub> values represent the concentration required to produce 50% enzyme inhibition. Standard error of the mean (SEM) is ≤10%.</p></div><div class="footnote" id="t1fn2"><sup>b</sup><p class="last">Percentage of kinase inhibition at 100 μM test compound.</p></div></div></div><div class="NLM_p">At the same time, docking of <b>CLM3</b> in the ATP domain of RET kinase (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2IVV">2IVV</a><a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a>) resulted in the binding mode shown in Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>. Specifically, in the lowest-energy binding pose, the N5 atom of the pyrazolopyrimidine ring establishes an H-bond with the A807 backbone, <b>CLM3</b> central core is stacked between A756, V738, and L881, while the phenylethyl moiety occupies the N-lobe, thus establishing hydrophobic interactions with V804, L802, I788, L779, and K758 side chains. The phenylethanamine moiety is pretty solvent exposed, and this position could reasonably account for the lower activity of <b>CLM3</b> toward RET, deduced through functional evaluation on 8305C and TT cell lines, expressing the target receptor kinase, and on the human recombinant protein.</div><figure id="fig2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401358b/production/images/medium/jm-2013-01358b_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401358b/production/images/large/jm-2013-01358b_0002.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Putative binding pose of <b>CLM3</b> (gold sticks) in the active site of RET kinase shown as green cartoons. H-bonds are represented as black dashed lines and part of the backbone is in transparent ribbon, for clarity reason.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401358b/production/images/large/jm-2013-01358b_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401358b&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Thus, binding modes obtained for <b>CLM3</b> in both VEGFR and RET sites clearly suggested the structural limitations of <b>CLM3</b>, but at same time, they pave the way for a <b>CLM3</b> rational modification. Actually, on the bases of the docking results obtained with VEGFR2, we decided to functionalize the meta position of the phenylethanamine ring with a number of substituents able to fill the RDP of the protein. Accordingly, differently para-substituted phenyl rings bridged with amide, urea, or sulfonamide moieties, already exploited for the obtainment of VEGFR2 inhibitors from the literature,<a onclick="showRef(event, 'ref23 ref33 ref34'); return false;" href="javascript:void(0);" class="ref ref23 ref33 ref34">(23, 33, 34)</a> were inserted on the ring. At same time, to confer major flexibility to this substituent, thus allowing an easier accommodation inside the RDP, the methyl group of the phenylethanamine function was removed. On the basis of the suggested <b>CLM3</b> binding mode in the RET active site, the introduction of polar substituents on the phenylethanamine group was expected to be beneficial.</div></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> Synthesis and Functional Evaluation of Novel Pyrazolo[3,4-<i>d</i>]pyrimidines</h3><div class="NLM_p">Guided by the preliminary docking studies, we started our structural optimization synthesizing compounds <b>8a</b>–<b>g</b>, characterized by the presence of a benzamide residue in the meta position of the <i>N</i><sup>4</sup>-benzyl group of <b>CLM3</b>. As reported in Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>, listing functional activities expressed as IC<sub>50</sub> values, all the novel compounds showed a remarkable enhancement in inhibitory efficacy against the target proteins when compared to the starting lead. In the case of VEGFR2, compound <b>8a</b> (IC<sub>50</sub> = 8.57 μM) displayed a 6-fold increase in inhibitory potency with respect to <b>CLM3</b> (IC<sub>50</sub> = 52.5 μM). The insertion of electron-withdrawing substituents in the para position of the distal phenyl ring, as in <b>8b</b> (IC<sub>50</sub> = 3.48 μM), <b>8c</b> (IC<sub>50</sub> = 5.37 μM), and <b>8d</b> (IC<sub>50</sub> = 3.29 μM), enhanced the observed activity, but an even better raise in inhibitory potency was obtained through the insertion of electron-donating groups. Indeed, the presence of a methoxy function, as in <b>8e</b> (IC<sub>50</sub> = 2.66 μM), gave a 20-fold gain in inhibitory activity with respect to <b>CLM3</b>, and compound <b>8f</b>, bearing a dimethoxy substituent pattern, turned out to be the best VEGFR2 inhibitor of the whole subseries, showing an IC<sub>50</sub> value of 2.03 μM. Finally, an increase in the distance between the phenyl ring and the amide linker through a methylene spacer was well tolerated, with <b>8g</b> (IC<sub>50</sub> = 6.45 μM) being almost equipotent to the unsubstituted parent <b>8a</b>. As regard to RET, a significant inhibitory efficacy was observed as well. Moving from <b>8a</b> (IC<sub>50</sub> = 22.4 μM), the insertion of electron-donating groups like methoxy (<b>8e</b>, IC<sub>50</sub> = 24.1 μM) and dimethoxy (<b>8f</b>, IC<sub>50</sub> = 28.1 μM) did not affect the activity, and the same was also true for the lengthened derivative <b>8g</b> (IC<sub>50</sub> = 22.6 μM). On the contrary, the presence of electron-withdrawing groups as in <b>8b</b> (IC<sub>50</sub> = 4.26 μM), <b>8c</b> (IC<sub>50</sub> = 9.64 μM), and <b>8d</b> (IC<sub>50</sub> = 17.1 μM) gave a 1.5- to 5-fold increase of efficacy. Significantly, the presence of a bromine atom in the para position of the distal ring guaranteed the highest inhibitory activity against the target protein, with <b>8b</b> being the best dual inhibitor of the whole subseries.</div><div class="NLM_p">Analogous results were obtained through the synthesis of derivatives <b>9a</b>–<b>g</b>, where the <i>N</i><sup>4</sup>-benzyl group of the lead, <b>CLM3</b>, was functionalized with a phenylureido moiety. Concerning VEGFR2, all the compounds displayed a remarkable activity. Actually, with respect to the lead, the unsubstituted <b>9a</b> (IC<sub>50</sub> = 2.16 μM) showed an almost 25-fold gain in efficacy. The different substituents in the para position of its distal ring, independent of their electronic nature, keep unaltered this excellent inhibitory property, as the resulting compounds <b>9b</b>–<b>f</b> showed IC<sub>50</sub> values ranging from 1.09 to 3.40 μM. The lengthened <b>9g</b> (IC<sub>50</sub> = 6.74 μM) was active as well. As regards RET, the significant activity of the unsubstitued <b>9a</b> (IC<sub>50</sub> = 7.04 μM) was gradually reduced by the presence of a bromine atom, as in <b>9b</b> (IC<sub>50</sub> = 9.07 μM), a methoxy (<b>9e</b>, IC<sub>50</sub> = 9.26 μM), and a dimethoxy group (IC<sub>50</sub> = 15.3 μM). The observed trend reached the peak with <b>9d</b>, bearing a nitro group, which reduced slightly the kinase activity of the target protein. On the contrary, the lengthened derivative <b>9g</b> proved to be almost equipotent to the unsubstituted parent compound <b>9a</b>. Also in this subseries, the presence of an halogen atom turned out to be the best substitution pattern to obtain a potent dual inhibitor, as compound <b>9c</b>, bearing a para fluorine atom (VEGFR2, IC<sub>50</sub> = 3.17 μM, RET, IC<sub>50</sub> = 4.80 μM), displayed the best inhibitory profile.</div><div class="NLM_p">The choice to modify the lead, <b>CLM3</b>, exploiting a benzenesulfonamide group, as in <b>10a</b>–<b>g</b>, led to potent VEGFR2 inhibitors. Moving from the unsubstituted <b>10a</b> (IC<sub>50</sub> = 4.96 μM) the insertion of either a bromine atom, as in <b>10b</b> (IC<sub>50</sub> = 4.89 μM), or methoxy groups, as in <b>10e</b> (IC<sub>50</sub> = 3.87 μM) and <b>10f</b> (IC<sub>50</sub> = 7.21 μM), did not modify significantly the inhibitory activity, while the selective presence of a nitro group (<b>10d</b>, IC<sub>50</sub> = 1.03 μM), as well as the insertion of a methylene spacer (<b>10g</b>, IC<sub>50</sub> = 2.23 μM) exerted a positive effect on the observed efficacy. On the contrary, with respect to the tyrosine kinase RET, the benzenesulfonamide moiety gave rise to contrasting results. Actually, for the unsubstituted <b>10a</b> (IC<sub>50</sub> = 7.90 μM), the presence of either a bromine atom (<b>10b</b>, IC<sub>50</sub> = 12.8 μM) or a nitro function (<b>10d</b>, 57% inhibition at 100 μM), a methoxy (<b>10e</b>, IC<sub>50</sub> = 57.2 μM), and a dimethoxy group (<b>10f</b>, 8% inhibition at 100 μM) gave rise to a progressive loss of activity. The same was also true for the lengthened derivative <b>10g</b>, showing an IC<sub>50</sub> value of 58.6 μM. On the contrary, the insertion of a fluorine atom restored a remarkable inhibitory efficacy. Indeed, once again, also in this subseries, the presence of this kind of substituent led to the best dual inhibitory pattern, and compound <b>10c</b>, with IC<sub>50</sub> values of 2.89 and 4.83 μM against VEGFR2 and RET, respectively, turned out to be the most effective one of all the benzenesulfonamide derivatives.</div><div class="NLM_p">The best performing derivatives, <b>8b</b>, <b>9c</b>, and <b>10c</b>, were also assayed on the mutant human recombinant RET<sup>V804L</sup>, occurring in both spontaneous and familial MTC, which proved to be insensitive to the already known kinase inhibitors, including the commercially approved vandetanib. Significantly, all the test compounds were demonstrated to block the kinase activity of the mutant protein, showing IC<sub>50</sub> values ranging from 5.47 to 9.31 μM (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>).</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. RET<sup>V804L</sup> Inhibitory Data of Derivatives <b>8b</b>, <b>9c</b>, and <b>10c</b></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">RET<sup>V804L</sup> IC<sub>50</sub>,<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a> μM</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8b</b></td><td class="colsep0 rowsep0" align="left">9.31</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9c</b></td><td class="colsep0 rowsep0" align="left">7.96</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10c</b></td><td class="colsep0 rowsep0" align="left">5.47</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>a</sup><p class="last">IC<sub>50</sub> values represent the concentration required to produce 50% enzyme inhibition. Standard error of the mean (SEM) is ≤10%.</p></div></div></div></div><div id="sec3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Functional Evaluation on HUVEC, TT, and HNDF Cell Lines</h3><div class="NLM_p">Representative examples of the three subseries <b>8a</b>–<b>d</b>, <b>9a</b>,<b>b</b>, and <b>10a</b>,<b>g</b> were tested on HUVEC and TT cells to explore their ability to inhibit proliferation of these selected lines. After a 72-h exposure, all the test derivatives proved to block cells growth in a concentration dependent manner (Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>). Significantly, when compared to <b>CLM3</b>, the novel compounds determined a greater and very promising activity on TT cell proliferation, showing IC<sub>50</sub> values in the low micromolar range and a 5-fold gain of efficacy with respect to the parent lead. The functional efficacy observed on TT cell lines was further investigated by evaluating the ability of the most active derivatives, namely, <b>8d</b>, <b>9a</b>, and <b>10a</b>,<b>g</b>, to inhibit the phosphorylation of the target receptor. After exposure to the test compounds, the ratio of phosphorylated/nonphosphorylated RET protein of treated cells was significantly decreased in TT cell lines (Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>), thus confirming that the antiproliferative activity of the compounds is mainly due to their inhibition of phosphorylation of RET.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Inhibitory Activity of Derivatives <b>8a</b>–<b>d</b>, <b>9a</b>,<b>b</b>, and <b>10a</b>,<b>g</b> against HUVEC and TT Cell Lines</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">IC<sub>50</sub>,<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a> μM</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">HUVEC</th><th class="colsep0 rowsep0" align="center">TT</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8a</b></td><td class="colsep0 rowsep0" align="left">15.31 ± 0.59</td><td class="colsep0 rowsep0" align="left">13.82 ± 1.32</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8b</b></td><td class="colsep0 rowsep0" align="left">9.83 ± 0.97</td><td class="colsep0 rowsep0" align="left">13.48 ± 2.30</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8c</b></td><td class="colsep0 rowsep0" align="left">15.93 ± 1.31</td><td class="colsep0 rowsep0" align="left">13.57 ± 3.88</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8d</b></td><td class="colsep0 rowsep0" align="left">16.64 ± 0.88</td><td class="colsep0 rowsep0" align="left">6.13 ± 1.74</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9a</b></td><td class="colsep0 rowsep0" align="left">13.43 ± 4.55</td><td class="colsep0 rowsep0" align="left">8.42 ± 1.26</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9b</b></td><td class="colsep0 rowsep0" align="left">18.55 ± 0.007</td><td class="colsep0 rowsep0" align="left">9.86 ± 0.72</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10a</b></td><td class="colsep0 rowsep0" align="left">22.64 ± 1.13</td><td class="colsep0 rowsep0" align="left">8.08 ± 1.10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10g</b></td><td class="colsep0 rowsep0" align="left">50.73 ± 9.25</td><td class="colsep0 rowsep0" align="left">5.97 ± 1.17</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>a</sup><p class="last">IC<sub>50</sub> ± SD values represent the concentration of drug that decreased cell count by 50%.</p></div></div></div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Inhibitory Activity of RET Phosphorilation of Derivatives <b>8d</b>, <b>9a</b>, <b>10a</b>, and <b>10g</b><a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">% of (pRET)/(total RET) vs 100% of control</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8d</b></td><td class="colsep0 rowsep0" align="left">66.4 ± 4.9*</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9a</b></td><td class="colsep0 rowsep0" align="left">64.5 ± 12.6*</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10a</b></td><td class="colsep0 rowsep0" align="left">88.7 ± 4.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10g</b></td><td class="colsep0 rowsep0" align="left">68.9 ± 1.7*</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>a</sup><p class="last">Results were obtained from experiments using compounds at their respective antiproliferative IC<sub>50</sub> values: mean ± SD, (∗) <i>P</i> < 0.05 vs control.</p></div></div></div><div class="NLM_p last">Finally, compounds <b>8d</b> and <b>10g</b> were also tested on cycling normal human fibroblast HNDF line to investigate their antiproliferative activity on a noncancerous cell line. Test compounds showed IC<sub>50</sub> values of 22.0 ± 2.0 μM (mean ± SD) and 23.6 ± 1.2 μM (mean ± SD), respectively. These IC<sub>50</sub> values were almost 4-fold higher than the ones observed in the TT tumor cell line, thus confirming the preferential activity of the compounds on the cell line with mutated RET.</div></div><div id="sec3_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Structure–Activity Relationships and Docking Studies</h3><div class="NLM_p">All the compounds reported in Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a> were docked in the VEGFR2 active site. Here, we have shown and analyzed in detail the binding mode of compound <b>10c</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>a) as the main representative of the three new series of VEGFR2 inhibitors. Binding modes obtained for <b>CLM3</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>) and <b>10c</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>a) in VEGFR2 were highly superimposable. The main differences reside in further interactions with E885 and D1046, established by the sulfonamide group of <b>10c</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>a), and with L889, I892, V899, L1019, H1026 (RDP), engaged with the pendent phenyl ring, which accounts for the 11-fold increase in inhibitory potency observed for <b>10c</b> when compared to <b>CLM3</b>. Notably, all the novel derivatives, regardless their polar bridge groups, CO, CONH, and SO<sub>2</sub>, showed highly similar pattern of interactions as described for <b>10c</b> (see Figure 1-SI in <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>), thus legitimating the gain in inhibitory potency of all the novel derivatives with respect to <b>CLM3</b>. Specifically, in the <b>8a</b>–<b>g</b> subseries, the short bridge did not allow a complete fill of the RDP. Indeed, compounds <b>8a</b> was less active than <b>9a</b> and <b>10a</b>, but the introduction of 4-substituents on the distant phenyl ring further improved the inhibitory potency. Regarding the RET kinase, binding modes obtained for the most active compounds of the amide and urea series, <b>8b</b> and <b>9c</b>, respectively (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>), were pretty superimposable with that of <b>CLM3</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>), with main differences residing in further possible interactions of amide and urea linkers and the terminal phenyl ring lodged near the region of where the AMP phosphate group binds (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2IVT">2IVT</a>,<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>a). Indeed, both linkers are in proximity to S811 and an H-bond is likely to occur. Meanwhile the 4-substituted benzene ring is just above the N879 amidic side chain, thus justifying a general improvement in the IC<sub>50</sub> values toward RET. Furthermore, the substitution of the aforementioned benzene with a bromine atom, in the case of the shorter amide linker (<b>8b</b>), and with a fluorine atom, in the case of the longer urea bridge (<b>9c</b>), gave the possibility of establishing an H-bond with the NH group of the E734, thus producing lower IC<sub>50</sub> values with respect to their nonhalogenated counterparts (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>a and Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>b). Finally, docking of <b>10c</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>b) shown that the sulfonamide moiety establishes multiple H-bonds with the hydroxyl and ammonium groups of the Y806, K728, and K740 side chains, respectively. However, the peculiar geometry of the sulfonamide group forces the phenyl ring to occupy a different portion, where it is partially solvent exposed, thus accounting for the lower activity of <b>10e</b>–<b>10g</b>, while a general improved activity is observed for the halogenated compounds, as for <b>10c</b>.</div><figure id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401358b/production/images/medium/jm-2013-01358b_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401358b/production/images/large/jm-2013-01358b_0003.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Binding pose of <b>10c</b> (gold sticks) in the active site of VEGFR-2 (a) and RET (b) shown as blue and green cartoons, respectively. H-bonds are shown as black dashed lines and part of the backbone is in transparent ribbon, for clarity reason.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401358b/production/images/large/jm-2013-01358b_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401358b&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401358b/production/images/medium/jm-2013-01358b_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401358b/production/images/large/jm-2013-01358b_0004.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Binding pose of <b>8b</b> (a) and <b>9c</b> (b) represented as gold sticks in the active site of RET, shown as green cartoon. H-bonds are shown as black dashed lines and part of the backbone is in transparent ribbon, for clarity reason. Cocrystallyzed AMP molecule is superimposed with <b>8b</b> (a).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401358b/production/images/large/jm-2013-01358b_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401358b&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Finally, with the aim to gain information about the capability of <b>8b</b>, <b>9c</b>, and <b>10c</b> to bind RET<sup>V804L</sup>, docking was performed using the mutated RET as the target receptor, showing that the flexible phenylethyl moiety is able to shift its position with respect to that observed when calculations are performed on RET wild type. Particularly, when the three compounds are docked in RET<sup>V804L</sup>, the phenylethyl branch rearranges itself and occupies the region where AMP phosphate group binds, thus losing interactions with L779 and L802 side chains and, at the same time, gaining hydrophobic contacts with V738 and L881 side chains. Obviously, while for <b>10c</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>a) the novel position of the phenylethyl moiety does not affect the rest of the binding mode, in the case of <b>8b</b> and <b>9c</b>, the amide and ureidic linkers with the distant phenyl ring have to readjust altogether, and as shown in Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>b, these branches come to occupy the same region of the sulfonamide moiety of <b>10c</b>.</div><figure id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401358b/production/images/medium/jm-2013-01358b_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401358b/production/images/large/jm-2013-01358b_0005.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Superposition of the docking binding poses of <b>10c</b> (a) and <b>9c</b> (b) into the WT (golden sticks) and V804L mutant (magenta sticks) RET kinase. The active site of RET is shown as green cartoon although part of the backbone is in transparent ribbon, for clarity reason. The L804 residue is represented as balls and sticks.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401358b/production/images/large/jm-2013-01358b_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401358b&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">Concluding Remarks</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_13842" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_13842" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In this work we presented a successful example of structure-based optimization, pursued on the known tyrosine kinase inhibitor <b>CLM3</b>.<a onclick="showRef(event, 'ref27 ref28'); return false;" href="javascript:void(0);" class="ref ref27 ref28">(27, 28)</a> Guided by preliminary docking studies, we rationally explored different substitution patterns on the heterocyclic core, with the purpose of improving the dual inhibitory profile of the starting lead.</div><div class="NLM_p">The novel synthesized compounds displayed a remarkable increase in inhibitory potency against the target proteins, showing IC<sub>50</sub> values in the micromolar range. Significantly, the best performing ones, <b>8b</b>, <b>9c</b>, and <b>10c</b>, proved to inhibit also the mutant RET<sup>V804L</sup> which, to date, is the main cause of functional failure of the well-known tyrosine kinase inhibitors from the literature, including the commercially approved vandetanib which is devoid of any inhibitory efficacy against this form of protein.</div><div class="NLM_p">A preliminary evaluation on both endothelial and medullary thyroid cancer cell lines revealed the promising antiproliferative profile of the novel derivatives. Compared to the lead, <b>CLM3</b>, the test compounds exhibited a remarkable increase in efficacy against the target thyroid cancer cell line TT, expressing mutated RET, showing an almost 5-fold decrease of IC<sub>50</sub> values, as in <b>8d</b> (6.13 ± 1.74 μM) and <b>10g</b> (5.97 ± 1.17 μM). Despite a concurrent inflection in the antiproliferative activity against the HUVEC cell lines, the novel compounds possess a better balanced dual target profile, thus improving, in principle, their therapeutic efficacy against the complex network of proteins accountable for both the pathogenesis and progression of TCs.</div><div class="NLM_p">Interestingly, the functional efficacy observed for the novel compounds here described is fully comparable to the ones shown by the already commercially approved tyrosine kinase inhibitors cabozantinib and vandetanib, tested by Verbeek and co-workers<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> in analogous assays conditions.</div><div class="NLM_p last">Further studies in animal models will prove their robustness as prototypical drug candidates exploitable for the treatment of TCs, including the medullary thyroid cancer, which is caused by RET activating mutations and still needs a viable and effective therapeutic solution.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i15">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_44146" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_44146" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Chemistry</h3><div class="NLM_p">Melting points were determined using a Reichert Köfler hot-stage apparatus and are uncorrected. Routine <sup>1</sup>H NMR spectra were recorded in DMSO-<i>d</i><sub>6</sub> solution on a Varian Gemini 200 spectrometer operating at 200 MHz. Mass spectra were obtained on a Hewlett-Packard 5988 A spectrometer using a direct injection probe and an electron beam energy of 70 eV. Evaporation was performed in vacuo (rotary evaporator). Analytical TLC was carried out on Merck 0.2 mm precoated silica gel aluminum sheets (60 F-254). Microwave-assisted reactions were carried out in sealed vessels using a Biotage initiator 2.5 microwave synthesizer. Purity of the target inhibitors, <b>8a</b>–<b>g</b>, <b>9a</b>–<b>g</b>, and <b>10a</b>–<b>g</b>, was determined by HPLC analysis, using a Merck Hitachi D-7000 liquid chromatograph (UV detection at 242 nm) and a Discovery C18 column (250 mm × 4.6 mm, 5 μm, Supelco), with a gradient of 30% water and 70% methanol and a flow rate of 1.5 mL/min. All the compounds showed percent purity values of ≥95% (Table 7-SI, <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>).</div><div class="NLM_p last">2-(Ethoxymethylene)malononitrile, 3-nitrobenzylamine hydrochloride, and the suitably substituted aroyl chlorides, arylsulfonyl chlorides, and aryl isocyanates, used to obtain the target inhibitors, were from Alfa Aesar, Aldrich, and Fluka.</div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Synthesis of 5-Amino-1-phenethyl-1<i>H</i>-pyrazole-4-carbonitrile, <b>3</b></h3><div class="NLM_p last">Commercially available 2-(ethoxymethylene)malononitrile (<b>2</b>, 1.22 g, 10.0 mmol) was added portionwise to an ice-cooled solution of phenethylhydrazine (<b>1</b>, 1.36 g, 10.0 mmol) in ethanol. Once the addition was complete, the reaction mixture was refluxed under stirring until the disappearance of the starting materials (TLC analysis). After the mixture was cooled to room temperature, the solid was collected by filtration and purified by crystallization from toluene. Mp 166–170 °C. Yield: 56%. <sup>1</sup>H NMR (δ, ppm): 7.53 (s, 1H, H<sub>3</sub>), 7.27–7.18 (m, 5H, ArH), 6.56 (s, 2H, NH<sub>2</sub>, exc), 4.08 (t, 2H, <i>J</i> = 8.06 Hz), 2.93 (t, 2H, <i>J</i> = 8.06 Hz).</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Synthesis of 1-Phenethyl-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4(5<i>H</i>)-one, <b>4</b></h3><div class="NLM_p last">5-Amino-1-phenethyl-1<i>H</i>-pyrazole-4-carbonitrile, <b>4</b> (0.21 g, 1.00 mmol) was suspended in formic acid (0.5 mL) and heated overnight under stirring at <i>T</i> = 120 °C. The resulting mixture was poured into crushed ice, and the separated solid was collected by filtration and purified by crystallization from methanol. Mp 244–248 (dec). Yield: 78%. <sup>1</sup>H NMR (δ, ppm): 12.10 (s, 1H, NH, exc), 8.05 (s, 1H, H<sub>3</sub>), 7.99 (s, 1H, H<sub>6</sub>), 7.20–7.06 (m, 5H, ArH), 4.49 (t, 2H, <i>J</i> = 7.08 Hz), 3.12 (t, 2H, <i>J</i> = 7.08 Hz).</div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Synthesis of 4-Chloro-1-phenethyl-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidine, <b>5</b></h3><div class="NLM_p last">Vielsmeier complex (POCl<sub>3</sub>, 40.0 mmol, and DMF, 40.0 mmol) was added dropwise to an ice-cooled solution of 1-phenethyl-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4(5<i>H</i>)-one (<b>4</b>, 10.0 mmol) in anhydrous dichloromethane. Once addition was complete, the mixture was refluxed under stirring until the disappearance of the starting material (24 h, TLC analysis, 5/5 AcOEt/petroleum ether, 60–80 °C). The mixture was then ice-cooled, and the excess of POCl<sub>3</sub> was quenched with water. The crude was extracted with dichloromethane, dried over MgSO<sub>4</sub>, and evaporated to dyness in vacuo to afford the target 4-chloro-1-phenethyl-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidine, <b>5</b>, which was exploited in the following reaction without further purification.</div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> Synthesis of <i>N</i>-(3-Nitrobenzyl)-1-phenethyl-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-amine, <b>6</b></h3><div class="NLM_p last">4-Chloro-1-phenethyl-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidine <b>5</b> (0.258 g, 1.0 mmol), 3-nitrobenzylamine hydrochloride (0.188 g, 1.0 mmol), and Et<sub>3</sub>N (0.278 mL, 2.0 mmol) were suspended in toluene and irradiated with microwave at a temperature of 80 °C for 5 min. The cooled residue was poured into crushed ice and the solid separated was collected by filtration and purified by crystallization from toluene to obtain the desired derivative, <b>6</b>, as a yellow solid. Mp 113–114 °C. Yield: 61%. <sup>1</sup>H NMR (δ, ppm): 8.90 (t, 1H, NH, <i>J</i> = 5.86 Hz, exc), 8.20–8.09 (m, 4H), 7.80 (d, 1H, <i>J</i> = 7.30 Hz), 7.62 (t, 1H, <i>J</i> = 7.81 Hz), 7.24–7.10 (m, 5H), 4.84 (d, 2H, <i>J</i> = 5.86 Hz), 4.51 (t, 2H, <i>J</i> = 7.08 Hz), 3.13 (t, 2H, <i>J</i> = 7.08 Hz).</div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> Synthesis of <i>N</i>-(3-Aminobenzyl)-1-phenethyl-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-amine, <b>7</b></h3><div class="NLM_p last">A solution of <i>N</i>-(3-nitrobenzyl)-1-phenethyl-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-amine, <b>6</b> (0.374 g, 1.00 mmol), in absolute ethanol was added by 10% palladium on carbon (0.10 mmol) and hydrogenated at atmospheric pressure and room temperature until the disappearance of the starting material (TLC analysis). After filtration of the catalyst, the solvent was evaporated to dryness to give the target derivative, <b>7</b>, as a white solid which was purified by crystallization from toluene. Mp 120–122 °C. Yield: 83%. <sup>1</sup>H NMR (δ, ppm): 8.63 (t, 1H, exc, <i>J</i> = 5.86 Hz), 8.18 (s, 1H), 8.13 (s, 1H), 7.20–7.14 (m, 5H), 6.93 (t, 1H, <i>J</i> = 7.32 Hz), 6.49–6.39 (m, 3H), 5.02 (bs, 2H, NH<sub>2</sub>, exc), 4.56 (d, 2H, <i>J</i> = 5.86 Hz), 4.49 (t, 2H, <i>J</i> = 6.84 Hz), 3.13 (t, 2H, <i>J</i> = 6.10 Hz).</div></div><div id="sec5_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> General Procedure for the Synthesis of <i>N</i>-(3-((1-Phenethyl-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-ylamino)methyl)phenyl)-4-substituted-benzamide, <b>8a</b>–<b>g</b></h3><div class="NLM_p last"><i>N</i>-(3-Aminobenzyl)-1-phenethyl-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-amine <b>7</b> (0.344 g, 1.00 mmol) was suspended either in anhydrous toluene (to obtain derivatives <b>8a</b>–<b>d</b>) or in anhydrous xylene (to obtain derivatives <b>8e</b>–<b>g</b>), and to it were added the suitable benzoyl chloride (1.00 mmol), Et<sub>3</sub>N (1.00 mmol), and DMAP (12 mg, 0.1 mmol). The resulting mixture was refluxed under stirring until the disappearance of the starting material (TLC analysis). The crude so obtained was evaporated to dryness, and water was added. The resulting compound, separated as a white solid, was collected by filtration, purified through flash chromatography (eluting system 5/5 AcOEt/petroleum ether, 60–80 °C), and crystallized from the suitable solveny (<a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>, Tables 1-SI and 2-SI).</div></div><div id="sec5_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> General Procedure for the Synthesis of 1-(3-((1-Phenethyl-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-ylamino)methyl)phenyl)-3-urea, <b>9a</b>–<b>g</b></h3><div class="NLM_p last">A suspension of <i>N</i>-(3-aminobenzyl)-1-phenethyl-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-amine <b>7</b> (0.344 g, 1.00 mmol) and the suitable isocyanate (1.00 mmol) in toluene was irradiated with microwave at a temperature of 90 °C for 5 min. The cooled residue was then poured into crushed ice, and the solid obtained was collected by filtration and purified through crystallization from the suitable solvent and characterized with physicochemical and spectroscopic data (<a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>, Tables 3-SI and 4-SI).</div></div><div id="sec5_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> General Procedure for the Synthesis of <i>N</i>-(3-((1-Phenethyl-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-ylamino)methyl)phenyl)sulfonamide, <b>10a</b>–<b>g</b></h3><div class="NLM_p last">A solution of <i>N</i>-(3-aminobenzyl)-1-phenethyl-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-amine <b>7</b> (0.344 g, 1.00 mmol) and the suitable sulfonyl chloride (1.00 mmol) in DMF solution was used. Then pyridine, 1 mL, was added and the mixture was left under stirring at room temperature until the disappearance of the starting materials (TLC analysis: 8/2 AcOEt/petroleum ether, 60–80 °C). Once the reaction was complete, the crude was ice-cooled and 1 M HCl was added. The solution was extracted with AcOEt, dried over MgSO<sub>4</sub>, evaporated to dryness, and triturated with diethyl ether. The resulting solid was collected by filtration and recrystallized from the suitable solvent. (<a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>, Tables 5-SI and 6-SI).</div></div><div id="sec5_10_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> Biology. Materials and Methods</h3><div class="NLM_p last">Human recombinant protein tyrosine kinases VEGFR2, RET and RET<sup>V804L</sup>, and Omnia Tyr peptide 7 kit were from Invitrogen. All solvents were from Sigma-Aldrich.</div></div><div id="sec5_10_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> Tyrosine Kinase Assays</h3><div class="NLM_p last">Assays were performed in 96-well microtiter plates using the Omnia Tyr peptide 7 kit and following a previously reported protocol.<a onclick="showRef(event, 'ref36 ref37'); return false;" href="javascript:void(0);" class="ref ref36 ref37">(36, 37)</a> Tests were carried out at 30 °C in a reaction mixture containing 5 μL of tyrosine kinase reaction buffer, 5 μL of tyrosine kinase substrate, 5 μL of 1 mM ATP, 5 μL of 1 mM DTT, 25 μL of ultrapure water, and 5 μL of 3 mU/μL of the target kinase, in a total volume of 50 μL. All the above reagents, except the protein, were incubated at 30 °C for 5 min. Protein was then added to start the reaction, which was monitored with the fluorescence meter Victor3 PerkinElmer at 360 nm (excitation) and 485 nm (emission). Kinase activity was calculated from a linear least-squares fit of the data for fluorescence intensity versus time.</div></div><div id="sec5_10_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> Enzymatic Inhibition</h3><div class="NLM_p last">The inhibitory activity of the test compounds was assayed by adding 5 μL of the inhibitor solution to the reaction mixture described above. All the products were dissolved in 100% DMSO and diluted to the appropriate concentrations with tyrosine kinase reaction buffer, provided by the kit. Final concentration of DMSO in assay solutions never exceed 1% and proved to have no effects on protein activity. The inhibitory effect of the products was routinely estimated at 100 μM. Those compounds found to be active were then tested at additional concentrations between 100 μM and 10 nM. For a proper comparison, vandetanib was employed as the reference standard. The determination of the IC<sub>50</sub> values was performed by linear regression analysis of the log dose response curve, which was generated using at least five concentrations of the inhibitor causing an inhibition between 20% and 80%, with two replicates at each concentration. The 95% confidence limits (95% CL) were calculated from <i>t</i> values for <i>n</i> – 2, where <i>n</i> is the total number of determinations (Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a> and <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>).</div></div><div id="sec5_11_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> Cell Cultures and Viability Assays. Reagents and Cell Lines</h3><div class="NLM_p last">Test compounds were dissolved in a stock solution of 10 mM in 100% dimethylsulfoxide for in vitro studies. The DMSO concentration in control media was the one used to dilute the highest concentration of test compounds in the same experiment. Recombinant human epidermal growth factor (EGF) and basic fibroblast growth factor (bFGF) were from PeproTechEC Ltd. (London, U.K.). Cell culture media MCDB131 and F-12K, fetal bovine serum (FBS), <span class="smallcaps smallerCapital">l</span>-glutamine, penicillin, streptomycin, and antibiotics were from Gibco (Gaithersburg, MD). Type A gelatin from porcine skin, supplements, and all other chemicals not listed in this section were obtained from Sigma Chemical Co. (St. Louis, MO). Plastics for cell culture were supplied by Sarsted (Verona, Italy). Human umbilical vein endothelial cells (HUVEC; Clonetics, San Diego, CA) were maintained in MCDB131 culture medium supplemented with 10% heat-inactivated FBS, <span class="smallcaps smallerCapital">l</span>-glutamine 2 mM, heparin 10 units/mL, EGF 10 ng/mL, and bFGF 5 ng/mL and kept in a humidified atmosphere of 5% CO<sub>2</sub> at 37 °C. Human medullary thyroid cancer cell line (TT; ATCC, Manassas, VA, USA) was maintained in 10% FBS F-12K medium supplemented with <span class="smallcaps smallerCapital">l</span>-glutamine 2 mM and kept in a humidified atmosphere of 5% CO<sub>2</sub> at 37 °C. Normal human fibroblast cell line (HNDF) was maintained in 10% FBS fibroblast basal medium supplemented with <span class="smallcaps smallerCapital">l</span>-glutamine 2 mM and kept in a humidified atmosphere of 5% CO<sub>2</sub> at 37 °C.</div></div><div id="sec5_11_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> Proliferation Assay</h3><div class="NLM_p last">In vitro chemosensitivity was tested on HUVEC, TT, and HNDF cell lines. Cells were plated in sterile 24-well plastic plates (which were coated with 1% of gelatin in the case of endothelial cells) and treated for 72 h (using 3 × 10<sup>4</sup> cells/well of normal and cancer cells, in 1 mL of medium) with added test compounds (50, 10, 5, 1, and 0.1 μM) or with added vehicle (DMSO) alone. At the end of the experiment, cells were harvested with trypsin/EDTA, and viable cells were quantified using the automatic cell counter ADAM MC digital B (Twin Helix, Milano, Italy). The data are presented as the percentage of vehicle-treated cells. The concentration of drugs that decreased cell count by 50% (IC<sub>50</sub>) compared with controls was calculated by nonlinear fitting of experimental data. All experiments were repeated, independently, three times with at least nine samples for each concentration (Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>).</div></div><div id="sec5_11_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> Cell-Based Phospho-RET Inhibition Assay</h3><div class="NLM_p last">TT cells (5 × 10<sup>4</sup> cells/well) were seeded and maintained with 1% FBS medium. After 24 h, cells were treated continuously for 72 h with test compounds at a concentration corresponding to the experimental IC<sub>50</sub> of cell proliferation. At the end of the experiment, the medium was removed and cells were rinsed with ice-cold PBS and directly lysed with 0.5 mL of ice-cold 1× lysis buffer (20 mM Tris, pH 7.5, 150 mM, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM β-glycerol phosphate, 1 mM Na<sub>3</sub>VO<sub>4</sub>, 1 μg/mL leupetin; Cell Signaling Technology, MA, USA, catalog no. 9803) and 1 mM PMSF to each plate for 5 min at 4 °C. Lysates were collected and sonicated on ice for 10 s. The samples were microcentrifuged for 10 min at 4 °C, and the supernatant was collected. Cell lysates were assayed per manufacturer’s instructions with PathScan1 phospo-ret (panTyr) and Total Ret sandwich ELISA kits (Cell Signaling Technology). The optical density was determined using the microplate reader Multiskan Spectrum (Thermo Labsystems, Milan, Italy) set to 450 nm. All experiments were repeated independently six times with at least nine samples for each concentration (Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>).</div></div><div id="sec5_12_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> Molecular Modeling. VEGFR-2 and RET X-ray Selection</h3><div class="NLM_p">So far, more than 30 X-ray structures are available in PDB for the VEGFR2 kinase. A detailed comparison of all these structures shows that, depending on the inhibitor type, the tyrosine kinase domain of VEGFR2 undergoes important conformational rearrangements: (i) at DFG activation loop level (DFG<sub>in</sub> = loop in active conformation, inhibitor type I, and DFG<sub>out</sub> = loop in inactive conformation, inhibitor type II); (ii) at the juxtamembrane level (JM<sub>in</sub> = autoinhibitory conformation, inhibitor type IV; JM<sub>out</sub> = nonautoinhibitory conformation, inhibitor type II).<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a></div><div class="NLM_p">Thus, we initially selected for docking studies eight X-ray structures representative for the enzyme flexibility (<a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>, Table 8-SI), preferring those cocrystallized with ligands similar to our reference compound (<b>CLM3</b>, Chart <a class="ref internalNav" href="#cht1" aria-label="1">1</a>). Particularly, we chose <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1YWN">1YWN</a> as representative of the DFG<sub>in</sub> conformation, while <a href="https://" class="ext-link">2XIR</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3VHE">3VHE</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ASE">4ASE</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4AGC">4AGC</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ASD">4ASD</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4AGD">4AGD</a>, and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4AG8">4AG8</a> have been chosen to represent the DFG<sub>out</sub> and JM<sub>in</sub>/JM<sub>out</sub> conformations. Among these, the structure <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4AG8">4AG8</a> was used because it was demonstrated to be the best performing one in Glide cross-docking experiments. In particular, employing this structure, Glide was able to reproduce almost all the X-ray conformations of all the analyzed cocrystal ligands with an average root mean squared deviation (rmsd) of 3.33 Å (<a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>, Table 9-SI).</div><div class="NLM_p last">As for the RET X-ray selection, a detailed comparison among the phosphorylated structures currently available, superposing on the α carbon atoms using <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2IVV">2IVV</a><a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> as the reference, indicated that the protein folding was highly preserved. A further analysis of two structures with the highest resolutions (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2IVV">2IVV</a> and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2X2L">2X2L</a><a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a>), both cocrystallized with an organic inhibitor, reveals that the K758 can assume different orientations upon ligand binding. In fact, in <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2X2L">2X2L</a>, the phenylmethylidenedihydroindolone inhibitor does not occupy the N-lobe hydrophobic cavity, and the K758 partially blocks the pocket entrance. Conversely, the PP1 inhibitor in <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2IVV">2IVV</a> enters the small cavity with its methylphenyl moiety forcing the long K758 side chain to shift its orientation. Cross-docking experiments showed that <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2IVV">2IVV</a> can allocate also larger inhibitors like vandetenib, while <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2X2L">2X2L</a> does not. Thus, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2IVV">2IVV</a> was chosen for our docking experiments.</div></div><div id="sec5_12_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> Dockings</h3><div class="NLM_p">The binding mode of <b>CLM3</b> was studied by means of docking experiments, with the Glide tool available in the Maestro Package of Schrodinger, version 9.1.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> The 3D structure of the ligand was generated with the Maestro fragment Build tool and then geometrically optimized with Macromodel. The VEGFR-2 and RET proteins structures were prepared through the Protein Preparation Wizard of the Maestro 9.1 graphical user interface which assigns bond orders, adds hydrogen atoms, deletes water molecules, and generates appropriate protonation states.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a></div><div class="NLM_p last">The docking grid box was centered on the reference ligand for each X-ray structure, and docking runs were carried out using the standard precision (SP) method. The selected docking pose was minimized using OPLSA2005 as force field, the PRCG methods until a gradient of 0.001 kcal/(mol·Å<sup>2</sup>) was obtained, and the implicit water model implemented in Macromodel.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> Figures were rendered by the Chimera software package.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i33"><a href="/doi/suppl/10.1021/jm401358b">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_11031" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_11031" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Tables 1-SI to 9-SI, including physical, spectral, computational, and purity data of compounds described, and Figure 1-SI, including putative binding poses of <b>8b</b> and <b>9c</b> in the active site of VEGFR-2. This material is available free of charge via the Internet at <a href="http://pubs.acs.org" class="extLink">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm401358b/suppl_file/jm401358b_si_001.pdf">jm401358b_si_001.pdf (198.94 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/jm401358b" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_44368" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_44368" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Concettina La Motta</span> - <span class="hlFld-Affiliation affiliation">Dipartimento
di Farmacia, Università di Pisa, Via Bonanno 6, 56126 Pisa, Italy</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#89eae6e7eaecfdfde0e7e8a7e5e8e4e6fdfde8c9efe8fbe4a7fce7e0f9e0a7e0fd"><span class="__cf_email__" data-cfemail="ddbeb2b3beb8a9a9b4b3bcf3b1bcb0b2a9a9bc9dbbbcafb0f3a8b3b4adb4f3b4a9">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stefania Sartini</span> - <span class="hlFld-Affiliation affiliation">Dipartimento
di Farmacia, Università di Pisa, Via Bonanno 6, 56126 Pisa, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Vito Coviello</span> - <span class="hlFld-Affiliation affiliation">Dipartimento
di Farmacia, Università di Pisa, Via Bonanno 6, 56126 Pisa, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Agostino Bruno</span> - <span class="hlFld-Affiliation affiliation">Dipartimento
di Farmacia, Università di Napoli
“Federico II”, Via D. Montesano, 49, 80131 Napoli, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Valeria La Pietra</span> - <span class="hlFld-Affiliation affiliation">Dipartimento
di Farmacia, Università di Napoli
“Federico II”, Via D. Montesano, 49, 80131 Napoli, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Luciana Marinelli</span> - <span class="hlFld-Affiliation affiliation">Dipartimento
di Farmacia, Università di Napoli
“Federico II”, Via D. Montesano, 49, 80131 Napoli, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Francesca Simorini</span> - <span class="hlFld-Affiliation affiliation">Dipartimento
di Farmacia, Università di Pisa, Via Bonanno 6, 56126 Pisa, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sabrina Taliani</span> - <span class="hlFld-Affiliation affiliation">Dipartimento
di Farmacia, Università di Pisa, Via Bonanno 6, 56126 Pisa, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Silvia Salerno</span> - <span class="hlFld-Affiliation affiliation">Dipartimento
di Farmacia, Università di Pisa, Via Bonanno 6, 56126 Pisa, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Anna Maria Marini</span> - <span class="hlFld-Affiliation affiliation">Dipartimento
di Farmacia, Università di Pisa, Via Bonanno 6, 56126 Pisa, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Anna Fioravanti</span> - <span class="hlFld-Affiliation affiliation">Dipartimento
di Medicina Clinica e Sperimentale, Università
di Pisa, Via Roma 55, 56126 Pisa, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Paola Orlandi</span> - <span class="hlFld-Affiliation affiliation">Dipartimento
di Medicina Clinica e Sperimentale, Università
di Pisa, Via Roma 55, 56126 Pisa, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Alessandro Antonelli</span> - <span class="hlFld-Affiliation affiliation">Dipartimento
di Medicina Clinica e Sperimentale, Università
di Pisa, Via Roma 55, 56126 Pisa, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Federico Da Settimo</span> - <span class="hlFld-Affiliation affiliation">Dipartimento
di Farmacia, Università di Pisa, Via Bonanno 6, 56126 Pisa, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ettore Novellino</span> - <span class="hlFld-Affiliation affiliation">Dipartimento
di Farmacia, Università di Napoli
“Federico II”, Via D. Montesano, 49, 80131 Napoli, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Guido Bocci</span> - <span class="hlFld-Affiliation affiliation">Dipartimento
di Medicina Clinica e Sperimentale, Università
di Pisa, Via Roma 55, 56126 Pisa, Italy</span>; 
    <span class="hlFld-Affiliation affiliation">Istituto
Toscano Tumori, Via T.
Alderotti 26N, 50139 Firenze, Italy</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d270e2732-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i34">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_15165" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_15165" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The study has been funded in part by the Ministero dell’Istruzione, dell’Università e della Ricerca (MIUR), to C.L.M. and in part by the Associazione Italiana per la Ricerca sul Cancro (AIRC) to G.B.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i35" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i35"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i36" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i36"> Abbreviations Used</h2><tr><td class="NLM_term">TC</td><td class="NLM_def"><p class="first last">thyroid carcinoma</p></td></tr><tr><td class="NLM_term">MTC</td><td class="NLM_def"><p class="first last">medullary thyroid carcinoma</p></td></tr><tr><td class="NLM_term">PTC</td><td class="NLM_def"><p class="first last">papillary thyroid carcinoma</p></td></tr><tr><td class="NLM_term">DePTC</td><td class="NLM_def"><p class="first last">dedifferentiated thyroid carcinoma</p></td></tr><tr><td class="NLM_term">EGFR</td><td class="NLM_def"><p class="first last">epidermal growth factor receptor</p></td></tr><tr><td class="NLM_term">RET</td><td class="NLM_def"><p class="first last">REarranged during Transfection</p></td></tr><tr><td class="NLM_term">VEGF</td><td class="NLM_def"><p class="first last">vascular endothelial growth factor</p></td></tr><tr><td class="NLM_term">VEGFR2</td><td class="NLM_def"><p class="first last">vascular endothelial growth factor receptor 2</p></td></tr><tr><td class="NLM_term">ATP</td><td class="NLM_def"><p class="first last">adenosine triphosphate</p></td></tr><tr><td class="NLM_term">RDP</td><td class="NLM_def"><p class="first last">regulatory domain pocket</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i37">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_22551" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_22551" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 40 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Ito, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nikiforov, Y. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlumberger, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vigneri, R.</span><span> </span><span class="NLM_article-title">Increasing incidence of thyroid cancer: controversies explored</span> <span class="citation_source-journal">Nat. Rev. Endocrinol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">178</span><span class="NLM_x">–</span> <span class="NLM_lpage">184</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm401358b&amp;key=10.1038%2Fnrendo.2012.257" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm401358b&amp;key=23358352" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm401358b&amp;key=1%3ACAS%3A280%3ADC%252BC3szjt1yrtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2013&pages=178-184&author=Y.+Itoauthor=Y.+E.+Nikiforovauthor=M.+Schlumbergerauthor=R.+Vigneri&title=Increasing+incidence+of+thyroid+cancer%3A+controversies+explored"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Increasing incidence of thyroid cancer: controversies explored</span></div><div class="casAuthors">Ito Yasuhiro; Nikiforov Yuri E; Schlumberger Martin; Vigneri Riccardo</div><div class="citationInfo"><span class="NLM_cas:title">Nature reviews. Endocrinology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">178-84</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Thyroid cancer is the most common endocrine malignancy and its incidence has been increasing considerably in the past few decades.  Many studies have been published providing evidence for this increase; however, why thyroid cancer incidence keeps rising is still debated and there are conflicting reports of factors leading to the increase in its incidence.  In this article, Nature Reviews Endocrinology asks four experts their opinions on some of the controversies surrounding the changing trends in thyroid cancer incidence.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRPwiOr3vbNwzMsgLhIoICsfW6udTcc2eZ6fqXSyGstHrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3szjt1yrtA%253D%253D&md5=8ca5f03318aaaf72045a75bd5895c3ea</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrendo.2012.257&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrendo.2012.257%26sid%3Dliteratum%253Aachs%26aulast%3DIto%26aufirst%3DY.%26aulast%3DNikiforov%26aufirst%3DY.%2BE.%26aulast%3DSchlumberger%26aufirst%3DM.%26aulast%3DVigneri%26aufirst%3DR.%26atitle%3DIncreasing%2520incidence%2520of%2520thyroid%2520cancer%253A%2520controversies%2520explored%26jtitle%3DNat.%2520Rev.%2520Endocrinol.%26date%3D2013%26volume%3D9%26spage%3D178%26epage%3D184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Aschebrook-Kilfoy, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schechter, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shih, Y. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaplan, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiu, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angelos, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grogan, R. H.</span><span> </span><span class="NLM_article-title">The clinical and economic burden of a sustained increase in thyroid cancer incidence</span> <span class="citation_source-journal">Cancer Epidemiol. Biomarkers Prev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">1252</span><span class="NLM_x">–</span> <span class="NLM_lpage">1259</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2013&pages=1252-1259&author=B.+Aschebrook-Kilfoyauthor=R.+B.+Schechterauthor=Y.+C.+Shihauthor=E.+L.+Kaplanauthor=B.+C.+Chiuauthor=P.+Angelosauthor=R.+H.+Grogan&title=The+clinical+and+economic+burden+of+a+sustained+increase+in+thyroid+cancer+incidence"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAschebrook-Kilfoy%26aufirst%3DB.%26aulast%3DSchechter%26aufirst%3DR.%2BB.%26aulast%3DShih%26aufirst%3DY.%2BC.%26aulast%3DKaplan%26aufirst%3DE.%2BL.%26aulast%3DChiu%26aufirst%3DB.%2BC.%26aulast%3DAngelos%26aufirst%3DP.%26aulast%3DGrogan%26aufirst%3DR.%2BH.%26atitle%3DThe%2520clinical%2520and%2520economic%2520burden%2520of%2520a%2520sustained%2520increase%2520in%2520thyroid%2520cancer%2520incidence%26jtitle%3DCancer%2520Epidemiol.%2520Biomarkers%2520Prev.%26date%3D2013%26volume%3D22%26spage%3D1252%26epage%3D1259" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Boufraqech, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiong, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kebebew, E.</span><span> </span><span class="NLM_article-title">Diagnosis of thyroid cancer: state of art</span> <span class="citation_source-journal">Expert Opin. Med. Diagn.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">331</span><span class="NLM_x">–</span> <span class="NLM_lpage">342</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm401358b&amp;key=10.1517%2F17530059.2013.800481" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm401358b&amp;key=1%3ACAS%3A280%3ADC%252BC3snmt1OrsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2013&pages=331-342&author=M.+Boufraqechauthor=D.+Patelauthor=Y.+Xiongauthor=E.+Kebebew&title=Diagnosis+of+thyroid+cancer%3A+state+of+art"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Diagnosis of thyroid cancer: state of art</span></div><div class="casAuthors">Boufraqech Myriem; Patel Dhaval; Xiong Yin; Kebebew Electron</div><div class="citationInfo"><span class="NLM_cas:title">Expert opinion on medical diagnostics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">331-42</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">INTRODUCTION:  Thyroid cancer is the most common endocrine cancer in the USA and its incidence is increasing worldwide.  Thyroid fine-needle aspiration biopsy (FNA) and cytologic analysis is the most cost-effective approach to distinguish between malignant and benign thyroid nodules.  However, up to 30% of thyroid FNA biopsy results are inconclusive.  AREAS COVERED:  In this article, the authors provide an update on the current status and emerging approaches for improving thyroid cancer diagnosis.  This review covers imaging, genetic and genomic approaches being used or in development to help distinguish between malignant and benign thyroid nodules.  EXPERT OPINION:  There has been considerable progress in improving thyroid cancer diagnosis.  The molecular markers analysis to avoid diagnostic surgeries seems to be promising.  However, the clinical utility and accuracy of some markers reported in this review are not conclusive and need to be validated as clinical diagnostic tool.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRdnIW_nAzuwDjk2McQZ6XmfW6udTcc2eZ6fqXSyGstHrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3snmt1OrsA%253D%253D&md5=1024ded229de18e71f008e535f553682</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1517%2F17530059.2013.800481&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17530059.2013.800481%26sid%3Dliteratum%253Aachs%26aulast%3DBoufraqech%26aufirst%3DM.%26aulast%3DPatel%26aufirst%3DD.%26aulast%3DXiong%26aufirst%3DY.%26aulast%3DKebebew%26aufirst%3DE.%26atitle%3DDiagnosis%2520of%2520thyroid%2520cancer%253A%2520state%2520of%2520art%26jtitle%3DExpert%2520Opin.%2520Med.%2520Diagn.%26date%3D2013%26volume%3D7%26spage%3D331%26epage%3D342" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Vini, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harmer, C.</span><span> </span><span class="NLM_article-title">Management of thyroid cancer</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">407</span><span class="NLM_x">–</span> <span class="NLM_lpage">414</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm401358b&amp;key=10.1016%2FS1470-2045%2802%2900787-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm401358b&amp;key=12142170" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm401358b&amp;key=1%3ACAS%3A280%3ADC%252BD38zpt1CntQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2002&pages=407-414&author=L.+Viniauthor=C.+Harmer&title=Management+of+thyroid+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Management of thyroid cancer</span></div><div class="casAuthors">Vini Louiza; Harmer Clive</div><div class="citationInfo"><span class="NLM_cas:title">The lancet oncology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">407-14</span>
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    </div><div class="casAbstract">Thyroid cancers are a diverse group of malignant disorders ranging from indolent micropapillary carcinoma, which has no effect on life expectancy, to anaplastic tumours, which are invariably fatal even with aggressive treatment.  Although the estimated incidence has increased by 14.6% over the past 40 years, the estimated death rate has fallen by 21%, probably as a result of earlier diagnosis.  The natural history of thyroid tumours is no longer a mystery, and the prognostic factors identified can predict outcome fairly accurately.  Improvements in management have mostly depended on information from large retrospective series, though there are still many areas open to debate.  There has been, however, a general acceptance that thyroid cancer should be managed by multidisciplinary teams in specialised units following evidence-based guidelines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR0Pb8oo74K7RLDWw4HIq2sfW6udTcc2eZ6fqXSyGstHrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD38zpt1CntQ%253D%253D&md5=0421ff2c669c053764c373ea2b8a38f8</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2802%2900787-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252802%252900787-8%26sid%3Dliteratum%253Aachs%26aulast%3DVini%26aufirst%3DL.%26aulast%3DHarmer%26aufirst%3DC.%26atitle%3DManagement%2520of%2520thyroid%2520cancer%26jtitle%3DLancet%2520Oncol.%26date%3D2002%26volume%3D3%26spage%3D407%26epage%3D414" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Stassi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Todaro, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zerilli, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ricci-Vitiani, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Liberto, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Florena, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Gaudio, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Gesù, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Maria, M.</span><span> </span><span class="NLM_article-title">Thyroid cancer resistance to chemotherapeutic drugs via autocrine production of interleukin-4 and interleukin-10</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">6784</span><span class="NLM_x">–</span> <span class="NLM_lpage">6790</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2003&pages=6784-6790&author=G.+Stassiauthor=M.+Todaroauthor=M.+Zerilliauthor=L.+Ricci-Vitianiauthor=D.+Di+Libertoauthor=M.+Pattiauthor=A.+Florenaauthor=F.+Di+Gaudioauthor=G.+Di+Ges%C3%B9author=M.+De+Maria&title=Thyroid+cancer+resistance+to+chemotherapeutic+drugs+via+autocrine+production+of+interleukin-4+and+interleukin-10"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DStassi%26aufirst%3DG.%26aulast%3DTodaro%26aufirst%3DM.%26aulast%3DZerilli%26aufirst%3DM.%26aulast%3DRicci-Vitiani%26aufirst%3DL.%26aulast%3DDi%2BLiberto%26aufirst%3DD.%26aulast%3DPatti%26aufirst%3DM.%26aulast%3DFlorena%26aufirst%3DA.%26aulast%3DDi%2BGaudio%26aufirst%3DF.%26aulast%3DDi%2BGes%25C3%25B9%26aufirst%3DG.%26aulast%3DDe%2BMaria%26aufirst%3DM.%26atitle%3DThyroid%2520cancer%2520resistance%2520to%2520chemotherapeutic%2520drugs%2520via%2520autocrine%2520production%2520of%2520interleukin-4%2520and%2520interleukin-10%26jtitle%3DCancer%2520Res.%26date%3D2003%26volume%3D63%26spage%3D6784%26epage%3D6790" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Ye, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santarpia, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gagel, R. F.</span><span> </span><span class="NLM_article-title">The evolving field of tyrosine kinase inhibitors in the treatment of endocrine tumors</span> <span class="citation_source-journal">Endocr. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">578</span><span class="NLM_x">–</span> <span class="NLM_lpage">599</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Fjm401358b&amp;key=10.1210%2Fer.2009-0031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Fjm401358b&amp;key=20605972" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm401358b&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVCrurvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2010&pages=578-599&author=L.+Yeauthor=L.+Santarpiaauthor=R.+F.+Gagel&title=The+evolving+field+of+tyrosine+kinase+inhibitors+in+the+treatment+of+endocrine+tumors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">The evolving fields of tyrosine kinase inhibitors in the treatment of endocrine tumors</span></div><div class="casAuthors">Ye, Lei; Santarpia, Libero; Gagel, Robert F.</div><div class="citationInfo"><span class="NLM_cas:title">Endocrine Reviews</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">578-599</span>CODEN:
                <span class="NLM_cas:coden">ERVIDP</span>;
        ISSN:<span class="NLM_cas:issn">0163-769X</span>.
    
            (<span class="NLM_cas:orgname">Endocrine Society</span>)
        </div><div class="casAbstract">A review.  Activation of tyrosine kinase receptors (TKRs) and their related pathways has been assocd. with development of endocrine tumors.  Compds. that target and inactivate the kinase function of these receptors, tyrosine kinase inhibitors (TKIs), are now being applied to the treatment of endocrine tumors.  Recent clin. trials of TKIs in patients with advanced thyroid cancer, islet cell carcinoma, and carcinoid have shown promising preliminary results.  Significant redns. in tumor size have been described in medullary and papillary thyroid carcinoma, although no complete responses have been reported.  Case reports have described significant tumor vol. redns. of malignant pheochromocytomas and paragangliomas.  In addn., these compds. showed an initial tumoricidal or apoptotic response followed by long-term static effects on tumor growth.  Despite the promising preliminary results, this class of therapeutic agents has a broad spectrum of adverse effects, mediated by inhibition of kinase activities in normal tissues.  These adverse effects will have to be balanced with their benefit in clin. use.  New strategies will have to be applied in clin. research to achieve optimal benefits.  In this review, we will address the genetic alterations of TKRs, the rationale for utilizing TKIs for endocrine tumors, and current information on tumor and patient responses to specific TKIs.  We will also discuss the adverse effects related to TKI treatment and the mechanisms involved.  Finally, we will summarize the challenges assocd. with use of this class of compds. and potential solns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphtWXuS57hGLVg90H21EOLACvtfcHk0ligscLyu34Whg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVCrurvL&md5=80adc8d78a48362b7c8330ec7b1cd030</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1210%2Fer.2009-0031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fer.2009-0031%26sid%3Dliteratum%253Aachs%26aulast%3DYe%26aufirst%3DL.%26aulast%3DSantarpia%26aufirst%3DL.%26aulast%3DGagel%26aufirst%3DR.%2BF.%26atitle%3DThe%2520evolving%2520field%2520of%2520tyrosine%2520kinase%2520inhibitors%2520in%2520the%2520treatment%2520of%2520endocrine%2520tumors%26jtitle%3DEndocr.%2520Rev.%26date%3D2010%26volume%3D31%26spage%3D578%26epage%3D599" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Elisei, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cosci, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romei, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bottici, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ronzini, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molinaro, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agate, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vivaldi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faviana, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Basolo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miccoli, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berti, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pacini, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinchera, A.</span><span> </span><span class="NLM_article-title">Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study</span> <span class="citation_source-journal">J Clin. Endocrinol. Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">93</span><span class="NLM_x">, </span> <span class="NLM_fpage">682</span><span class="NLM_x">–</span> <span class="NLM_lpage">687</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm401358b&amp;key=10.1210%2Fjc.2007-1714" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm401358b&amp;key=18073307" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm401358b&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjsFyntL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2008&pages=682-687&author=R.+Eliseiauthor=B.+Cosciauthor=C.+Romeiauthor=V.+Botticiauthor=G.+Ronziniauthor=E.+Molinaroauthor=L.+Agateauthor=A.+Vivaldiauthor=P.+Favianaauthor=F.+Basoloauthor=P.+Miccoliauthor=P.+Bertiauthor=F.+Paciniauthor=A.+Pinchera&title=Prognostic+significance+of+somatic+RET+oncogene+mutations+in+sporadic+medullary+thyroid+cancer%3A+a+10-year+follow-up+study"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study</span></div><div class="casAuthors">Elisei, Rossella; Cosci, Barbara; Romei, Cristina; Bottici, Valeria; Renzini, Giulia; Molinaro, Eleonora; Agate, Laura; Vivaldi, Agnese; Faviana, Pinuccia; Basolo, Fulvio; Miccoli, Paolo; Berti, Piero; Pacini, Furio; Pinchera, Aldo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Endocrinology and Metabolism</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">682-687</span>CODEN:
                <span class="NLM_cas:coden">JCEMAZ</span>;
        ISSN:<span class="NLM_cas:issn">0021-972X</span>.
    
            (<span class="NLM_cas:orgname">Endocrine Society</span>)
        </div><div class="casAbstract">Medullary thyroid carcinoma (MTC) is a well-differentiated thyroid tumor that maintains the typical features of C cells.  An advanced stage and the presence of lymph node metastases at diagnosis were demonstrated to be the most important bad prognostic factors.  Somatic RET mutations were found in 40-50% of MTCs.  Although a relationship between somatic mutations and bad prognosis was described, data are controversial and were performed in small series with short-term follow ups.  The aim of this study was to verify the prognostic value of somatic RET mutations in a large series of MTCs with a long follow up.  The authors studied 100 sporadic MTC patients with a 10.2 yr mean follow-up.  RET gene exons 10-11 and 13-16 were analyzed.  The correlation between the presence/absence of a somatic RET mutation, clin./pathol. features, and outcome of MTC patients was evaluated.  A somatic RET mutation was found in 43 of 100 (43%) sporadic MTCs.  The most frequent mutation (34 of 43, 79%) was M918T.  RET mutation occurrence was more frequent in larger tumors (P = 0.03), and in MTC with node and distant metastases (P < 0.0001 and P = 0.02, resp.), thus, a significant correlation was found with a more advanced stage at diagnosis (P = 0.004).  A worse outcome was also significantly correlated with the presence of a somatic RET mutation (P = 0.002).  Among all prognostic factors found to be correlated with a worse outcome, at multivariate anal. only the advanced stage at diagnosis and the presence of a RET mutation showed an independent correlation (P < 0.0001 and P = 0.01, resp.).  Finally, the survival curves of MTC patients showed a significantly lower percentage of surviving patients in the group with RET mutations (P = 0.006).  The authors demonstrated that the presence of a somatic RET mutation correlates with a worse outcome of MTC patients, not only for the highest probability to have persistence of the disease, but also for a lower survival rate in a long-term follow up.  More interestingly, the presence of a somatic RET mutation correlates with the presence of lymph node metastases at diagnosis, which is a known bad prognostic factor for the definitive cure of MTC patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQugeT2yd0RrVg90H21EOLACvtfcHk0ligscLyu34Whg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjsFyntL8%253D&md5=367e449cdca70528e0457a902ef26562</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1210%2Fjc.2007-1714&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fjc.2007-1714%26sid%3Dliteratum%253Aachs%26aulast%3DElisei%26aufirst%3DR.%26aulast%3DCosci%26aufirst%3DB.%26aulast%3DRomei%26aufirst%3DC.%26aulast%3DBottici%26aufirst%3DV.%26aulast%3DRonzini%26aufirst%3DG.%26aulast%3DMolinaro%26aufirst%3DE.%26aulast%3DAgate%26aufirst%3DL.%26aulast%3DVivaldi%26aufirst%3DA.%26aulast%3DFaviana%26aufirst%3DP.%26aulast%3DBasolo%26aufirst%3DF.%26aulast%3DMiccoli%26aufirst%3DP.%26aulast%3DBerti%26aufirst%3DP.%26aulast%3DPacini%26aufirst%3DF.%26aulast%3DPinchera%26aufirst%3DA.%26atitle%3DPrognostic%2520significance%2520of%2520somatic%2520RET%2520oncogene%2520mutations%2520in%2520sporadic%2520medullary%2520thyroid%2520cancer%253A%2520a%252010-year%2520follow-up%2520study%26jtitle%3DJ%2520Clin.%2520Endocrinol.%2520Metab.%26date%3D2008%26volume%3D93%26spage%3D682%26epage%3D687" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Lanzi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cassinelli, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicolini, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zunino, F.</span><span> </span><span class="NLM_article-title">Targeting RET for thyroid cancer therapy</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">77</span><span class="NLM_x">, </span> <span class="NLM_fpage">297</span><span class="NLM_x">–</span> <span class="NLM_lpage">309</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2009&pages=297-309&author=C.+Lanziauthor=G.+Cassinelliauthor=V.+Nicoliniauthor=F.+Zunino&title=Targeting+RET+for+thyroid+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLanzi%26aufirst%3DC.%26aulast%3DCassinelli%26aufirst%3DG.%26aulast%3DNicolini%26aufirst%3DV.%26aulast%3DZunino%26aufirst%3DF.%26atitle%3DTargeting%2520RET%2520for%2520thyroid%2520cancer%2520therapy%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2009%26volume%3D77%26spage%3D297%26epage%3D309" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Biglietto, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maglione, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rambaldi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cerutti, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romano, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trapasso, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fedele, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ippolito, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiappetta, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Botti, G.</span><span> </span><span class="NLM_article-title">Upregulation of vascular endothelial growth factor (VEGF) and downregulation of placenta growth factor (PlGF) associated with malignancy in human thyroid tumors and cell lines</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1569</span><span class="NLM_x">–</span> <span class="NLM_lpage">1579</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=1995&pages=1569-1579&author=G.+Bigliettoauthor=D.+Maglioneauthor=M.+Rambaldiauthor=J.+Ceruttiauthor=A.+Romanoauthor=F.+Trapassoauthor=M.+Fedeleauthor=P.+Ippolitoauthor=G.+Chiappettaauthor=G.+Botti&title=Upregulation+of+vascular+endothelial+growth+factor+%28VEGF%29+and+downregulation+of+placenta+growth+factor+%28PlGF%29+associated+with+malignancy+in+human+thyroid+tumors+and+cell+lines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBiglietto%26aufirst%3DG.%26aulast%3DMaglione%26aufirst%3DD.%26aulast%3DRambaldi%26aufirst%3DM.%26aulast%3DCerutti%26aufirst%3DJ.%26aulast%3DRomano%26aufirst%3DA.%26aulast%3DTrapasso%26aufirst%3DF.%26aulast%3DFedele%26aufirst%3DM.%26aulast%3DIppolito%26aufirst%3DP.%26aulast%3DChiappetta%26aufirst%3DG.%26aulast%3DBotti%26aufirst%3DG.%26atitle%3DUpregulation%2520of%2520vascular%2520endothelial%2520growth%2520factor%2520%2528VEGF%2529%2520and%2520downregulation%2520of%2520placenta%2520growth%2520factor%2520%2528PlGF%2529%2520associated%2520with%2520malignancy%2520in%2520human%2520thyroid%2520tumors%2520and%2520cell%2520lines%26jtitle%3DOncogene%26date%3D1995%26volume%3D11%26spage%3D1569%26epage%3D1579" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Knauf, J. A.</span><span> </span><span class="NLM_article-title">Does the epidermal growth factor receptor play a role in the progression of thyroid cancer?</span> <span class="citation_source-journal">Thyroid.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">1171</span><span class="NLM_x">–</span> <span class="NLM_lpage">1174</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=1171-1174&author=J.+A.+Knauf&title=Does+the+epidermal+growth+factor+receptor+play+a+role+in+the+progression+of+thyroid+cancer%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKnauf%26aufirst%3DJ.%2BA.%26atitle%3DDoes%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520play%2520a%2520role%2520in%2520the%2520progression%2520of%2520thyroid%2520cancer%253F%26jtitle%3DThyroid.%26date%3D2011%26volume%3D21%26spage%3D1171%26epage%3D1174" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Ye, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santarpia, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gagel, R. F.</span><span> </span><span class="NLM_article-title">Targeted therapy for endocrine cancer: the medullary thyroid carcinoma paradigm</span> <span class="citation_source-journal">Endocr. Pract.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">597</span><span class="NLM_x">–</span> <span class="NLM_lpage">604</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Fjm401358b&amp;key=10.4158%2FEP09148.RAR" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Fjm401358b&amp;key=19546050" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm401358b&amp;key=1%3ACAS%3A280%3ADC%252BD1MjhsV2nuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=597-604&author=L.+Yeauthor=L.+Santarpiaauthor=R.+F.+Gagel&title=Targeted+therapy+for+endocrine+cancer%3A+the+medullary+thyroid+carcinoma+paradigm"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted therapy for endocrine cancer: the medullary thyroid carcinoma paradigm</span></div><div class="casAuthors">Ye Lei; Santarpia Libero; Gagel Robert F</div><div class="citationInfo"><span class="NLM_cas:title">Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">597-604</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVE:  To provide an overview of a new approach for treatment of medullary thyroid carcinoma (MTC) and other endocrine tumors.  METHODS:  This review compiles recent information from the medical literature and scientific meetings focused on the use of tyrosine kinase inhibitors (TKIs) for the treatment of MTC and other endocrine tumors.  RESULTS:  The elucidation during the past 2 decades of multiple genetic abnormalities in endocrine tumors has provided specific targets for therapy.  The identification of activating mutations of the RET tyrosine kinase receptor in both hereditary and sporadic MTC makes this malignant disease an excellent model for examination of the effect of a group of small organic molecule TKIs for treatment of metastatic MTC.  Clinical trials with several TKIs targeting RET and other tyrosine kinase receptors have shown positive results with generally tolerable toxicity.  Approximately one-third to one-half of patients with MTC have a reduction in tumor size of 0% to 50%, with the longest treatment duration of approximately 4 years.  The most common treatment-related toxic effects are cutaneous effects, nausea, and diarrhea.  Cardiovascular toxicity, such as hypertension, prolongation of the corrected QT interval, or heart failure, is uncommon but may be serious.  CONCLUSION:  Despite promising initial results, these studies are in their early stages, and none of these therapies is currently approved by the US Food and Drug Administration for treatment in the United States.  These studies highlight the potential for targeting endocrine cancer signaling pathways and provide a paradigm for treatment of endocrine cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRQlQm_c49yJkGy1nwu7K2mfW6udTcc2eZcT_MqBVmVsbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1MjhsV2nuw%253D%253D&md5=7a2294c883c223842c9af6d31db65745</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.4158%2FEP09148.RAR&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4158%252FEP09148.RAR%26sid%3Dliteratum%253Aachs%26aulast%3DYe%26aufirst%3DL.%26aulast%3DSantarpia%26aufirst%3DL.%26aulast%3DGagel%26aufirst%3DR.%2BF.%26atitle%3DTargeted%2520therapy%2520for%2520endocrine%2520cancer%253A%2520the%2520medullary%2520thyroid%2520carcinoma%2520paradigm%26jtitle%3DEndocr.%2520Pract.%26date%3D2009%26volume%3D15%26spage%3D597%26epage%3D604" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Gild, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bullock, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, B. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clifton-Bligh, R.</span><span> </span><span class="NLM_article-title">Multikinase inhibitors: a new option for the treatment of thyroid cancer</span> <span class="citation_source-journal">Nat. Rev. Endocrinol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">617</span><span class="NLM_x">–</span> <span class="NLM_lpage">624</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Fjm401358b&amp;key=10.1038%2Fnrendo.2011.141" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Fjm401358b&amp;key=21862995" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Fjm401358b&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1ajsr3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2011&pages=617-624&author=M.+L.+Gildauthor=M.+Bullockauthor=B.+G.+Robinsonauthor=R.+Clifton-Bligh&title=Multikinase+inhibitors%3A+a+new+option+for+the+treatment+of+thyroid+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Multikinase inhibitors: a new option for the treatment of thyroid cancer</span></div><div class="casAuthors">Gild, Matti L.; Bullock, Martyn; Robinson, Bruce G.; Clifton-Bligh, Roderick</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Endocrinology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">617-624</span>CODEN:
                <span class="NLM_cas:coden">NREABD</span>;
        ISSN:<span class="NLM_cas:issn">1759-5029</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Preclin. models have shown that inhibition of kinases in mitogenic and angiogenic signaling pathways can have antitumoral effects.  Starting with a brief synopsis of a malignancy that responds well to kinase inhibition (chronic myeloid leukemia) compared with one with less durable responses as yet (melanoma), this Review highlights challenges that must be overcome in order to successfully translate small-mol. therapies to thyroid cancer in the future.  Thyroid cancer typically has a good outcome following std. treatments, which include surgery, radioactive iodine ablation and treatment with TSH-suppressive levothyroxine.  Thyroid cancers that persist or recur following these therapies have a poorer prognosis.  Activation of mitogenic and angiogenic signaling pathways occurs in these cancers, and preclin. models have shown that inhibition of key kinase steps in these pathways can have antitumoral effects.  Several of these kinase inhibitors have now been tested in phase II and phase III trials, with modestly encouraging results.  Some promising data exist for the use of vandetanib (also known as ZD6474), motesanib, axitinib, cabozantinib (also known as XL184), sorafenib, sunitinib, pazopanib and lenvatinib (also known as E7080) in progressive thyroid cancer of medullary, papillary and follicular subtypes.  These drugs are generally well-tolerated, although dose-limiting toxicities are common, and a few (probable) treatment-related deaths have been reported.  Addnl. phase III trials will be needed to conclusively show that treatment benefit exceeds risk.  Drug resistance can occur via activation of alternate mitogenic signals (pathway switching), as has been reported for the use of kinase inhibitors in other malignancies, such as melanoma.  The hypothesis that combinations of kinase inhibitors targeting different pathways might produce better results is currently being tested in several clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXsZ46UZpqrbVg90H21EOLACvtfcHk0lj501uEH11B6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1ajsr3F&md5=7ac1c2c3f6693ac567c1c2000eda01c0</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fnrendo.2011.141&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrendo.2011.141%26sid%3Dliteratum%253Aachs%26aulast%3DGild%26aufirst%3DM.%2BL.%26aulast%3DBullock%26aufirst%3DM.%26aulast%3DRobinson%26aufirst%3DB.%2BG.%26aulast%3DClifton-Bligh%26aufirst%3DR.%26atitle%3DMultikinase%2520inhibitors%253A%2520a%2520new%2520option%2520for%2520the%2520treatment%2520of%2520thyroid%2520cancer%26jtitle%3DNat.%2520Rev.%2520Endocrinol.%26date%3D2011%26volume%3D7%26spage%3D617%26epage%3D624" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Wilhelm, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adnane, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newell, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villanueva, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Llovet, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, M.</span><span> </span><span class="NLM_article-title">Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">3129</span><span class="NLM_x">–</span> <span class="NLM_lpage">3140</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Fjm401358b&amp;key=10.1158%2F1535-7163.MCT-08-0013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Fjm401358b&amp;key=18852116" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm401358b&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1ensLfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=3129-3140&author=S.+M.+Wilhelmauthor=L.+Adnaneauthor=P.+Newellauthor=A.+Villanuevaauthor=J.+M.+Llovetauthor=M.+Lynch&title=Preclinical+overview+of+sorafenib%2C+a+multikinase+inhibitor+that+targets+both+Raf+and+VEGF+and+PDGF+receptor+tyrosine+kinase+signaling"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling</span></div><div class="casAuthors">Wilhelm, Scott M.; Adnane, Lila; Newell, Philippa; Villanueva, Augusto; Llovet, Josep M.; Lynch, Mark</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3129-3140</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Although patients with advanced refractory solid tumors have poor prognosis, the clin. development of targeted protein kinase inhibitors offers hope for the future treatment of many cancers.  In vivo and in vitro studies have shown that the oral multikinase inhibitor, sorafenib, inhibits tumor growth and disrupts tumor microvasculature through antiproliferative, antiangiogenic, and/or proapoptotic effects.  Sorafenib has shown antitumor activity in phase II/III trials involving patients with advanced renal cell carcinoma and hepatocellular carcinoma.  The multiple mol. targets of sorafenib (the serine/threonine kinase Raf and receptor tyrosine kinases) may explain its broad preclin. and clin. activity.  This review highlights the antitumor activity of sorafenib across a variety of tumor types, including renal cell, hepatocellular, breast, and colorectal carcinomas in the preclin. setting.  In particular, preclin. evidence that supports the different mechanisms of action of sorafenib is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUzT2_aZFYYLVg90H21EOLACvtfcHk0lj501uEH11B6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1ensLfE&md5=5811a502a95fc01db8b44da17e17f590</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-08-0013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-08-0013%26sid%3Dliteratum%253Aachs%26aulast%3DWilhelm%26aufirst%3DS.%2BM.%26aulast%3DAdnane%26aufirst%3DL.%26aulast%3DNewell%26aufirst%3DP.%26aulast%3DVillanueva%26aufirst%3DA.%26aulast%3DLlovet%26aufirst%3DJ.%2BM.%26aulast%3DLynch%26aufirst%3DM.%26atitle%3DPreclinical%2520overview%2520of%2520sorafenib%252C%2520a%2520multikinase%2520inhibitor%2520that%2520targets%2520both%2520Raf%2520and%2520VEGF%2520and%2520PDGF%2520receptor%2520tyrosine%2520kinase%2520signaling%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2008%26volume%3D7%26spage%3D3129%26epage%3D3140" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Gan, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seruga, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knox, J. J.</span><span> </span><span class="NLM_article-title">Sunitinib in solid tumors</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">821</span><span class="NLM_x">–</span> <span class="NLM_lpage">834</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Fjm401358b&amp;key=10.1517%2F13543780902980171" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Fjm401358b&amp;key=19453268" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm401358b&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmtlWqsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2009&pages=821-834&author=H.+K.+Ganauthor=B.+Serugaauthor=J.+J.+Knox&title=Sunitinib+in+solid+tumors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Sunitinib in solid tumors</span></div><div class="casAuthors">Gan, Hui K.; Seruga, Bostjan; Knox, Jennifer J.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">821-834</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Background: Until recently, few treatments were available for renal cell carcinoma (RCC) and gastrointestinal stromal tumors (GIST).  Several targeted agents inhibiting key pathogenetic pathways have since been developed for RCC (sunitinib, sorafenib, bevacizumab, temsirolimus, everolimus) and GIST (imatinib, sunitinib).  Sunitinib is a multi-kinase inhibitor of VEGFR-2, PDGFR (α,β), FLT-3, KIT, CSF-1 and RET.  Objective: To summarize the literature regarding the structure, pharmacokinetics, pharmacodynamics, toxicity and current clin. use of sunitinib.  Other potential roles for this drug in RCC, GIST and other tumor types will be discussed.  Methods: A literature search identified relevant (pre)clin. studies of sunitinib and other relevant agents.  Results/conclusions: Sunitinib revolutionized the management of advanced RCC and GIST.  With the realization that cross-resistance between targeted agents is incomplete, evolving strategies include sequential treatment, concurrent treatment, and biomarker development.  Sunitinib also shows promise in several other tumor types that lack therapeutic options.  What remains less clear is its role in tumors that are not heavily dependent on a central pathogenetic pathway, esp. if effective cytotoxic therapies exist.  Future clin. trials will clarify whether there is a role for sunitinib in these tumors, possibly in combination with cytotoxic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqShpbTMsQw4bVg90H21EOLACvtfcHk0lj501uEH11B6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmtlWqsLY%253D&md5=3d6fd5375ce16825e4a02d10b6545392</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1517%2F13543780902980171&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543780902980171%26sid%3Dliteratum%253Aachs%26aulast%3DGan%26aufirst%3DH.%2BK.%26aulast%3DSeruga%26aufirst%3DB.%26aulast%3DKnox%26aufirst%3DJ.%2BJ.%26atitle%3DSunitinib%2520in%2520solid%2520tumors%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2009%26volume%3D18%26spage%3D821%26epage%3D834" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Mologni, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Redaelli, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morandi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plaza-Menacho, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gambacorti-Passerini, C.</span><span> </span><span class="NLM_article-title">Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase</span> <span class="citation_source-journal">Mol. Cell. Endocrinol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">377</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">6</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Fjm401358b&amp;key=10.1016%2Fj.mce.2013.06.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Fjm401358b&amp;key=23811235" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Fjm401358b&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1GmurfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=377&publication_year=2013&pages=1-6&author=L.+Mologniauthor=S.+Redaelliauthor=A.+Morandiauthor=I.+Plaza-Menachoauthor=C.+Gambacorti-Passerini&title=Ponatinib+is+a+potent+inhibitor+of+wild-type+and+drug-resistant+gatekeeper+mutant+RET+kinase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase</span></div><div class="casAuthors">Mologni, Luca; Redaelli, Sara; Morandi, Andrea; Plaza-Menacho, Ivan; Gambacorti-Passerini, Carlo</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Endocrinology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">377</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">1-6</span>CODEN:
                <span class="NLM_cas:coden">MCEND6</span>;
        ISSN:<span class="NLM_cas:issn">0303-7207</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">RET kinase is aberrantly activated in thyroid cancers and in rare cases of lung and colon cancer, and has been validated as a mol. target in these tumors.  Vandetanib was recently approved for the treatment of medullary thyroid cancer.  However, vandetanib is ineffective in vitro against RET mutants carrying bulky aminoacids at position 804, the gatekeeper residue, similarly to drug-resistant BCR-ABL mutants in chronic myeloid leukemia.  Ponatinib is a multi-target kinase inhibitor that was recently approved for treatment-refractory Philadelphia-pos. leukemia.  We show here potent inhibition of oncogenic RET by ponatinib, including the drug-insensitive V804M/L mutants.  Ponatinib inhibited the growth of RET+ and BCR-ABL+ cells with similar potency, while not affecting RET-neg. cells.  Both in biochem. and in cellular assays ponatinib compared favorably with known RET inhibitors, such as vandetanib, cabozantinib, sorafenib, sunitinib and motesanib, used as ref. compds.  We suggest that ponatinib should be considered for the treatment of RET+ tumors, in particular those expressing vandetanib-resistant V804M/L mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrA1KRyhCS6ULVg90H21EOLACvtfcHk0liZrHqbYMKZMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1GmurfP&md5=f08de33f80af574f3ec843d26269ed98</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.mce.2013.06.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mce.2013.06.025%26sid%3Dliteratum%253Aachs%26aulast%3DMologni%26aufirst%3DL.%26aulast%3DRedaelli%26aufirst%3DS.%26aulast%3DMorandi%26aufirst%3DA.%26aulast%3DPlaza-Menacho%26aufirst%3DI.%26aulast%3DGambacorti-Passerini%26aufirst%3DC.%26atitle%3DPonatinib%2520is%2520a%2520potent%2520inhibitor%2520of%2520wild-type%2520and%2520drug-resistant%2520gatekeeper%2520mutant%2520RET%2520kinase%26jtitle%3DMol.%2520Cell.%2520Endocrinol.%26date%3D2013%26volume%3D377%26spage%3D1%26epage%3D6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Santos, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gomez, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raez, L. E.</span> <span class="citation_source-journal">Invest. New Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">1261</span><span class="NLM_x">–</span> <span class="NLM_lpage">1269</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Santos%2C+E.+S.%3B+Gomez%2C+J.+E.%3B+Raez%2C+L.+E.Invest.+New+Drugs+2012%2C+30%2C+1261%E2%80%931269"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSantos%26aufirst%3DE.%2BS.%26aulast%3DGomez%26aufirst%3DJ.%2BE.%26aulast%3DRaez%26aufirst%3DL.%2BE.%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2012%26volume%3D30%26spage%3D1261%26epage%3D1269" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Kelly, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rixe, O.</span><span> </span><span class="NLM_article-title">Axitinib—a selective inhibitor of the vascular endothelial growth factor (VEGF) receptor</span> <span class="citation_source-journal">Target Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">297</span><span class="NLM_x">–</span> <span class="NLM_lpage">305</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Fjm401358b&amp;key=10.1007%2Fs11523-009-0126-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm401358b&amp;key=1%3ACAS%3A280%3ADC%252BC3c%252FjvVemsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2009&pages=297-305&author=R.+J.+Kellyauthor=O.+Rixe&title=Axitinib%E2%80%94a+selective+inhibitor+of+the+vascular+endothelial+growth+factor+%28VEGF%29+receptor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Axitinib--a selective inhibitor of the vascular endothelial growth factor (VEGF) receptor</span></div><div class="casAuthors">Kelly Ronan J; Rixe Olivier</div><div class="citationInfo"><span class="NLM_cas:title">Targeted oncology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">297-305</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">An improved understanding of the molecular biology involved in many solid tumors has led to the development of novel targeted agents.  Axitinib is a potent and selective inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases 1, 2, and 3.  This review presents preclinical and clinical data available for axitinib, including findings from key phase II clinical trials in a wide variety of tumors including melanomas and renal, pancreatic, thyroid, breast, lung, and colorectal carcinomas.  The differences between axitinib and other VEGFR inhibitors are explored and details of the possible use of blood pressure elevation and erythropoietin blood levels as predictive markers of VEGF/VEGFR pathway inhibition are outlined.  Ongoing Phase III studies in pancreatic and metastatic renal cell carcinoma should help to determine the optimum utilization of these agents at the appropriate stage of disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS4hztAWPIRGr5oR8RchjrrfW6udTcc2eb3nmU1xgIaI7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3c%252FjvVemsA%253D%253D&md5=bc0d9cec7c1f2e72dc68001ad4d7a5e0</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1007%2Fs11523-009-0126-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11523-009-0126-9%26sid%3Dliteratum%253Aachs%26aulast%3DKelly%26aufirst%3DR.%2BJ.%26aulast%3DRixe%26aufirst%3DO.%26atitle%3DAxitinib%25E2%2580%2594a%2520selective%2520inhibitor%2520of%2520the%2520vascular%2520endothelial%2520growth%2520factor%2520%2528VEGF%2529%2520receptor%26jtitle%3DTarget%2520Oncol.%26date%3D2009%26volume%3D4%26spage%3D297%26epage%3D305" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Bible, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suman, V. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menefee, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smallridge, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molina, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maples, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karlin, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Traynor, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumar, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goh, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lim, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bossou, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isham, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webster, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kukla, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bieber, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burton, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erlichman, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayo Phase 2 Consortium</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayo Clinic Endocrine Malignances Disease Oriented Group.</span><span> </span><span class="NLM_article-title">A multiinstitutional phase 2 trial of pazopanib monotherapy in advanced anaplastic thyroid cancer</span> <span class="citation_source-journal">J. Clin. Endocrinol. Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">97</span><span class="NLM_x">, </span> <span class="NLM_fpage">3179</span><span class="NLM_x">–</span> <span class="NLM_lpage">3184</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Fjm401358b&amp;key=10.1210%2Fjc.2012-1520" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Fjm401358b&amp;key=22774206" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Fjm401358b&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhtlymu7vM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2012&pages=3179-3184&author=K.+C.+Bibleauthor=V.+J.+Sumanauthor=M.+E.+Menefeeauthor=R.+C.+Smallridgeauthor=J.+R.+Molinaauthor=W.+J.+Maplesauthor=N.+J.+Karlinauthor=A.+M.+Traynorauthor=P.+Kumarauthor=B.+C.+Gohauthor=W.+T.+Limauthor=A.+R.+Bossouauthor=C.+R.+Ishamauthor=K.+P.+Websterauthor=A.+K.+Kuklaauthor=C.+Bieberauthor=J.+K.+Burtonauthor=P.+Harrisauthor=C.+Erlichmanauthor=Mayo+Phase+2+Consortiumauthor=Mayo+Clinic+Endocrine+Malignances+Disease+Oriented+Group.&title=A+multiinstitutional+phase+2+trial+of+pazopanib+monotherapy+in+advanced+anaplastic+thyroid+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">A multiinstitutional phase 2 trial of pazopanib monotherapy in advanced anaplastic thyroid cancer</span></div><div class="casAuthors">Bible, Keith C.; Suman, Vera J.; Menefee, Michael E.; Smallridge, Robert C.; Molina, Julian R.; Maples, William J.; Karlin, Nina J.; Traynor, Anne M.; Kumar, Priya; Goh, Boon Cher; Lim, Wan-Teck; Bossou, Ayoko R.; Isham, Crescent R.; Webster, Kevin P.; Kukla, Andrea K.; Bieber, Carolyn; Burton, Jill K.; Harris, Pamela; Erlichman, Charles</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Endocrinology and Metabolism</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3179-3184</span>CODEN:
                <span class="NLM_cas:coden">JCEMAZ</span>;
        ISSN:<span class="NLM_cas:issn">0021-972X</span>.
    
            (<span class="NLM_cas:orgname">Endocrine Society</span>)
        </div><div class="casAbstract">Context/Objectives: Pazopanib, an inhibitor of kinases including vascular endothelial growth factor receptor, demonstrated impressive activity in progressive metastatic differentiated thyroid cancer, prompting its evaluation in anaplastic thyroid cancer (ATC).  Design/Setting/Patients/Interventions/Outcome Measures: Preclin. studies, followed by a multicenter single arm phase 2 trial of continuously administered 800 mg pazopanib daily by mouth (designed to provide 90% chance of detecting a response rate of >20% at the 0.10 significance level when the true response rate is >5%), were undertaken.  The primary trial end point was Response Evaluation Criteria in Solid Tumors (RECIST) response.  Results: Pazopanib displayed activity in the KTC2 ATC xenograft model, prompting clin. evaluation.  Sixteen trial patients were enrolled; 15 were treated: 66.7% were female, median age was 66 yr (range 45-77 yr), and 11 of 15 had progressed through prior systemic therapy.  Enrollment was halted, triggered by a stopping rule requiring more than one confirmed RECIST response among the first 14 of 33 potential patients.  Four patients required one to two dose redns.; severe toxicities (National Cancer Institute Common Toxicity Criteria-Adverse Events version 3.0 grades >3) were hypertension (13%) and pharyngolaryngeal pain (13%).  Treatment was discontinued because of the following: disease progression (12 patients), death due to a possibly treatment-related tumor hemorrhage (one patient), and intolerability (radiation recall tracheitis and uncontrolled hypertension, one patient each).  Although transient disease regression was obsd. in several patients, there were no confirmed RECIST responses.  Median time to progression was 62 d; median survival time was 111 d.  Two patients are alive with disease 9.9 and 35 mo after the registration; 13 died of disease.  Conclusions: Despite preclin. in vivo activity in ATC, pazopanib has minimal single-agent clin. activity in advanced ATC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGzLGUlkfYkLVg90H21EOLACvtfcHk0liZrHqbYMKZMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhtlymu7vM&md5=99a0db07f2d9c2df87915629e9e991bf</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1210%2Fjc.2012-1520&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fjc.2012-1520%26sid%3Dliteratum%253Aachs%26aulast%3DBible%26aufirst%3DK.%2BC.%26aulast%3DSuman%26aufirst%3DV.%2BJ.%26aulast%3DMenefee%26aufirst%3DM.%2BE.%26aulast%3DSmallridge%26aufirst%3DR.%2BC.%26aulast%3DMolina%26aufirst%3DJ.%2BR.%26aulast%3DMaples%26aufirst%3DW.%2BJ.%26aulast%3DKarlin%26aufirst%3DN.%2BJ.%26aulast%3DTraynor%26aufirst%3DA.%2BM.%26aulast%3DKumar%26aufirst%3DP.%26aulast%3DGoh%26aufirst%3DB.%2BC.%26aulast%3DLim%26aufirst%3DW.%2BT.%26aulast%3DBossou%26aufirst%3DA.%2BR.%26aulast%3DIsham%26aufirst%3DC.%2BR.%26aulast%3DWebster%26aufirst%3DK.%2BP.%26aulast%3DKukla%26aufirst%3DA.%2BK.%26aulast%3DBieber%26aufirst%3DC.%26aulast%3DBurton%26aufirst%3DJ.%2BK.%26aulast%3DHarris%26aufirst%3DP.%26aulast%3DErlichman%26aufirst%3DC.%26aulast%3D%26aulast%3D%26atitle%3DA%2520multiinstitutional%2520phase%25202%2520trial%2520of%2520pazopanib%2520monotherapy%2520in%2520advanced%2520anaplastic%2520thyroid%2520cancer%26jtitle%3DJ.%2520Clin.%2520Endocrinol.%2520Metab.%26date%3D2012%26volume%3D97%26spage%3D3179%26epage%3D3184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Durante, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paciaroni, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plasmati, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trulli, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Filetti, S.</span><span> </span><span class="NLM_article-title">Vandetanib: opening a new treatment practice in advanced medullary thyroid carcinoma</span> <span class="citation_source-journal">Endocrine</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">334</span><span class="NLM_x">–</span> <span class="NLM_lpage">342</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2013&pages=334-342&author=C.+Duranteauthor=A.+Paciaroniauthor=K.+Plasmatiauthor=F.+Trulliauthor=S.+Filetti&title=Vandetanib%3A+opening+a+new+treatment+practice+in+advanced+medullary+thyroid+carcinoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDurante%26aufirst%3DC.%26aulast%3DPaciaroni%26aufirst%3DA.%26aulast%3DPlasmati%26aufirst%3DK.%26aulast%3DTrulli%26aufirst%3DF.%26aulast%3DFiletti%26aufirst%3DS.%26atitle%3DVandetanib%253A%2520opening%2520a%2520new%2520treatment%2520practice%2520in%2520advanced%2520medullary%2520thyroid%2520carcinoma%26jtitle%3DEndocrine%26date%3D2013%26volume%3D44%26spage%3D334%26epage%3D342" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Nagilla, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, E. E.</span><span> </span><span class="NLM_article-title">Cabozantinib for the treatment of advanced medullary thyroid cancer</span> <span class="citation_source-journal">Adv Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">925</span><span class="NLM_x">–</span> <span class="NLM_lpage">934</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2012&pages=925-934&author=M.+Nagillaauthor=R.+L.+Brownauthor=E.+E.+Cohen&title=Cabozantinib+for+the+treatment+of+advanced+medullary+thyroid+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNagilla%26aufirst%3DM.%26aulast%3DBrown%26aufirst%3DR.%2BL.%26aulast%3DCohen%26aufirst%3DE.%2BE.%26atitle%3DCabozantinib%2520for%2520the%2520treatment%2520of%2520advanced%2520medullary%2520thyroid%2520cancer%26jtitle%3DAdv%2520Ther.%26date%3D2012%26volume%3D29%26spage%3D925%26epage%3D934" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Chaud, N. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haddad, R. I.</span><span> </span><span class="NLM_article-title">Vandetanib for the treatment of medullary thyroid cancer</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">6</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2012&pages=1-6&author=N.+G.+Chaudauthor=R.+I.+Haddad&title=Vandetanib+for+the+treatment+of+medullary+thyroid+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChaud%26aufirst%3DN.%2BG.%26aulast%3DHaddad%26aufirst%3DR.%2BI.%26atitle%3DVandetanib%2520for%2520the%2520treatment%2520of%2520medullary%2520thyroid%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D19%26spage%3D1%26epage%3D6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Lombardo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baudin, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiefari, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arturi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bardet, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caillou, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conte, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dallapiccola, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giuffrida, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bidart, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlumberger, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Filetti, S.</span><span> </span><span class="NLM_article-title">Familial medullary thyroid carcinoma: clinical variability and low aggressiveness associated with RET mutation at codon 804</span> <span class="citation_source-journal">J. Clin. Endocrinol. Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">87</span><span class="NLM_x">, </span> <span class="NLM_fpage">1674</span><span class="NLM_x">–</span> <span class="NLM_lpage">1680</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Fjm401358b&amp;key=10.1210%2Fjcem.87.4.8403" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Fjm401358b&amp;key=11932300" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Fjm401358b&amp;key=1%3ACAS%3A528%3ADC%252BD38XivFKltb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2002&pages=1674-1680&author=F.+Lombardoauthor=E.+Baudinauthor=E.+Chiefariauthor=F.+Arturiauthor=S.+Bardetauthor=B.+Caillouauthor=C.+Conteauthor=B.+Dallapiccolaauthor=D.+Giuffridaauthor=J.+M.+Bidartauthor=M.+Schlumbergerauthor=S.+Filetti&title=Familial+medullary+thyroid+carcinoma%3A+clinical+variability+and+low+aggressiveness+associated+with+RET+mutation+at+codon+804"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Familial medullary thyroid carcinoma: clinical variability and low aggressiveness associated with RET mutation at codon 804</span></div><div class="casAuthors">Lombardo, Francesca; Baudin, Eric; Chiefari, Eusebio; Arturi, Franco; Bardet, Stephane; Caillou, Bernard; Conte, Chiara; Dallapiccola, Bruno; Giuffrida, Dario; Bidart, Jean-Michel; Schlumberger, Martin; Filetti, Sebastiano</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Endocrinology and Metabolism</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1674-1680</span>CODEN:
                <span class="NLM_cas:coden">JCEMAZ</span>;
        ISSN:<span class="NLM_cas:issn">0021-972X</span>.
    
            (<span class="NLM_cas:orgname">Endocrine Society</span>)
        </div><div class="casAbstract">Sixty-one heterozygotes harboring the germline V804L mutation of the RET protooncogene were identified in five independent families.  A total of 31 subjects underwent surgery.  Histol. identified C cell hyperplasia in 30 cases, isolated in 12 and assocd. with medullary thyroid carcinoma (MTC) in 18.  Six patients with MTC had lymph node metastases.  Among the 14 patients with basal detectable calcitonin (CT) level, 12 had MTC and 2 had isolated C cell hyperplasia.  In most individuals carrying 804 RET mutation, C cell disease displayed late onset and an indolent course; a pentagastrin test was neg. in the majority of heterozygotes during the first 2 decades and was pos. in only half of them during the third and fourth decades of life.  Interestingly, concomitant somatic M918T was detected in a 12-yr-old girl with MTC and was likely to be responsible for both the early clin. appearance and the aggressiveness of the disease.  Our data show that in these gene carriers, surgery may be postponed to the fourth decade of life or until the pentagastrin stimulation test becomes pos.  Indeed, our data should be confirmed on a larger series of V804L carriers, but may offer a balanced strategy to keep under control and prevent development of the full disease phenotype.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGA2T8pRs9YrVg90H21EOLACvtfcHk0lhLjrf6kD2kmw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XivFKltb8%253D&md5=f7b24f6215486b5b35b9164f08ab65b2</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1210%2Fjcem.87.4.8403&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fjcem.87.4.8403%26sid%3Dliteratum%253Aachs%26aulast%3DLombardo%26aufirst%3DF.%26aulast%3DBaudin%26aufirst%3DE.%26aulast%3DChiefari%26aufirst%3DE.%26aulast%3DArturi%26aufirst%3DF.%26aulast%3DBardet%26aufirst%3DS.%26aulast%3DCaillou%26aufirst%3DB.%26aulast%3DConte%26aufirst%3DC.%26aulast%3DDallapiccola%26aufirst%3DB.%26aulast%3DGiuffrida%26aufirst%3DD.%26aulast%3DBidart%26aufirst%3DJ.%2BM.%26aulast%3DSchlumberger%26aufirst%3DM.%26aulast%3DFiletti%26aufirst%3DS.%26atitle%3DFamilial%2520medullary%2520thyroid%2520carcinoma%253A%2520clinical%2520variability%2520and%2520low%2520aggressiveness%2520associated%2520with%2520RET%2520mutation%2520at%2520codon%2520804%26jtitle%3DJ.%2520Clin.%2520Endocrinol.%2520Metab.%26date%3D2002%26volume%3D87%26spage%3D1674%26epage%3D1680" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Radi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tintori, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Musumeci, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brullo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zamperini, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drenassi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fallacara, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vignaioli, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crespan, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zanoli, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laurenzana, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Filippi, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maga, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schenone, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angelucci, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Botta, M.</span><span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of pyrazolo[3,4-<i>d</i>]pyrimidines active in vivo on the Bcr-Abl T315I mutant</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">5382</span><span class="NLM_x">–</span> <span class="NLM_lpage">5394</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm400233w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=5382-5394&author=M.+Radiauthor=C.+Tintoriauthor=F.+Musumeciauthor=C.+Brulloauthor=C.+Zamperiniauthor=E.+Drenassiauthor=A.+Fallacaraauthor=G.+Vignaioliauthor=E.+Crespanauthor=S.+Zanoliauthor=I.+Laurenzanaauthor=I.+Filippiauthor=G.+Magaauthor=S.+Schenoneauthor=A.+Angelucciauthor=M.+Botta&title=Design%2C+synthesis%2C+and+biological+evaluation+of+pyrazolo%5B3%2C4-d%5Dpyrimidines+active+in+vivo+on+the+Bcr-Abl+T315I+mutant"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fjm400233w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400233w%26sid%3Dliteratum%253Aachs%26aulast%3DRadi%26aufirst%3DM.%26aulast%3DTintori%26aufirst%3DC.%26aulast%3DMusumeci%26aufirst%3DF.%26aulast%3DBrullo%26aufirst%3DC.%26aulast%3DZamperini%26aufirst%3DC.%26aulast%3DDrenassi%26aufirst%3DE.%26aulast%3DFallacara%26aufirst%3DA.%26aulast%3DVignaioli%26aufirst%3DG.%26aulast%3DCrespan%26aufirst%3DE.%26aulast%3DZanoli%26aufirst%3DS.%26aulast%3DLaurenzana%26aufirst%3DI.%26aulast%3DFilippi%26aufirst%3DI.%26aulast%3DMaga%26aufirst%3DG.%26aulast%3DSchenone%26aufirst%3DS.%26aulast%3DAngelucci%26aufirst%3DA.%26aulast%3DBotta%26aufirst%3DM.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520pyrazolo%255B3%252C4-d%255Dpyrimidines%2520active%2520in%2520vivo%2520on%2520the%2520Bcr-Abl%2520T315I%2520mutant%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D5382%26epage%3D5394" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Yang, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, G. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, Q. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, S. Y.</span><span> </span><span class="NLM_article-title">Structure–activity relationship studies of pyrazolo[3,4-<i>d</i>]pyrimidine derivatives leading to the discovery of a novel multikinase inhibitor that potently inhibits FLT3 and VEGFR2 and evaluation of its activity against acute myeloid leukemia in vitro and in vivo</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">1641</span><span class="NLM_x">–</span> <span class="NLM_lpage">1655</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm301537p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=1641-1655&author=L.+L.+Yangauthor=G.+B.+Liauthor=S.+Maauthor=C.+Zouauthor=S.+Zhouauthor=Q.+Z.+Sunauthor=C.+Chengauthor=X.+Chenauthor=L.+J.+Wangauthor=S.+Fengauthor=L.+L.+Liauthor=S.+Y.+Yang&title=Structure%E2%80%93activity+relationship+studies+of+pyrazolo%5B3%2C4-d%5Dpyrimidine+derivatives+leading+to+the+discovery+of+a+novel+multikinase+inhibitor+that+potently+inhibits+FLT3+and+VEGFR2+and+evaluation+of+its+activity+against+acute+myeloid+leukemia+in+vitro+and+in+vivo"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fjm301537p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301537p%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DL.%2BL.%26aulast%3DLi%26aufirst%3DG.%2BB.%26aulast%3DMa%26aufirst%3DS.%26aulast%3DZou%26aufirst%3DC.%26aulast%3DZhou%26aufirst%3DS.%26aulast%3DSun%26aufirst%3DQ.%2BZ.%26aulast%3DCheng%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DL.%2BJ.%26aulast%3DFeng%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DL.%2BL.%26aulast%3DYang%26aufirst%3DS.%2BY.%26atitle%3DStructure%25E2%2580%2593activity%2520relationship%2520studies%2520of%2520pyrazolo%255B3%252C4-d%255Dpyrimidine%2520derivatives%2520leading%2520to%2520the%2520discovery%2520of%2520a%2520novel%2520multikinase%2520inhibitor%2520that%2520potently%2520inhibits%2520FLT3%2520and%2520VEGFR2%2520and%2520evaluation%2520of%2520its%2520activity%2520against%2520acute%2520myeloid%2520leukemia%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D1641%26epage%3D1655" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Dinér, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alao, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Söderlund, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sunnerhagen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grøtli, M.</span><span> </span><span class="NLM_article-title">Preparation of 3-substituted-1-isopropyl-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-amines as RET kinase inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">4872</span><span class="NLM_x">–</span> <span class="NLM_lpage">4876</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm3003944" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=4872-4876&author=P.+Din%C3%A9rauthor=J.+P.+Alaoauthor=J.+S%C3%B6derlundauthor=P.+Sunnerhagenauthor=M.+Gr%C3%B8tli&title=Preparation+of+3-substituted-1-isopropyl-1H-pyrazolo%5B3%2C4-d%5Dpyrimidin-4-amines+as+RET+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm3003944&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3003944%26sid%3Dliteratum%253Aachs%26aulast%3DDin%25C3%25A9r%26aufirst%3DP.%26aulast%3DAlao%26aufirst%3DJ.%2BP.%26aulast%3DS%25C3%25B6derlund%26aufirst%3DJ.%26aulast%3DSunnerhagen%26aufirst%3DP.%26aulast%3DGr%25C3%25B8tli%26aufirst%3DM.%26atitle%3DPreparation%2520of%25203-substituted-1-isopropyl-1H-pyrazolo%255B3%252C4-d%255Dpyrimidin-4-amines%2520as%2520RET%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D4872%26epage%3D4876" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Le Brazidec, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pasis, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tam, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boykin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Black, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Claassen, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chong, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silvian, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ling, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teng, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pathan, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taveras, A.</span><span> </span><span class="NLM_article-title">Synthesis, SAR and biological evaluation of 1,6-disubstituted-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidines as dual inhibitors of Aurora kinases and CDK1</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">2070</span><span class="NLM_x">–</span> <span class="NLM_lpage">2074</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=2070-2074&author=J.+Y.+Le+Brazidecauthor=A.+Pasisauthor=B.+Tamauthor=C.+Boykinauthor=C.+Blackauthor=D.+Wangauthor=G.+Claassenauthor=J.+H.+Chongauthor=J.+Chaoauthor=J.+Fanauthor=K.+Nguyenauthor=L.+Silvianauthor=L.+Lingauthor=L.+Zhangauthor=M.+Choiauthor=M.+Tengauthor=N.+Pathanauthor=S.+Zhaoauthor=T.+Liauthor=A.+Taveras&title=Synthesis%2C+SAR+and+biological+evaluation+of+1%2C6-disubstituted-1H-pyrazolo%5B3%2C4-d%5Dpyrimidines+as+dual+inhibitors+of+Aurora+kinases+and+CDK1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLe%2BBrazidec%26aufirst%3DJ.%2BY.%26aulast%3DPasis%26aufirst%3DA.%26aulast%3DTam%26aufirst%3DB.%26aulast%3DBoykin%26aufirst%3DC.%26aulast%3DBlack%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DClaassen%26aufirst%3DG.%26aulast%3DChong%26aufirst%3DJ.%2BH.%26aulast%3DChao%26aufirst%3DJ.%26aulast%3DFan%26aufirst%3DJ.%26aulast%3DNguyen%26aufirst%3DK.%26aulast%3DSilvian%26aufirst%3DL.%26aulast%3DLing%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DChoi%26aufirst%3DM.%26aulast%3DTeng%26aufirst%3DM.%26aulast%3DPathan%26aufirst%3DN.%26aulast%3DZhao%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DT.%26aulast%3DTaveras%26aufirst%3DA.%26atitle%3DSynthesis%252C%2520SAR%2520and%2520biological%2520evaluation%2520of%25201%252C6-disubstituted-1H-pyrazolo%255B3%252C4-d%255Dpyrimidines%2520as%2520dual%2520inhibitors%2520of%2520Aurora%2520kinases%2520and%2520CDK1%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D2070%26epage%3D2074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Antonelli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bocci, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">La Motta, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrari, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fallahi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fioravanti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sartini, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minuto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piaggi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alì, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berti, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fontanini, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Danesi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Da Settimo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miccoli, P.</span><span> </span><span class="NLM_article-title">Novel pyrazolopyrimidine derivatives as tyrosine kinase inhibitors with antitumoral activity in vitro and in vivo in papillary dedifferentiated thyroid cancer</span> <span class="citation_source-journal">J. Clin. Endocrinol. Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">96</span><span class="NLM_x">, </span> <span class="NLM_fpage">E288</span><span class="NLM_x">–</span> <span class="NLM_lpage">E296</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2011&pages=E288-E296&author=A.+Antonelliauthor=G.+Bocciauthor=C.+La+Mottaauthor=S.+M.+Ferrariauthor=P.+Fallahiauthor=A.+Fioravantiauthor=S.+Sartiniauthor=M.+Minutoauthor=S.+Piaggiauthor=A.+Cortiauthor=G.+Al%C3%ACauthor=P.+Bertiauthor=G.+Fontaniniauthor=R.+Danesiauthor=F.+Da+Settimoauthor=P.+Miccoli&title=Novel+pyrazolopyrimidine+derivatives+as+tyrosine+kinase+inhibitors+with+antitumoral+activity+in+vitro+and+in+vivo+in+papillary+dedifferentiated+thyroid+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAntonelli%26aufirst%3DA.%26aulast%3DBocci%26aufirst%3DG.%26aulast%3DLa%2BMotta%26aufirst%3DC.%26aulast%3DFerrari%26aufirst%3DS.%2BM.%26aulast%3DFallahi%26aufirst%3DP.%26aulast%3DFioravanti%26aufirst%3DA.%26aulast%3DSartini%26aufirst%3DS.%26aulast%3DMinuto%26aufirst%3DM.%26aulast%3DPiaggi%26aufirst%3DS.%26aulast%3DCorti%26aufirst%3DA.%26aulast%3DAl%25C3%25AC%26aufirst%3DG.%26aulast%3DBerti%26aufirst%3DP.%26aulast%3DFontanini%26aufirst%3DG.%26aulast%3DDanesi%26aufirst%3DR.%26aulast%3DDa%2BSettimo%26aufirst%3DF.%26aulast%3DMiccoli%26aufirst%3DP.%26atitle%3DNovel%2520pyrazolopyrimidine%2520derivatives%2520as%2520tyrosine%2520kinase%2520inhibitors%2520with%2520antitumoral%2520activity%2520in%2520vitro%2520and%2520in%2520vivo%2520in%2520papillary%2520dedifferentiated%2520thyroid%2520cancer%26jtitle%3DJ.%2520Clin.%2520Endocrinol.%2520Metab.%26date%3D2011%26volume%3D96%26spage%3DE288%26epage%3DE296" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Bocci, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fioravanti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">La Motta, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orlandi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Canu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Desidero, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mugnaini, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sartini, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cosconati, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frati, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Antonelli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berti, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miccoli, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Da Settimo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Danesi, R.</span><span> </span><span class="NLM_article-title">Antiproliferative and proapoptotic activity of CLM3, a novel multiple tyrosine kinase inhibitor, alone and in combination with SN-38 on endothelial and cancer cells</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">81</span><span class="NLM_x">, </span> <span class="NLM_fpage">1309</span><span class="NLM_x">–</span> <span class="NLM_lpage">1316</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2011&pages=1309-1316&author=G.+Bocciauthor=A.+Fioravantiauthor=C.+La+Mottaauthor=P.+Orlandiauthor=B.+Canuauthor=T.+Di+Desideroauthor=L.+Mugnainiauthor=S.+Sartiniauthor=S.+Cosconatiauthor=R.+Fratiauthor=A.+Antonelliauthor=P.+Bertiauthor=P.+Miccoliauthor=F.+Da+Settimoauthor=R.+Danesi&title=Antiproliferative+and+proapoptotic+activity+of+CLM3%2C+a+novel+multiple+tyrosine+kinase+inhibitor%2C+alone+and+in+combination+with+SN-38+on+endothelial+and+cancer+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBocci%26aufirst%3DG.%26aulast%3DFioravanti%26aufirst%3DA.%26aulast%3DLa%2BMotta%26aufirst%3DC.%26aulast%3DOrlandi%26aufirst%3DP.%26aulast%3DCanu%26aufirst%3DB.%26aulast%3DDi%2BDesidero%26aufirst%3DT.%26aulast%3DMugnaini%26aufirst%3DL.%26aulast%3DSartini%26aufirst%3DS.%26aulast%3DCosconati%26aufirst%3DS.%26aulast%3DFrati%26aufirst%3DR.%26aulast%3DAntonelli%26aufirst%3DA.%26aulast%3DBerti%26aufirst%3DP.%26aulast%3DMiccoli%26aufirst%3DP.%26aulast%3DDa%2BSettimo%26aufirst%3DF.%26aulast%3DDanesi%26aufirst%3DR.%26atitle%3DAntiproliferative%2520and%2520proapoptotic%2520activity%2520of%2520CLM3%252C%2520a%2520novel%2520multiple%2520tyrosine%2520kinase%2520inhibitor%252C%2520alone%2520and%2520in%2520combination%2520with%2520SN-38%2520on%2520endothelial%2520and%2520cancer%2520cells%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2011%26volume%3D81%26spage%3D1309%26epage%3D1316" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yin, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leonard, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sioson, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lapo, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, S.</span><span> </span><span class="NLM_article-title">A variation of the Fischer indolization involving condensation of quinone monoketals and aliphatic hydrazines</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">1753</span><span class="NLM_x">–</span> <span class="NLM_lpage">1757</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Fjm401358b&amp;key=10.1002%2Fanie.201207533" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Fjm401358b&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjtV2ntg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2013&pages=1753-1757&author=J.+Zhangauthor=Z.+Yinauthor=P.+Leonardauthor=J.+Wuauthor=K.+Siosonauthor=C.+Liuauthor=R.+Lapoauthor=S.+Zheng&title=A+variation+of+the+Fischer+indolization+involving+condensation+of+quinone+monoketals+and+aliphatic+hydrazines"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">A Variation of the Fischer Indolization Involving Condensation of Quinone Monoketals and Aliphatic Hydrazines</span></div><div class="casAuthors">Zhang, Jinzhu; Yin, Zhiwei; Leonard, Patrick; Wu, Jing; Sioson, Kate; Liu, Che; Lapo, Robert; Zheng, Shengping</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1753-1757</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A variation of the the Fischer indole synthesis was developed.  Reaction of quinone monoketals with aliph. hydrazines afforded the indoles, via alkylaryldiazenes, in a one-pot method.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPkRZHEdUS67Vg90H21EOLACvtfcHk0ljQ4bgABxg1dg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjtV2ntg%253D%253D&md5=066ab4287f9756ddf33c13e6aa3eb40d</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1002%2Fanie.201207533&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201207533%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DYin%26aufirst%3DZ.%26aulast%3DLeonard%26aufirst%3DP.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DSioson%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DLapo%26aufirst%3DR.%26aulast%3DZheng%26aufirst%3DS.%26atitle%3DA%2520variation%2520of%2520the%2520Fischer%2520indolization%2520involving%2520condensation%2520of%2520quinone%2520monoketals%2520and%2520aliphatic%2520hydrazines%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2013%26volume%3D52%26spage%3D1753%26epage%3D1757" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span> <span class="citation_source-book">Glide</span>, version <span class="NLM_edition">5.5</span>; <span class="NLM_publisher-name">Schrodinger, LLC</span>: <span class="NLM_publisher-loc">New York</span>,<span class="NLM_x"> </span><span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Glide%2C+version+5.5%3B+Schrodinger%2C+LLC%3A+New+York%2C+2009."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26btitle%3DGlide%26pub%3DSchrodinger%252C%2520LLC%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">McTigue, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solowiej, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kania, R. S.</span><span> </span><span class="NLM_article-title">Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">109</span><span class="NLM_x">, </span> <span class="NLM_fpage">18281</span><span class="NLM_x">–</span> <span class="NLM_lpage">18289</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Fjm401358b&amp;key=10.1073%2Fpnas.1207759109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Fjm401358b&amp;key=22988103" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Fjm401358b&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhslymtb3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2012&pages=18281-18289&author=M.+McTigueauthor=B.+W.+Murrayauthor=J.+H.+Chenauthor=Y.+L.+Dengauthor=J.+Solowiejauthor=R.+S.+Kania&title=Molecular+conformations%2C+interactions%2C+and+properties+associated+with+drug+efficiency+and+clinical+performance+among+VEGFR+TK+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors</span></div><div class="casAuthors">McTigue, Michele; Murray, Brion William; Chen, Jeffrey H.; Deng, Ya-Li; Solowiej, James; Kania, Robert S.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">45</span>),
    <span class="NLM_cas:pages">18281-18289, S18281/1-S18281/7</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Analyses of compds. in clin. development have shown that ligand efficient-mols. with privileged phys. properties and low dose are less likely to fail in the various stages of clin. testing, have fewer postapproval withdrawals, and are less likely to receive black box safety warnings.  However, detailed side-by-side examn. of mol. interactions and properties within single drug classes are lacking.  As a class, VEGF receptor tyrosine kinase inhibitors (VEGFR TKIs) have changed the landscape of how cancer is treated, particularly in clear cell renal cell carcinoma, which is molecularly linked to the VEGF signaling axis.  Despite the clear role of the mol. target, member mols. of this validated drug class exhibit distinct clin. efficacy and safety profiles in comparable renal cell carcinoma clin. studies.  The first head-to-head randomized phase III comparative study between active VEGFR TKIs has confirmed significant differences in clin. performance.  To elucidate how fundamental drug potency-efficiency is achieved and impacts differentiation within the VEGFR TKI class, we detd. potencies, time dependence, selectivities, and X-ray structures of the drug-kinase complexes using a VEGFR2 TK construct inclusive of the important juxtamembrane domain.  Collectively, the studies elucidate unique drug-kinase interactions that are dependent on distinct juxtamembrane domain conformations, resulting in significant potency and ligand efficiency differences.  The identified structural trends are consistent with in vitro measurements, which translate well to clin. performance, underscoring a principle that may be broadly applicable to prospective drug design for optimal in vivo performance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsIUWiD4sXtbVg90H21EOLACvtfcHk0lhre0L57ya95g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhslymtb3I&md5=4a5ec677298a8c924c0f9557ca688a79</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1207759109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1207759109%26sid%3Dliteratum%253Aachs%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DMurray%26aufirst%3DB.%2BW.%26aulast%3DChen%26aufirst%3DJ.%2BH.%26aulast%3DDeng%26aufirst%3DY.%2BL.%26aulast%3DSolowiej%26aufirst%3DJ.%26aulast%3DKania%26aufirst%3DR.%2BS.%26atitle%3DMolecular%2520conformations%252C%2520interactions%252C%2520and%2520properties%2520associated%2520with%2520drug%2520efficiency%2520and%2520clinical%2520performance%2520among%2520VEGFR%2520TK%2520inhibitors%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2012%26volume%3D109%26spage%3D18281%26epage%3D18289" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Knowles, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray-Rust, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kjaer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanrahan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santoro, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ibáñez, C. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonald, N. Q.</span><span> </span><span class="NLM_article-title">Structure and chemical inhibition of the RET tyrosine kinase domain</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">281</span><span class="NLM_x">, </span> <span class="NLM_fpage">33577</span><span class="NLM_x">–</span> <span class="NLM_lpage">33587</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Fjm401358b&amp;key=10.1074%2Fjbc.M605604200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Fjm401358b&amp;key=16928683" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Fjm401358b&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFegsb3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=281&publication_year=2006&pages=33577-33587&author=P.+P.+Knowlesauthor=J.+Murray-Rustauthor=S.+Kjaerauthor=R.+P.+Scottauthor=S.+Hanrahanauthor=M.+Santoroauthor=C.+F.+Ib%C3%A1%C3%B1ezauthor=N.+Q.+McDonald&title=Structure+and+chemical+inhibition+of+the+RET+tyrosine+kinase+domain"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Structure and Chemical Inhibition of the RET Tyrosine Kinase Domain</span></div><div class="casAuthors">Knowles, Phillip P.; Murray-Rust, Judith; Kjaer, Svend; Scott, Rizaldy P.; Hanrahan, Sarah; Santoro, Massimo; Ibanez, Carlos F.; McDonald, Neil Q.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">281</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">33577-33587</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The RET proto-oncogene encodes a receptor tyrosine kinase for the glial cell line-derived neurotrophic factor family of ligands.  Loss-of-function mutations in RET are implicated in Hirschsprung disease, whereas activating mutations in RET are found in human cancers, including familial medullar thyroid carcinoma and multiple endocrine neoplasias 2A and 2B.  We report here the biochem. characterization of the human RET tyrosine kinase domain and the structure detn. of the non-phosphorylated and phosphorylated forms.  Both structures adopt the same active kinase conformation competent to bind ATP and substrate and have a pre-organized activation loop conformation that is independent of phosphorylation status.  In agreement with the structural data, enzyme kinetic data show that autophosphorylation produces only a modest increase in activity.  Longer forms of RET contg. the juxtamembrane domain and C-terminal tail exhibited similar kinetic behavior, implying that there is no cis-inhibitory mechanism within the RET intracellular domain.  Our results suggest the existence of alternative inhibitory mechanisms, possibly in trans, for the autoregulation of RET kinase activity.  We also present the structures of the RET tyrosine kinase domain bound to two inhibitors, the pyrazolopyrimidine PP1 and the clin. relevant 4-anilinoquinazoline ZD6474.  These structures explain why certain multiple endocrine neoplasia 2-assocd. RET mutants found in patients are resistant to inhibition and form the basis for design of more effective inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2p2bSJFNWxbVg90H21EOLACvtfcHk0lhre0L57ya95g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFegsb3K&md5=005ddc426f2c1a0a48bf7dc6c6083c88</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M605604200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M605604200%26sid%3Dliteratum%253Aachs%26aulast%3DKnowles%26aufirst%3DP.%2BP.%26aulast%3DMurray-Rust%26aufirst%3DJ.%26aulast%3DKjaer%26aufirst%3DS.%26aulast%3DScott%26aufirst%3DR.%2BP.%26aulast%3DHanrahan%26aufirst%3DS.%26aulast%3DSantoro%26aufirst%3DM.%26aulast%3DIb%25C3%25A1%25C3%25B1ez%26aufirst%3DC.%2BF.%26aulast%3DMcDonald%26aufirst%3DN.%2BQ.%26atitle%3DStructure%2520and%2520chemical%2520inhibition%2520of%2520the%2520RET%2520tyrosine%2520kinase%2520domain%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2006%26volume%3D281%26spage%3D33577%26epage%3D33587" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">McTigue, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, Y.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solowiej, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kania, R. S.</span><span> </span><span class="NLM_article-title">Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">109</span><span class="NLM_x">, </span> <span class="NLM_fpage">18281</span><span class="NLM_x">–</span> <span class="NLM_lpage">18289</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Fjm401358b&amp;key=10.1073%2Fpnas.1207759109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Fjm401358b&amp;key=22988103" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Fjm401358b&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhslymtb3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2012&pages=18281-18289&author=M.+McTigueauthor=B.+W.+Murrayauthor=J.+H.+Chenauthor=Y.-L.+Dengauthor=J.+Solowiejauthor=R.+S.+Kania&title=Molecular+conformations%2C+interactions%2C+and+properties+associated+with+drug+efficiency+and+clinical+performance+among+VEGFR+TK+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors</span></div><div class="casAuthors">McTigue, Michele; Murray, Brion William; Chen, Jeffrey H.; Deng, Ya-Li; Solowiej, James; Kania, Robert S.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">45</span>),
    <span class="NLM_cas:pages">18281-18289, S18281/1-S18281/7</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Analyses of compds. in clin. development have shown that ligand efficient-mols. with privileged phys. properties and low dose are less likely to fail in the various stages of clin. testing, have fewer postapproval withdrawals, and are less likely to receive black box safety warnings.  However, detailed side-by-side examn. of mol. interactions and properties within single drug classes are lacking.  As a class, VEGF receptor tyrosine kinase inhibitors (VEGFR TKIs) have changed the landscape of how cancer is treated, particularly in clear cell renal cell carcinoma, which is molecularly linked to the VEGF signaling axis.  Despite the clear role of the mol. target, member mols. of this validated drug class exhibit distinct clin. efficacy and safety profiles in comparable renal cell carcinoma clin. studies.  The first head-to-head randomized phase III comparative study between active VEGFR TKIs has confirmed significant differences in clin. performance.  To elucidate how fundamental drug potency-efficiency is achieved and impacts differentiation within the VEGFR TKI class, we detd. potencies, time dependence, selectivities, and X-ray structures of the drug-kinase complexes using a VEGFR2 TK construct inclusive of the important juxtamembrane domain.  Collectively, the studies elucidate unique drug-kinase interactions that are dependent on distinct juxtamembrane domain conformations, resulting in significant potency and ligand efficiency differences.  The identified structural trends are consistent with in vitro measurements, which translate well to clin. performance, underscoring a principle that may be broadly applicable to prospective drug design for optimal in vivo performance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsIUWiD4sXtbVg90H21EOLACvtfcHk0ljuzRGg8gOILQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhslymtb3I&md5=4a5ec677298a8c924c0f9557ca688a79</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1207759109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1207759109%26sid%3Dliteratum%253Aachs%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DMurray%26aufirst%3DB.%2BW.%26aulast%3DChen%26aufirst%3DJ.%2BH.%26aulast%3DDeng%26aufirst%3DY.-L.%26aulast%3DSolowiej%26aufirst%3DJ.%26aulast%3DKania%26aufirst%3DR.%2BS.%26atitle%3DMolecular%2520conformations%252C%2520interactions%252C%2520and%2520properties%2520associated%2520with%2520drug%2520efficiency%2520and%2520clinical%2520performance%2520among%2520VEGFR%2520TK%2520inhibitors%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2012%26volume%3D109%26spage%3D18281%26epage%3D18289" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Kubo, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimizu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohyama, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murooka, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwai, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakamura, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hasegawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobayashi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takahashi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takahashi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kato, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Izawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isoe, T.</span><span> </span><span class="NLM_article-title">Novel potent orally active selective VEGFR-2 tyrosine kinase inhibitors: synthesis, structure–activity relationships, and antitumor activities of <i>N</i>-phenyl-<i>N</i>′-{4-(4-quinolyloxy)phenyl}ureas</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">1359</span><span class="NLM_x">–</span> <span class="NLM_lpage">1366</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm030427r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=1359-1366&author=K.+Kuboauthor=T.+Shimizuauthor=S.+Ohyamaauthor=H.+Murookaauthor=A.+Iwaiauthor=K.+Nakamuraauthor=K.+Hasegawaauthor=Y.+Kobayashiauthor=N.+Takahashiauthor=K.+Takahashiauthor=S.+Katoauthor=T.+Izawaauthor=T.+Isoe&title=Novel+potent+orally+active+selective+VEGFR-2+tyrosine+kinase+inhibitors%3A+synthesis%2C+structure%E2%80%93activity+relationships%2C+and+antitumor+activities+of+N-phenyl-N%E2%80%B2-%7B4-%284-quinolyloxy%29phenyl%7Dureas"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Fjm030427r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm030427r%26sid%3Dliteratum%253Aachs%26aulast%3DKubo%26aufirst%3DK.%26aulast%3DShimizu%26aufirst%3DT.%26aulast%3DOhyama%26aufirst%3DS.%26aulast%3DMurooka%26aufirst%3DH.%26aulast%3DIwai%26aufirst%3DA.%26aulast%3DNakamura%26aufirst%3DK.%26aulast%3DHasegawa%26aufirst%3DK.%26aulast%3DKobayashi%26aufirst%3DY.%26aulast%3DTakahashi%26aufirst%3DN.%26aulast%3DTakahashi%26aufirst%3DK.%26aulast%3DKato%26aufirst%3DS.%26aulast%3DIzawa%26aufirst%3DT.%26aulast%3DIsoe%26aufirst%3DT.%26atitle%3DNovel%2520potent%2520orally%2520active%2520selective%2520VEGFR-2%2520tyrosine%2520kinase%2520inhibitors%253A%2520synthesis%252C%2520structure%25E2%2580%2593activity%2520relationships%252C%2520and%2520antitumor%2520activities%2520of%2520N-phenyl-N%25E2%2580%25B2-%257B4-%25284-quinolyloxy%2529phenyl%257Dureas%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D1359%26epage%3D1366" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Verbeek, H. H. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alves, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Groot, J.-V. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osinga, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plukker, J. T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Links, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hofstra, R. M. W.</span><span> </span><span class="NLM_article-title">The effects of four different tyrosine kinase inhibitors on medullary and papillary thyroid cancer cells</span> <span class="citation_source-journal">J. Clin. Endocrinol. Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">96</span><span class="NLM_x">, </span> <span class="NLM_fpage">E991</span><span class="NLM_x">–</span> <span class="NLM_lpage">E995</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2011&pages=E991-E995&author=H.+H.+G.+Verbeekauthor=M.+M.+Alvesauthor=J.-V.+B.+de+Grootauthor=J.+Osingaauthor=J.+T.+M.+Plukkerauthor=T.+P.+Linksauthor=R.+M.+W.+Hofstra&title=The+effects+of+four+different+tyrosine+kinase+inhibitors+on+medullary+and+papillary+thyroid+cancer+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVerbeek%26aufirst%3DH.%2BH.%2BG.%26aulast%3DAlves%26aufirst%3DM.%2BM.%26aulast%3Dde%2BGroot%26aufirst%3DJ.-V.%2BB.%26aulast%3DOsinga%26aufirst%3DJ.%26aulast%3DPlukker%26aufirst%3DJ.%2BT.%2BM.%26aulast%3DLinks%26aufirst%3DT.%2BP.%26aulast%3DHofstra%26aufirst%3DR.%2BM.%2BW.%26atitle%3DThe%2520effects%2520of%2520four%2520different%2520tyrosine%2520kinase%2520inhibitors%2520on%2520medullary%2520and%2520papillary%2520thyroid%2520cancer%2520cells%26jtitle%3DJ.%2520Clin.%2520Endocrinol.%2520Metab.%26date%3D2011%26volume%3D96%26spage%3DE991%26epage%3DE995" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Perspicace, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jouan-Hureaux, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ragno, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballante, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sartini, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">La Motta, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Da Settimo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirsch, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schneider, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faivre, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hesse, S.</span><span> </span><span class="NLM_article-title">Design, synthesis and biological evaluation of new classes of thieno[3,2-<i>d</i>]pyrimidinone and thieno[1,2,3]triazine as inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2)</span> <span class="citation_source-journal">Eur. J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">765</span><span class="NLM_x">–</span> <span class="NLM_lpage">781</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2013&pages=765-781&author=E.+Perspicaceauthor=V.+Jouan-Hureauxauthor=R.+Ragnoauthor=F.+Ballanteauthor=S.+Sartiniauthor=C.+La+Mottaauthor=F.+Da+Settimoauthor=B.+Chenauthor=G.+Kirschauthor=S.+Schneiderauthor=B.+Faivreauthor=S.+Hesse&title=Design%2C+synthesis+and+biological+evaluation+of+new+classes+of+thieno%5B3%2C2-d%5Dpyrimidinone+and+thieno%5B1%2C2%2C3%5Dtriazine+as+inhibitor+of+vascular+endothelial+growth+factor+receptor-2+%28VEGFR-2%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPerspicace%26aufirst%3DE.%26aulast%3DJouan-Hureaux%26aufirst%3DV.%26aulast%3DRagno%26aufirst%3DR.%26aulast%3DBallante%26aufirst%3DF.%26aulast%3DSartini%26aufirst%3DS.%26aulast%3DLa%2BMotta%26aufirst%3DC.%26aulast%3DDa%2BSettimo%26aufirst%3DF.%26aulast%3DChen%26aufirst%3DB.%26aulast%3DKirsch%26aufirst%3DG.%26aulast%3DSchneider%26aufirst%3DS.%26aulast%3DFaivre%26aufirst%3DB.%26aulast%3DHesse%26aufirst%3DS.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520new%2520classes%2520of%2520thieno%255B3%252C2-d%255Dpyrimidinone%2520and%2520thieno%255B1%252C2%252C3%255Dtriazine%2520as%2520inhibitor%2520of%2520vascular%2520endothelial%2520growth%2520factor%2520receptor-2%2520%2528VEGFR-2%2529%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2013%26volume%3D63%26spage%3D765%26epage%3D781" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">La Motta, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sartini, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tuccinardi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nerini, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Da Settimo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinelli, A.</span><span> </span><span class="NLM_article-title">Computational studies of epidermal growth factor receptor: docking reliability, three-dimensional quantitative structure–activity relationship analysis, and virtual screening studies</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">964</span><span class="NLM_x">–</span> <span class="NLM_lpage">975</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2007&pages=964-975&author=C.+La+Mottaauthor=S.+Sartiniauthor=T.+Tuccinardiauthor=E.+Neriniauthor=F.+Da+Settimoauthor=A.+Martinelli&title=Computational+studies+of+epidermal+growth+factor+receptor%3A+docking+reliability%2C+three-dimensional+quantitative+structure%E2%80%93activity+relationship+analysis%2C+and+virtual+screening+studies"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLa%2BMotta%26aufirst%3DC.%26aulast%3DSartini%26aufirst%3DS.%26aulast%3DTuccinardi%26aufirst%3DT.%26aulast%3DNerini%26aufirst%3DE.%26aulast%3DDa%2BSettimo%26aufirst%3DF.%26aulast%3DMartinelli%26aufirst%3DA.%26atitle%3DComputational%2520studies%2520of%2520epidermal%2520growth%2520factor%2520receptor%253A%2520docking%2520reliability%252C%2520three-dimensional%2520quantitative%2520structure%25E2%2580%2593activity%2520relationship%2520analysis%252C%2520and%2520virtual%2520screening%2520studies%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D52%26spage%3D964%26epage%3D975" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Mologni, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rostagno, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brussolo, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knowles, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kjaer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray-Rust, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosso, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zambon, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scapozza, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mcdonald, N. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucchini, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gambacorti-Passerini, C.</span><span> </span><span class="NLM_article-title">Synthesis, structure–activity relationship and crystallographic studies of 3-substituted indolin-2-one RET inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">1482</span><span class="NLM_x">–</span> <span class="NLM_lpage">1496</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2010&pages=1482-1496&author=L.+Mologniauthor=R.+Rostagnoauthor=S.+Brussoloauthor=P.+P.+Knowlesauthor=S.+Kjaerauthor=J.+Murray-Rustauthor=E.+Rossoauthor=A.+Zambonauthor=L.+Scapozzaauthor=N.+Q.+Mcdonaldauthor=V.+Lucchiniauthor=C.+Gambacorti-Passerini&title=Synthesis%2C+structure%E2%80%93activity+relationship+and+crystallographic+studies+of+3-substituted+indolin-2-one+RET+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMologni%26aufirst%3DL.%26aulast%3DRostagno%26aufirst%3DR.%26aulast%3DBrussolo%26aufirst%3DS.%26aulast%3DKnowles%26aufirst%3DP.%2BP.%26aulast%3DKjaer%26aufirst%3DS.%26aulast%3DMurray-Rust%26aufirst%3DJ.%26aulast%3DRosso%26aufirst%3DE.%26aulast%3DZambon%26aufirst%3DA.%26aulast%3DScapozza%26aufirst%3DL.%26aulast%3DMcdonald%26aufirst%3DN.%2BQ.%26aulast%3DLucchini%26aufirst%3DV.%26aulast%3DGambacorti-Passerini%26aufirst%3DC.%26atitle%3DSynthesis%252C%2520structure%25E2%2580%2593activity%2520relationship%2520and%2520crystallographic%2520studies%2520of%25203-substituted%2520indolin-2-one%2520RET%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2010%26volume%3D18%26spage%3D1482%26epage%3D1496" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span> <span class="citation_source-book">Maestro</span>, version <span class="NLM_edition">9.1</span>; <span class="NLM_publisher-name">Schrödinger, LLC</span>: <span class="NLM_publisher-loc">New York</span>,<span class="NLM_x"> </span><span class="NLM_year">2009</span><span class="NLM_x">; </span><a href="http://www.schrodinger.com/" class="extLink">http://www.schrodinger.com/</a> (accessed May 15,<span class="NLM_x"> </span><span class="NLM_year">2011</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Maestro%2C+version+9.1%3B+Schr%C3%B6dinger%2C+LLC%3A+New+York%2C+2009%3B+http%3A%2F%2Fwww.schrodinger.com%2F+%28accessed+May+15%2C+2011%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26btitle%3DMaestro%26pub%3DSchr%25C3%25B6dinger%252C%2520LLC%26date%3D2009%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Pettersen, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goddard, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Couch, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greenblatt, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meng, E. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrin, T. E.</span><span> </span><span class="NLM_article-title">UCSF chimera: a visualization system for exploratory research and analysis</span> <span class="citation_source-journal">J. Comput. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">1605</span><span class="NLM_x">–</span> <span class="NLM_lpage">1612</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Fjm401358b&amp;key=10.1002%2Fjcc.20084" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Fjm401358b&amp;key=15264254" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Fjm401358b&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmvVOhsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2004&pages=1605-1612&author=E.+F.+Pettersenauthor=T.+D.+Goddardauthor=C.+C.+Huangauthor=G.+S.+Couchauthor=D.+M.+Greenblattauthor=E.+C.+Mengauthor=T.+E.+Ferrin&title=UCSF+chimera%3A+a+visualization+system+for+exploratory+research+and+analysis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">UCSF Chimera-A visualization system for exploratory research and analysis</span></div><div class="casAuthors">Pettersen, Eric F.; Goddard, Thomas D.; Huang, Conrad C.; Couch, Gregory S.; Greenblatt, Daniel M.; Meng, Elaine C.; Ferrin, Thomas E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Computational Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1605-1612</span>CODEN:
                <span class="NLM_cas:coden">JCCHDD</span>;
        ISSN:<span class="NLM_cas:issn">0192-8651</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">The design, implementation, and capabilities of an extensible visualization system, UCSF Chimera, are discussed.  Chimera is segmented into a core that provides basic services and visualization, and extensions that provide most higher level functionality.  This architecture ensures that the extension mechanism satisfies the demands of outside developers who wish to incorporate new features.  Two unusual extensions are presented: Multiscale, which adds the ability to visualize large-scale mol. assemblies such as viral coats, and Collab., which allows researchers to share a Chimera session interactively despite being at sep. locales.  Other extensions include Multalign Viewer, for showing multiple sequence alignments and assocd. structures; ViewDock, for screening docked ligand orientations; Movie, for replaying mol. dynamics trajectories; and Vol. Viewer, for display and anal. of volumetric data.  A discussion of the usage of Chimera in real-world situations is given, along with anticipated future directions.  Chimera includes full user documentation, is free to academic and nonprofit users, and is available for Microsoft Windows, Linux, Apple Mac OS X, SGI IRIX, and HP Tru64 Unix from http://www.cgl.ucsf.edu/chimera/.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFmD4M5S0cPbVg90H21EOLACvtfcHk0lh5TnKdbBzurw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmvVOhsbs%253D&md5=944b175f440c1ff323705987cf937ee7</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1002%2Fjcc.20084&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcc.20084%26sid%3Dliteratum%253Aachs%26aulast%3DPettersen%26aufirst%3DE.%2BF.%26aulast%3DGoddard%26aufirst%3DT.%2BD.%26aulast%3DHuang%26aufirst%3DC.%2BC.%26aulast%3DCouch%26aufirst%3DG.%2BS.%26aulast%3DGreenblatt%26aufirst%3DD.%2BM.%26aulast%3DMeng%26aufirst%3DE.%2BC.%26aulast%3DFerrin%26aufirst%3DT.%2BE.%26atitle%3DUCSF%2520chimera%253A%2520a%2520visualization%2520system%2520for%2520exploratory%2520research%2520and%2520analysis%26jtitle%3DJ.%2520Comput.%2520Chem.%26date%3D2004%26volume%3D25%26spage%3D1605%26epage%3D1612" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 15 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Vito  Coviello</span>, <span class="hlFld-ContribAuthor ">Beatrice  Marchi</span>, <span class="hlFld-ContribAuthor ">Stefania  Sartini</span>, <span class="hlFld-ContribAuthor ">Luca  Quattrini</span>, <span class="hlFld-ContribAuthor ">Anna Maria  Marini</span>, <span class="hlFld-ContribAuthor ">Francesca  Simorini</span>, <span class="hlFld-ContribAuthor ">Sabrina  Taliani</span>, <span class="hlFld-ContribAuthor ">Silvia  Salerno</span>, <span class="hlFld-ContribAuthor ">Paola  Orlandi</span>, <span class="hlFld-ContribAuthor ">Anna  Fioravanti</span>, <span class="hlFld-ContribAuthor ">Teresa Di  Desidero</span>, <span class="hlFld-ContribAuthor ">Daniela  Vullo</span>, <span class="hlFld-ContribAuthor ">Federico  Da Settimo</span>, <span class="hlFld-ContribAuthor ">Claudiu T.  Supuran</span>, <span class="hlFld-ContribAuthor ">Guido  Bocci</span>, and <span class="hlFld-ContribAuthor ">Concettina  La Motta</span>  . </span><span class="cited-content_cbyCitation_article-title">1,2-Benzisothiazole Derivatives Bearing 4-, 5-, or 6-Alkyl/arylcarboxamide Moieties Inhibit Carbonic Anhydrase Isoform IX (CAIX) and Cell Proliferation under Hypoxic Conditions. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (13)
                                     , 6547-6552. <a href="https://doi.org/10.1021/acs.jmedchem.6b00616" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00616</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00616&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b00616%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3D1%25252C2-Benzisothiazole%252BDerivatives%252BBearing%252B4-%25252C%252B5-%25252C%252Bor%252B6-Alkyl%25252Farylcarboxamide%252BMoieties%252BInhibit%252BCarbonic%252BAnhydrase%252BIsoform%252BIX%252B%252528CAIX%252529%252Band%252BCell%252BProliferation%252Bunder%252BHypoxic%252BConditions%26aulast%3DCoviello%26aufirst%3DVito%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D21042016%26date%3D27062016%26date%3D14072016%26date%3D15062016%26volume%3D59%26issue%3D13%26spage%3D6547%26epage%3D6552" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ting  Guo</span>, <span class="hlFld-ContribAuthor ">Shutao  Ma</span>. </span><span class="cited-content_cbyCitation_article-title">Recent Advances in the Discovery of Multitargeted Tyrosine Kinase Inhibitors as Anticancer Agents. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2021,</strong> <em>16 </em>
                                    (4)
                                     , 600-620. <a href="https://doi.org/10.1002/cmdc.202000658" title="DOI URL">https://doi.org/10.1002/cmdc.202000658</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.202000658&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.202000658%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DRecent%252BAdvances%252Bin%252Bthe%252BDiscovery%252Bof%252BMultitargeted%252BTyrosine%252BKinase%252BInhibitors%252Bas%252BAnticancer%252BAgents%26aulast%3DGuo%26aufirst%3DTing%26date%3D2021%26date%3D2020%26volume%3D16%26issue%3D4%26spage%3D600%26epage%3D620" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Cong-Cong  Jia</span>, <span class="hlFld-ContribAuthor ">Wang  Chen</span>, <span class="hlFld-ContribAuthor ">Zi-Li  Feng</span>, <span class="hlFld-ContribAuthor ">Zhao-Peng  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Recent developments of RET protein kinase inhibitors with diverse scaffolds as hinge binders. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2021,</strong> <em>13 </em>
                                    (1)
                                     , 45-62. <a href="https://doi.org/10.4155/fmc-2020-0170" title="DOI URL">https://doi.org/10.4155/fmc-2020-0170</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc-2020-0170&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc-2020-0170%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DRecent%252Bdevelopments%252Bof%252BRET%252Bprotein%252Bkinase%252Binhibitors%252Bwith%252Bdiverse%252Bscaffolds%252Bas%252Bhinge%252Bbinders%26aulast%3DJia%26aufirst%3DCong-Cong%26date%3D2021%26volume%3D13%26issue%3D1%26spage%3D45%26epage%3D62" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Eddie L  Myers</span>. </span><span class="cited-content_cbyCitation_article-title">Bicyclic 5–6 Systems: Other Four Heteroatoms 2:2. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,<a href="https://doi.org/10.1016/B978-0-12-818655-8.00056-1" title="DOI URL">https://doi.org/10.1016/B978-0-12-818655-8.00056-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-818655-8.00056-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-818655-8.00056-1%26sid%3Dliteratum%253Aachs%26atitle%3DBicyclic%252B5%2525E2%252580%2525936%252BSystems%25253A%252BOther%252BFour%252BHeteroatoms%252B2%25253A2%26aulast%3DMyers%26aufirst%3DEddie%2BL%26date%3D2021%26pub%3DElsevier%26atitle%3DReference%252BModule%252Bin%252BChemistry%25252C%252BMolecular%252BSciences%252Band%252BChemical%252BEngineering%26date%3D2021%26volume%3D22" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Valeria  La Pietra</span>, <span class="hlFld-ContribAuthor ">Stefania  Sartini</span>, <span class="hlFld-ContribAuthor ">Lorenzo  Botta</span>, <span class="hlFld-ContribAuthor ">Alessandro  Antonelli</span>, <span class="hlFld-ContribAuthor ">Silvia Martina  Ferrari</span>, <span class="hlFld-ContribAuthor ">Poupak  Fallahi</span>, <span class="hlFld-ContribAuthor ">Alessio  Moriconi</span>, <span class="hlFld-ContribAuthor ">Vito  Coviello</span>, <span class="hlFld-ContribAuthor ">Luca  Quattrini</span>, <span class="hlFld-ContribAuthor ">Yi-Yu  Ke</span>, <span class="hlFld-ContribAuthor ">Hsieh  Hsing-Pang</span>, <span class="hlFld-ContribAuthor ">Federico  Da Settimo</span>, <span class="hlFld-ContribAuthor ">Ettore  Novellino</span>, <span class="hlFld-ContribAuthor ">Concettina  La Motta</span>, <span class="hlFld-ContribAuthor ">Luciana  Marinelli</span>. </span><span class="cited-content_cbyCitation_article-title">Challenging clinically unresponsive medullary thyroid cancer: Discovery and pharmacological activity of novel RET inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>150 </em>, 491-505. <a href="https://doi.org/10.1016/j.ejmech.2018.02.080" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.02.080</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.02.080&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.02.080%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DChallenging%252Bclinically%252Bunresponsive%252Bmedullary%252Bthyroid%252Bcancer%25253A%252BDiscovery%252Band%252Bpharmacological%252Bactivity%252Bof%252Bnovel%252BRET%252Binhibitors%26aulast%3DLa%2BPietra%26aufirst%3DValeria%26date%3D2018%26volume%3D150%26spage%3D491%26epage%3D505" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Swapnil P.  Bhujbal</span>, <span class="hlFld-ContribAuthor ">Pavithra K.  Balasubramanian</span>, <span class="hlFld-ContribAuthor ">Seung  Joo Cho</span>. </span><span class="cited-content_cbyCitation_article-title">In silico studies on 2-substituted phenol quinazoline derivatives as RET receptor tyrosine kinase antagonists. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Chemistry Research</span><span> <strong>2017,</strong> <em>26 </em>
                                    (12)
                                     , 3228-3239. <a href="https://doi.org/10.1007/s00044-017-2016-5" title="DOI URL">https://doi.org/10.1007/s00044-017-2016-5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00044-017-2016-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00044-017-2016-5%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Chemistry%2520Research%26atitle%3DIn%252Bsilico%252Bstudies%252Bon%252B2-substituted%252Bphenol%252Bquinazoline%252Bderivatives%252Bas%252BRET%252Breceptor%252Btyrosine%252Bkinase%252Bantagonists%26aulast%3DBhujbal%26aufirst%3DSwapnil%2BP.%26date%3D2017%26date%3D2017%26volume%3D26%26issue%3D12%26spage%3D3228%26epage%3D3239" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alessandro  Antonelli</span>, <span class="hlFld-ContribAuthor ">Concettina  La Motta</span>. </span><span class="cited-content_cbyCitation_article-title">Novel therapeutic clues in thyroid carcinomas: The role of targeting cancer stem cells. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Research Reviews</span><span> <strong>2017,</strong> <em>37 </em>
                                    (6)
                                     , 1299-1317. <a href="https://doi.org/10.1002/med.21448" title="DOI URL">https://doi.org/10.1002/med.21448</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/med.21448&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fmed.21448%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Research%2520Reviews%26atitle%3DNovel%252Btherapeutic%252Bclues%252Bin%252Bthyroid%252Bcarcinomas%25253A%252BThe%252Brole%252Bof%252Btargeting%252Bcancer%252Bstem%252Bcells%26aulast%3DAntonelli%26aufirst%3DAlessandro%26date%3D2017%26date%3D2017%26volume%3D37%26issue%3D6%26spage%3D1299%26epage%3D1317" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Phoebe F.  Lamie</span>. </span><span class="cited-content_cbyCitation_article-title">RETRACTED: Design, synthesis, structure–activity relationship and kinase inhibitory activity of substituted 3-methyl-1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-ones. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2016,</strong> <em>26 </em>
                                    (13)
                                     , 3093-3097. <a href="https://doi.org/10.1016/j.bmcl.2016.05.004" title="DOI URL">https://doi.org/10.1016/j.bmcl.2016.05.004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2016.05.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2016.05.004%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DRETRACTED%25253A%252BDesign%25252C%252Bsynthesis%25252C%252Bstructure%2525E2%252580%252593activity%252Brelationship%252Band%252Bkinase%252Binhibitory%252Bactivity%252Bof%252Bsubstituted%252B3-methyl-1-phenyl-1H-pyrazolo%25255B3%25252C4-d%25255Dpyrimidin-4-ones%26aulast%3DLamie%26aufirst%3DPhoebe%2BF.%26date%3D2016%26volume%3D26%26issue%3D13%26spage%3D3093%26epage%3D3097" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yong  Li</span>, <span class="hlFld-ContribAuthor ">Ting-Ting  Cao</span>, <span class="hlFld-ContribAuthor ">Shanchun  Guo</span>, <span class="hlFld-ContribAuthor ">Qiu  Zhong</span>, <span class="hlFld-ContribAuthor ">Cai-Hu  Li</span>, <span class="hlFld-ContribAuthor ">Ying  Li</span>, <span class="hlFld-ContribAuthor ">Lin  Dong</span>, <span class="hlFld-ContribAuthor ">Shilong  Zheng</span>, <span class="hlFld-ContribAuthor ">Guangdi  Wang</span>, <span class="hlFld-ContribAuthor ">Shu-Fan  Yin</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Novel Allopurinol Derivatives with Anticancer Activity and Attenuated Xanthine Oxidase Inhibition. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2016,</strong> <em>21 </em>
                                    (6)
                                     , 771. <a href="https://doi.org/10.3390/molecules21060771" title="DOI URL">https://doi.org/10.3390/molecules21060771</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules21060771&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules21060771%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DDiscovery%252Bof%252BNovel%252BAllopurinol%252BDerivatives%252Bwith%252BAnticancer%252BActivity%252Band%252BAttenuated%252BXanthine%252BOxidase%252BInhibition%26aulast%3DLi%26aufirst%3DYong%26date%3D2016%26date%3D2016%26volume%3D21%26issue%3D6%26spage%3D771" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wei  Yan</span>, <span class="hlFld-ContribAuthor ">Zhaoru  Huang</span>, <span class="hlFld-ContribAuthor ">Zhengyu  Wang</span>, <span class="hlFld-ContribAuthor ">Sufen  Cao</span>, <span class="hlFld-ContribAuthor ">Linjiang  Tong</span>, <span class="hlFld-ContribAuthor ">Tao  Zhang</span>, <span class="hlFld-ContribAuthor ">Chen  Wang</span>, <span class="hlFld-ContribAuthor ">Lin  Zhou</span>, <span class="hlFld-ContribAuthor ">Jian  Ding</span>, <span class="hlFld-ContribAuthor ">Cheng  Luo</span>, <span class="hlFld-ContribAuthor ">Jinpei  Zhou</span>, <span class="hlFld-ContribAuthor ">Hua  Xie</span>, <span class="hlFld-ContribAuthor ">Wenhu  Duan</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of 1,3-Diaryl-pyridones as Potent VEGFR-2 Inhibitors: Design, Synthesis, and Biological Evaluation. </span><span class="cited-content_cbyCitation_journal-name">Chemical Biology & Drug Design</span><span> <strong>2016,</strong> <em>87 </em>
                                    (5)
                                     , 694-703. <a href="https://doi.org/10.1111/cbdd.12703" title="DOI URL">https://doi.org/10.1111/cbdd.12703</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/cbdd.12703&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fcbdd.12703%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Biology%2520%2526%2520Drug%2520Design%26atitle%3DDiscovery%252Bof%252B1%25252C3-Diaryl-pyridones%252Bas%252BPotent%252BVEGFR-2%252BInhibitors%25253A%252BDesign%25252C%252BSynthesis%25252C%252Band%252BBiological%252BEvaluation%26aulast%3DYan%26aufirst%3DWei%26date%3D2016%26date%3D2016%26volume%3D87%26issue%3D5%26spage%3D694%26epage%3D703" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Silvia Martina  Ferrari</span>, <span class="hlFld-ContribAuthor ">Poupak  Fallahi</span>, <span class="hlFld-ContribAuthor ">Ugo  Politti</span>, <span class="hlFld-ContribAuthor ">Gabriele  Materazzi</span>, <span class="hlFld-ContribAuthor ">Enke  Baldini</span>, <span class="hlFld-ContribAuthor ">Salvatore  Ulisse</span>, <span class="hlFld-ContribAuthor ">Paolo  Miccoli</span>, <span class="hlFld-ContribAuthor ">Alessandro  Antonelli</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular Targeted Therapies of Aggressive Thyroid Cancer. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Endocrinology</span><span> <strong>2015,</strong> <em>6 </em><a href="https://doi.org/10.3389/fendo.2015.00176" title="DOI URL">https://doi.org/10.3389/fendo.2015.00176</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fendo.2015.00176&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffendo.2015.00176%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Endocrinology%26atitle%3DMolecular%252BTargeted%252BTherapies%252Bof%252BAggressive%252BThyroid%252BCancer%26aulast%3DFerrari%26aufirst%3DSilvia%2BMartina%26date%3D2015%26date%3D2015%26volume%3D6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Silvia  Salerno</span>, <span class="hlFld-ContribAuthor ">Anna Maria  Marini</span>, <span class="hlFld-ContribAuthor ">Giacomo  Fornaciari</span>, <span class="hlFld-ContribAuthor ">Francesca  Simorini</span>, <span class="hlFld-ContribAuthor ">Concettina  La Motta</span>, <span class="hlFld-ContribAuthor ">Sabrina  Taliani</span>, <span class="hlFld-ContribAuthor ">Stefania  Sartini</span>, <span class="hlFld-ContribAuthor ">Federico  Da Settimo</span>, <span class="hlFld-ContribAuthor ">Aída Nelly  García-Argáez</span>, <span class="hlFld-ContribAuthor ">Ornella  Gia</span>, <span class="hlFld-ContribAuthor ">Sandro  Cosconati</span>, <span class="hlFld-ContribAuthor ">Ettore  Novellino</span>, <span class="hlFld-ContribAuthor ">Pilar  D'Ocon</span>, <span class="hlFld-ContribAuthor ">Anna  Fioravanti</span>, <span class="hlFld-ContribAuthor ">Paola  Orlandi</span>, <span class="hlFld-ContribAuthor ">Guido  Bocci</span>, <span class="hlFld-ContribAuthor ">Lisa  Dalla Via</span>. </span><span class="cited-content_cbyCitation_article-title">Investigation of new 2-aryl substituted Benzothiopyrano[4,3-d]pyrimidines as kinase inhibitors targeting vascular endothelial growth factor receptor 2. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>103 </em>, 29-43. <a href="https://doi.org/10.1016/j.ejmech.2015.08.027" title="DOI URL">https://doi.org/10.1016/j.ejmech.2015.08.027</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2015.08.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2015.08.027%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DInvestigation%252Bof%252Bnew%252B2-aryl%252Bsubstituted%252BBenzothiopyrano%25255B4%25252C3-d%25255Dpyrimidines%252Bas%252Bkinase%252Binhibitors%252Btargeting%252Bvascular%252Bendothelial%252Bgrowth%252Bfactor%252Breceptor%252B2%26aulast%3DSalerno%26aufirst%3DSilvia%26date%3D2015%26volume%3D103%26spage%3D29%26epage%3D43" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Guo-Bo  Li</span>, <span class="hlFld-ContribAuthor ">Sen  Ji</span>, <span class="hlFld-ContribAuthor ">Ling-Ling  Yang</span>, <span class="hlFld-ContribAuthor ">Rong-Jie  Zhang</span>, <span class="hlFld-ContribAuthor ">Kai  Chen</span>, <span class="hlFld-ContribAuthor ">Lei  Zhong</span>, <span class="hlFld-ContribAuthor ">Shuang  Ma</span>, <span class="hlFld-ContribAuthor ">Sheng-Yong  Yang</span>. </span><span class="cited-content_cbyCitation_article-title">LEADOPT: An automatic tool for structure-based lead optimization, and its application in structural optimizations of VEGFR2 and SYK inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>93 </em>, 523-538. <a href="https://doi.org/10.1016/j.ejmech.2015.02.019" title="DOI URL">https://doi.org/10.1016/j.ejmech.2015.02.019</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2015.02.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2015.02.019%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DLEADOPT%25253A%252BAn%252Bautomatic%252Btool%252Bfor%252Bstructure-based%252Blead%252Boptimization%25252C%252Band%252Bits%252Bapplication%252Bin%252Bstructural%252Boptimizations%252Bof%252BVEGFR2%252Band%252BSYK%252Binhibitors%26aulast%3DLi%26aufirst%3DGuo-Bo%26date%3D2015%26volume%3D93%26spage%3D523%26epage%3D538" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Brendan  Frett</span>, <span class="hlFld-ContribAuthor ">Marialuisa  Moccia</span>, <span class="hlFld-ContribAuthor ">Francesca  Carlomagno</span>, <span class="hlFld-ContribAuthor ">Massimo  Santoro</span>, <span class="hlFld-ContribAuthor ">Hong-yu  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of two novel RET kinase inhibitors through MCR-based drug discovery: Design, synthesis and evaluation. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2014,</strong> <em>86 </em>, 714-723. <a href="https://doi.org/10.1016/j.ejmech.2014.09.023" title="DOI URL">https://doi.org/10.1016/j.ejmech.2014.09.023</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2014.09.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2014.09.023%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DIdentification%252Bof%252Btwo%252Bnovel%252BRET%252Bkinase%252Binhibitors%252Bthrough%252BMCR-based%252Bdrug%252Bdiscovery%25253A%252BDesign%25252C%252Bsynthesis%252Band%252Bevaluation%26aulast%3DFrett%26aufirst%3DBrendan%26date%3D2014%26volume%3D86%26spage%3D714%26epage%3D723" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alessandro  Antonelli</span>, <span class="hlFld-ContribAuthor ">Guido  Bocci</span>, <span class="hlFld-ContribAuthor ">Concettina  La Motta</span>, <span class="hlFld-ContribAuthor ">Silvia Martina  Ferrari</span>, <span class="hlFld-ContribAuthor ">Poupak  Fallahi</span>, <span class="hlFld-ContribAuthor ">Alda  Corrado</span>, <span class="hlFld-ContribAuthor ">Anna  Fioravanti</span>, <span class="hlFld-ContribAuthor ">Stefania  Sartini</span>, <span class="hlFld-ContribAuthor ">Paola  Orlandi</span>, <span class="hlFld-ContribAuthor ">Simona  Piaggi</span>, <span class="hlFld-ContribAuthor ">Alessandro  Corti</span>, <span class="hlFld-ContribAuthor ">Gabriele  Materazzi</span>, <span class="hlFld-ContribAuthor ">David  Galleri</span>, <span class="hlFld-ContribAuthor ">Salvatore  Ulisse</span>, <span class="hlFld-ContribAuthor ">Gabriella  Fontanini</span>, <span class="hlFld-ContribAuthor ">Romano  Danesi</span>, <span class="hlFld-ContribAuthor ">Federico  Da Settimo</span>, <span class="hlFld-ContribAuthor ">Paolo  Miccoli</span>. </span><span class="cited-content_cbyCitation_article-title">CLM29, a multi-target pyrazolopyrimidine derivative, has anti-neoplastic activity in medullary thyroid cancer in vitro and in vivo. </span><span class="cited-content_cbyCitation_journal-name">Molecular and Cellular Endocrinology</span><span> <strong>2014,</strong> <em>393 </em>
                                    (1-2)
                                     , 56-64. <a href="https://doi.org/10.1016/j.mce.2014.06.002" title="DOI URL">https://doi.org/10.1016/j.mce.2014.06.002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.mce.2014.06.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.mce.2014.06.002%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520and%2520Cellular%2520Endocrinology%26atitle%3DCLM29%25252C%252Ba%252Bmulti-target%252Bpyrazolopyrimidine%252Bderivative%25252C%252Bhas%252Banti-neoplastic%252Bactivity%252Bin%252Bmedullary%252Bthyroid%252Bcancer%252Bin%252Bvitro%252Band%252Bin%252Bvivo%26aulast%3DAntonelli%26aufirst%3DAlessandro%26date%3D2014%26volume%3D393%26issue%3D1-2%26spage%3D56%26epage%3D64" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401358b/production/images/medium/jm-2013-01358b_0008.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401358b/production/images/large/jm-2013-01358b_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401358b&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="cht1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Chart 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401358b/production/images/medium/jm-2013-01358b_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401358b/production/images/large/jm-2013-01358b_0010.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 1. Tyrosine Kinase Inhibitors</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401358b/production/images/large/jm-2013-01358b_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401358b&amp;id=cht1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401358b/production/images/medium/jm-2013-01358b_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401358b/production/images/large/jm-2013-01358b_0006.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Pyrazolo[3,4-<i>d</i>]pyrimidine Derivatives <b>8a</b>–<b>g</b>, <b>9a</b>–<b>g</b>, and <b>10a</b>–<b>g</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401358b/production/images/large/jm-2013-01358b_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401358b&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401358b/production/images/medium/jm-2013-01358b_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401358b/production/images/large/jm-2013-01358b_0001.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Putative binding pose of <b>CLM3</b> (gold sticks) in the active site of VEGFR-2 shown as blue cartoon and cyan sticks. H-bonds are represented as black dashed lines and part of the backbone is in transparent ribbon, for clarity reason.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401358b/production/images/large/jm-2013-01358b_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401358b&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401358b/production/images/medium/jm-2013-01358b_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401358b/production/images/large/jm-2013-01358b_0002.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Putative binding pose of <b>CLM3</b> (gold sticks) in the active site of RET kinase shown as green cartoons. H-bonds are represented as black dashed lines and part of the backbone is in transparent ribbon, for clarity reason.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401358b/production/images/large/jm-2013-01358b_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401358b&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401358b/production/images/medium/jm-2013-01358b_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401358b/production/images/large/jm-2013-01358b_0003.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Binding pose of <b>10c</b> (gold sticks) in the active site of VEGFR-2 (a) and RET (b) shown as blue and green cartoons, respectively. H-bonds are shown as black dashed lines and part of the backbone is in transparent ribbon, for clarity reason.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401358b/production/images/large/jm-2013-01358b_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401358b&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401358b/production/images/medium/jm-2013-01358b_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401358b/production/images/large/jm-2013-01358b_0004.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Binding pose of <b>8b</b> (a) and <b>9c</b> (b) represented as gold sticks in the active site of RET, shown as green cartoon. H-bonds are shown as black dashed lines and part of the backbone is in transparent ribbon, for clarity reason. Cocrystallyzed AMP molecule is superimposed with <b>8b</b> (a).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401358b/production/images/large/jm-2013-01358b_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401358b&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401358b/production/images/medium/jm-2013-01358b_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401358b/production/images/large/jm-2013-01358b_0005.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Superposition of the docking binding poses of <b>10c</b> (a) and <b>9c</b> (b) into the WT (golden sticks) and V804L mutant (magenta sticks) RET kinase. The active site of RET is shown as green cartoon although part of the backbone is in transparent ribbon, for clarity reason. The L804 residue is represented as balls and sticks.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401358b/production/images/large/jm-2013-01358b_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401358b&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i37">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_60766" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_60766" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 40 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Ito, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nikiforov, Y. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlumberger, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vigneri, R.</span><span> </span><span class="NLM_article-title">Increasing incidence of thyroid cancer: controversies explored</span> <span class="citation_source-journal">Nat. Rev. Endocrinol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">178</span><span class="NLM_x">–</span> <span class="NLM_lpage">184</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm401358b&amp;key=10.1038%2Fnrendo.2012.257" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm401358b&amp;key=23358352" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm401358b&amp;key=1%3ACAS%3A280%3ADC%252BC3szjt1yrtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2013&pages=178-184&author=Y.+Itoauthor=Y.+E.+Nikiforovauthor=M.+Schlumbergerauthor=R.+Vigneri&title=Increasing+incidence+of+thyroid+cancer%3A+controversies+explored"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Increasing incidence of thyroid cancer: controversies explored</span></div><div class="casAuthors">Ito Yasuhiro; Nikiforov Yuri E; Schlumberger Martin; Vigneri Riccardo</div><div class="citationInfo"><span class="NLM_cas:title">Nature reviews. Endocrinology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">178-84</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Thyroid cancer is the most common endocrine malignancy and its incidence has been increasing considerably in the past few decades.  Many studies have been published providing evidence for this increase; however, why thyroid cancer incidence keeps rising is still debated and there are conflicting reports of factors leading to the increase in its incidence.  In this article, Nature Reviews Endocrinology asks four experts their opinions on some of the controversies surrounding the changing trends in thyroid cancer incidence.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRPwiOr3vbNwzMsgLhIoICsfW6udTcc2eaaHRHXyLSojrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3szjt1yrtA%253D%253D&md5=8ca5f03318aaaf72045a75bd5895c3ea</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrendo.2012.257&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrendo.2012.257%26sid%3Dliteratum%253Aachs%26aulast%3DIto%26aufirst%3DY.%26aulast%3DNikiforov%26aufirst%3DY.%2BE.%26aulast%3DSchlumberger%26aufirst%3DM.%26aulast%3DVigneri%26aufirst%3DR.%26atitle%3DIncreasing%2520incidence%2520of%2520thyroid%2520cancer%253A%2520controversies%2520explored%26jtitle%3DNat.%2520Rev.%2520Endocrinol.%26date%3D2013%26volume%3D9%26spage%3D178%26epage%3D184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Aschebrook-Kilfoy, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schechter, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shih, Y. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaplan, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiu, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angelos, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grogan, R. H.</span><span> </span><span class="NLM_article-title">The clinical and economic burden of a sustained increase in thyroid cancer incidence</span> <span class="citation_source-journal">Cancer Epidemiol. Biomarkers Prev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">1252</span><span class="NLM_x">–</span> <span class="NLM_lpage">1259</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2013&pages=1252-1259&author=B.+Aschebrook-Kilfoyauthor=R.+B.+Schechterauthor=Y.+C.+Shihauthor=E.+L.+Kaplanauthor=B.+C.+Chiuauthor=P.+Angelosauthor=R.+H.+Grogan&title=The+clinical+and+economic+burden+of+a+sustained+increase+in+thyroid+cancer+incidence"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAschebrook-Kilfoy%26aufirst%3DB.%26aulast%3DSchechter%26aufirst%3DR.%2BB.%26aulast%3DShih%26aufirst%3DY.%2BC.%26aulast%3DKaplan%26aufirst%3DE.%2BL.%26aulast%3DChiu%26aufirst%3DB.%2BC.%26aulast%3DAngelos%26aufirst%3DP.%26aulast%3DGrogan%26aufirst%3DR.%2BH.%26atitle%3DThe%2520clinical%2520and%2520economic%2520burden%2520of%2520a%2520sustained%2520increase%2520in%2520thyroid%2520cancer%2520incidence%26jtitle%3DCancer%2520Epidemiol.%2520Biomarkers%2520Prev.%26date%3D2013%26volume%3D22%26spage%3D1252%26epage%3D1259" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Boufraqech, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiong, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kebebew, E.</span><span> </span><span class="NLM_article-title">Diagnosis of thyroid cancer: state of art</span> <span class="citation_source-journal">Expert Opin. Med. Diagn.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">331</span><span class="NLM_x">–</span> <span class="NLM_lpage">342</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm401358b&amp;key=10.1517%2F17530059.2013.800481" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm401358b&amp;key=1%3ACAS%3A280%3ADC%252BC3snmt1OrsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2013&pages=331-342&author=M.+Boufraqechauthor=D.+Patelauthor=Y.+Xiongauthor=E.+Kebebew&title=Diagnosis+of+thyroid+cancer%3A+state+of+art"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Diagnosis of thyroid cancer: state of art</span></div><div class="casAuthors">Boufraqech Myriem; Patel Dhaval; Xiong Yin; Kebebew Electron</div><div class="citationInfo"><span class="NLM_cas:title">Expert opinion on medical diagnostics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">331-42</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">INTRODUCTION:  Thyroid cancer is the most common endocrine cancer in the USA and its incidence is increasing worldwide.  Thyroid fine-needle aspiration biopsy (FNA) and cytologic analysis is the most cost-effective approach to distinguish between malignant and benign thyroid nodules.  However, up to 30% of thyroid FNA biopsy results are inconclusive.  AREAS COVERED:  In this article, the authors provide an update on the current status and emerging approaches for improving thyroid cancer diagnosis.  This review covers imaging, genetic and genomic approaches being used or in development to help distinguish between malignant and benign thyroid nodules.  EXPERT OPINION:  There has been considerable progress in improving thyroid cancer diagnosis.  The molecular markers analysis to avoid diagnostic surgeries seems to be promising.  However, the clinical utility and accuracy of some markers reported in this review are not conclusive and need to be validated as clinical diagnostic tool.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRdnIW_nAzuwDjk2McQZ6XmfW6udTcc2eZ3s0dz03Wlw7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3snmt1OrsA%253D%253D&md5=1024ded229de18e71f008e535f553682</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1517%2F17530059.2013.800481&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17530059.2013.800481%26sid%3Dliteratum%253Aachs%26aulast%3DBoufraqech%26aufirst%3DM.%26aulast%3DPatel%26aufirst%3DD.%26aulast%3DXiong%26aufirst%3DY.%26aulast%3DKebebew%26aufirst%3DE.%26atitle%3DDiagnosis%2520of%2520thyroid%2520cancer%253A%2520state%2520of%2520art%26jtitle%3DExpert%2520Opin.%2520Med.%2520Diagn.%26date%3D2013%26volume%3D7%26spage%3D331%26epage%3D342" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Vini, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harmer, C.</span><span> </span><span class="NLM_article-title">Management of thyroid cancer</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">407</span><span class="NLM_x">–</span> <span class="NLM_lpage">414</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm401358b&amp;key=10.1016%2FS1470-2045%2802%2900787-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm401358b&amp;key=12142170" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm401358b&amp;key=1%3ACAS%3A280%3ADC%252BD38zpt1CntQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2002&pages=407-414&author=L.+Viniauthor=C.+Harmer&title=Management+of+thyroid+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Management of thyroid cancer</span></div><div class="casAuthors">Vini Louiza; Harmer Clive</div><div class="citationInfo"><span class="NLM_cas:title">The lancet oncology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">407-14</span>
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    </div><div class="casAbstract">Thyroid cancers are a diverse group of malignant disorders ranging from indolent micropapillary carcinoma, which has no effect on life expectancy, to anaplastic tumours, which are invariably fatal even with aggressive treatment.  Although the estimated incidence has increased by 14.6% over the past 40 years, the estimated death rate has fallen by 21%, probably as a result of earlier diagnosis.  The natural history of thyroid tumours is no longer a mystery, and the prognostic factors identified can predict outcome fairly accurately.  Improvements in management have mostly depended on information from large retrospective series, though there are still many areas open to debate.  There has been, however, a general acceptance that thyroid cancer should be managed by multidisciplinary teams in specialised units following evidence-based guidelines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR0Pb8oo74K7RLDWw4HIq2sfW6udTcc2eZ3s0dz03Wlw7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD38zpt1CntQ%253D%253D&md5=0421ff2c669c053764c373ea2b8a38f8</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2802%2900787-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252802%252900787-8%26sid%3Dliteratum%253Aachs%26aulast%3DVini%26aufirst%3DL.%26aulast%3DHarmer%26aufirst%3DC.%26atitle%3DManagement%2520of%2520thyroid%2520cancer%26jtitle%3DLancet%2520Oncol.%26date%3D2002%26volume%3D3%26spage%3D407%26epage%3D414" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Stassi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Todaro, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zerilli, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ricci-Vitiani, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Liberto, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Florena, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Gaudio, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Gesù, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Maria, M.</span><span> </span><span class="NLM_article-title">Thyroid cancer resistance to chemotherapeutic drugs via autocrine production of interleukin-4 and interleukin-10</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">6784</span><span class="NLM_x">–</span> <span class="NLM_lpage">6790</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2003&pages=6784-6790&author=G.+Stassiauthor=M.+Todaroauthor=M.+Zerilliauthor=L.+Ricci-Vitianiauthor=D.+Di+Libertoauthor=M.+Pattiauthor=A.+Florenaauthor=F.+Di+Gaudioauthor=G.+Di+Ges%C3%B9author=M.+De+Maria&title=Thyroid+cancer+resistance+to+chemotherapeutic+drugs+via+autocrine+production+of+interleukin-4+and+interleukin-10"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DStassi%26aufirst%3DG.%26aulast%3DTodaro%26aufirst%3DM.%26aulast%3DZerilli%26aufirst%3DM.%26aulast%3DRicci-Vitiani%26aufirst%3DL.%26aulast%3DDi%2BLiberto%26aufirst%3DD.%26aulast%3DPatti%26aufirst%3DM.%26aulast%3DFlorena%26aufirst%3DA.%26aulast%3DDi%2BGaudio%26aufirst%3DF.%26aulast%3DDi%2BGes%25C3%25B9%26aufirst%3DG.%26aulast%3DDe%2BMaria%26aufirst%3DM.%26atitle%3DThyroid%2520cancer%2520resistance%2520to%2520chemotherapeutic%2520drugs%2520via%2520autocrine%2520production%2520of%2520interleukin-4%2520and%2520interleukin-10%26jtitle%3DCancer%2520Res.%26date%3D2003%26volume%3D63%26spage%3D6784%26epage%3D6790" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Ye, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santarpia, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gagel, R. F.</span><span> </span><span class="NLM_article-title">The evolving field of tyrosine kinase inhibitors in the treatment of endocrine tumors</span> <span class="citation_source-journal">Endocr. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">578</span><span class="NLM_x">–</span> <span class="NLM_lpage">599</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Fjm401358b&amp;key=10.1210%2Fer.2009-0031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Fjm401358b&amp;key=20605972" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm401358b&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVCrurvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2010&pages=578-599&author=L.+Yeauthor=L.+Santarpiaauthor=R.+F.+Gagel&title=The+evolving+field+of+tyrosine+kinase+inhibitors+in+the+treatment+of+endocrine+tumors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">The evolving fields of tyrosine kinase inhibitors in the treatment of endocrine tumors</span></div><div class="casAuthors">Ye, Lei; Santarpia, Libero; Gagel, Robert F.</div><div class="citationInfo"><span class="NLM_cas:title">Endocrine Reviews</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">578-599</span>CODEN:
                <span class="NLM_cas:coden">ERVIDP</span>;
        ISSN:<span class="NLM_cas:issn">0163-769X</span>.
    
            (<span class="NLM_cas:orgname">Endocrine Society</span>)
        </div><div class="casAbstract">A review.  Activation of tyrosine kinase receptors (TKRs) and their related pathways has been assocd. with development of endocrine tumors.  Compds. that target and inactivate the kinase function of these receptors, tyrosine kinase inhibitors (TKIs), are now being applied to the treatment of endocrine tumors.  Recent clin. trials of TKIs in patients with advanced thyroid cancer, islet cell carcinoma, and carcinoid have shown promising preliminary results.  Significant redns. in tumor size have been described in medullary and papillary thyroid carcinoma, although no complete responses have been reported.  Case reports have described significant tumor vol. redns. of malignant pheochromocytomas and paragangliomas.  In addn., these compds. showed an initial tumoricidal or apoptotic response followed by long-term static effects on tumor growth.  Despite the promising preliminary results, this class of therapeutic agents has a broad spectrum of adverse effects, mediated by inhibition of kinase activities in normal tissues.  These adverse effects will have to be balanced with their benefit in clin. use.  New strategies will have to be applied in clin. research to achieve optimal benefits.  In this review, we will address the genetic alterations of TKRs, the rationale for utilizing TKIs for endocrine tumors, and current information on tumor and patient responses to specific TKIs.  We will also discuss the adverse effects related to TKI treatment and the mechanisms involved.  Finally, we will summarize the challenges assocd. with use of this class of compds. and potential solns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphtWXuS57hGLVg90H21EOLACvtfcHk0lhFS3j4UIMLWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVCrurvL&md5=80adc8d78a48362b7c8330ec7b1cd030</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1210%2Fer.2009-0031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fer.2009-0031%26sid%3Dliteratum%253Aachs%26aulast%3DYe%26aufirst%3DL.%26aulast%3DSantarpia%26aufirst%3DL.%26aulast%3DGagel%26aufirst%3DR.%2BF.%26atitle%3DThe%2520evolving%2520field%2520of%2520tyrosine%2520kinase%2520inhibitors%2520in%2520the%2520treatment%2520of%2520endocrine%2520tumors%26jtitle%3DEndocr.%2520Rev.%26date%3D2010%26volume%3D31%26spage%3D578%26epage%3D599" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Elisei, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cosci, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romei, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bottici, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ronzini, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molinaro, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agate, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vivaldi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faviana, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Basolo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miccoli, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berti, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pacini, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinchera, A.</span><span> </span><span class="NLM_article-title">Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study</span> <span class="citation_source-journal">J Clin. Endocrinol. Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">93</span><span class="NLM_x">, </span> <span class="NLM_fpage">682</span><span class="NLM_x">–</span> <span class="NLM_lpage">687</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm401358b&amp;key=10.1210%2Fjc.2007-1714" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm401358b&amp;key=18073307" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm401358b&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjsFyntL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2008&pages=682-687&author=R.+Eliseiauthor=B.+Cosciauthor=C.+Romeiauthor=V.+Botticiauthor=G.+Ronziniauthor=E.+Molinaroauthor=L.+Agateauthor=A.+Vivaldiauthor=P.+Favianaauthor=F.+Basoloauthor=P.+Miccoliauthor=P.+Bertiauthor=F.+Paciniauthor=A.+Pinchera&title=Prognostic+significance+of+somatic+RET+oncogene+mutations+in+sporadic+medullary+thyroid+cancer%3A+a+10-year+follow-up+study"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study</span></div><div class="casAuthors">Elisei, Rossella; Cosci, Barbara; Romei, Cristina; Bottici, Valeria; Renzini, Giulia; Molinaro, Eleonora; Agate, Laura; Vivaldi, Agnese; Faviana, Pinuccia; Basolo, Fulvio; Miccoli, Paolo; Berti, Piero; Pacini, Furio; Pinchera, Aldo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Endocrinology and Metabolism</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">682-687</span>CODEN:
                <span class="NLM_cas:coden">JCEMAZ</span>;
        ISSN:<span class="NLM_cas:issn">0021-972X</span>.
    
            (<span class="NLM_cas:orgname">Endocrine Society</span>)
        </div><div class="casAbstract">Medullary thyroid carcinoma (MTC) is a well-differentiated thyroid tumor that maintains the typical features of C cells.  An advanced stage and the presence of lymph node metastases at diagnosis were demonstrated to be the most important bad prognostic factors.  Somatic RET mutations were found in 40-50% of MTCs.  Although a relationship between somatic mutations and bad prognosis was described, data are controversial and were performed in small series with short-term follow ups.  The aim of this study was to verify the prognostic value of somatic RET mutations in a large series of MTCs with a long follow up.  The authors studied 100 sporadic MTC patients with a 10.2 yr mean follow-up.  RET gene exons 10-11 and 13-16 were analyzed.  The correlation between the presence/absence of a somatic RET mutation, clin./pathol. features, and outcome of MTC patients was evaluated.  A somatic RET mutation was found in 43 of 100 (43%) sporadic MTCs.  The most frequent mutation (34 of 43, 79%) was M918T.  RET mutation occurrence was more frequent in larger tumors (P = 0.03), and in MTC with node and distant metastases (P < 0.0001 and P = 0.02, resp.), thus, a significant correlation was found with a more advanced stage at diagnosis (P = 0.004).  A worse outcome was also significantly correlated with the presence of a somatic RET mutation (P = 0.002).  Among all prognostic factors found to be correlated with a worse outcome, at multivariate anal. only the advanced stage at diagnosis and the presence of a RET mutation showed an independent correlation (P < 0.0001 and P = 0.01, resp.).  Finally, the survival curves of MTC patients showed a significantly lower percentage of surviving patients in the group with RET mutations (P = 0.006).  The authors demonstrated that the presence of a somatic RET mutation correlates with a worse outcome of MTC patients, not only for the highest probability to have persistence of the disease, but also for a lower survival rate in a long-term follow up.  More interestingly, the presence of a somatic RET mutation correlates with the presence of lymph node metastases at diagnosis, which is a known bad prognostic factor for the definitive cure of MTC patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQugeT2yd0RrVg90H21EOLACvtfcHk0lhFS3j4UIMLWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjsFyntL8%253D&md5=367e449cdca70528e0457a902ef26562</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1210%2Fjc.2007-1714&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fjc.2007-1714%26sid%3Dliteratum%253Aachs%26aulast%3DElisei%26aufirst%3DR.%26aulast%3DCosci%26aufirst%3DB.%26aulast%3DRomei%26aufirst%3DC.%26aulast%3DBottici%26aufirst%3DV.%26aulast%3DRonzini%26aufirst%3DG.%26aulast%3DMolinaro%26aufirst%3DE.%26aulast%3DAgate%26aufirst%3DL.%26aulast%3DVivaldi%26aufirst%3DA.%26aulast%3DFaviana%26aufirst%3DP.%26aulast%3DBasolo%26aufirst%3DF.%26aulast%3DMiccoli%26aufirst%3DP.%26aulast%3DBerti%26aufirst%3DP.%26aulast%3DPacini%26aufirst%3DF.%26aulast%3DPinchera%26aufirst%3DA.%26atitle%3DPrognostic%2520significance%2520of%2520somatic%2520RET%2520oncogene%2520mutations%2520in%2520sporadic%2520medullary%2520thyroid%2520cancer%253A%2520a%252010-year%2520follow-up%2520study%26jtitle%3DJ%2520Clin.%2520Endocrinol.%2520Metab.%26date%3D2008%26volume%3D93%26spage%3D682%26epage%3D687" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Lanzi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cassinelli, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicolini, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zunino, F.</span><span> </span><span class="NLM_article-title">Targeting RET for thyroid cancer therapy</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">77</span><span class="NLM_x">, </span> <span class="NLM_fpage">297</span><span class="NLM_x">–</span> <span class="NLM_lpage">309</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2009&pages=297-309&author=C.+Lanziauthor=G.+Cassinelliauthor=V.+Nicoliniauthor=F.+Zunino&title=Targeting+RET+for+thyroid+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLanzi%26aufirst%3DC.%26aulast%3DCassinelli%26aufirst%3DG.%26aulast%3DNicolini%26aufirst%3DV.%26aulast%3DZunino%26aufirst%3DF.%26atitle%3DTargeting%2520RET%2520for%2520thyroid%2520cancer%2520therapy%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2009%26volume%3D77%26spage%3D297%26epage%3D309" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Biglietto, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maglione, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rambaldi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cerutti, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romano, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trapasso, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fedele, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ippolito, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiappetta, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Botti, G.</span><span> </span><span class="NLM_article-title">Upregulation of vascular endothelial growth factor (VEGF) and downregulation of placenta growth factor (PlGF) associated with malignancy in human thyroid tumors and cell lines</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1569</span><span class="NLM_x">–</span> <span class="NLM_lpage">1579</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=1995&pages=1569-1579&author=G.+Bigliettoauthor=D.+Maglioneauthor=M.+Rambaldiauthor=J.+Ceruttiauthor=A.+Romanoauthor=F.+Trapassoauthor=M.+Fedeleauthor=P.+Ippolitoauthor=G.+Chiappettaauthor=G.+Botti&title=Upregulation+of+vascular+endothelial+growth+factor+%28VEGF%29+and+downregulation+of+placenta+growth+factor+%28PlGF%29+associated+with+malignancy+in+human+thyroid+tumors+and+cell+lines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBiglietto%26aufirst%3DG.%26aulast%3DMaglione%26aufirst%3DD.%26aulast%3DRambaldi%26aufirst%3DM.%26aulast%3DCerutti%26aufirst%3DJ.%26aulast%3DRomano%26aufirst%3DA.%26aulast%3DTrapasso%26aufirst%3DF.%26aulast%3DFedele%26aufirst%3DM.%26aulast%3DIppolito%26aufirst%3DP.%26aulast%3DChiappetta%26aufirst%3DG.%26aulast%3DBotti%26aufirst%3DG.%26atitle%3DUpregulation%2520of%2520vascular%2520endothelial%2520growth%2520factor%2520%2528VEGF%2529%2520and%2520downregulation%2520of%2520placenta%2520growth%2520factor%2520%2528PlGF%2529%2520associated%2520with%2520malignancy%2520in%2520human%2520thyroid%2520tumors%2520and%2520cell%2520lines%26jtitle%3DOncogene%26date%3D1995%26volume%3D11%26spage%3D1569%26epage%3D1579" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Knauf, J. A.</span><span> </span><span class="NLM_article-title">Does the epidermal growth factor receptor play a role in the progression of thyroid cancer?</span> <span class="citation_source-journal">Thyroid.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">1171</span><span class="NLM_x">–</span> <span class="NLM_lpage">1174</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=1171-1174&author=J.+A.+Knauf&title=Does+the+epidermal+growth+factor+receptor+play+a+role+in+the+progression+of+thyroid+cancer%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKnauf%26aufirst%3DJ.%2BA.%26atitle%3DDoes%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520play%2520a%2520role%2520in%2520the%2520progression%2520of%2520thyroid%2520cancer%253F%26jtitle%3DThyroid.%26date%3D2011%26volume%3D21%26spage%3D1171%26epage%3D1174" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Ye, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santarpia, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gagel, R. F.</span><span> </span><span class="NLM_article-title">Targeted therapy for endocrine cancer: the medullary thyroid carcinoma paradigm</span> <span class="citation_source-journal">Endocr. Pract.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">597</span><span class="NLM_x">–</span> <span class="NLM_lpage">604</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Fjm401358b&amp;key=10.4158%2FEP09148.RAR" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Fjm401358b&amp;key=19546050" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm401358b&amp;key=1%3ACAS%3A280%3ADC%252BD1MjhsV2nuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=597-604&author=L.+Yeauthor=L.+Santarpiaauthor=R.+F.+Gagel&title=Targeted+therapy+for+endocrine+cancer%3A+the+medullary+thyroid+carcinoma+paradigm"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted therapy for endocrine cancer: the medullary thyroid carcinoma paradigm</span></div><div class="casAuthors">Ye Lei; Santarpia Libero; Gagel Robert F</div><div class="citationInfo"><span class="NLM_cas:title">Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">597-604</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVE:  To provide an overview of a new approach for treatment of medullary thyroid carcinoma (MTC) and other endocrine tumors.  METHODS:  This review compiles recent information from the medical literature and scientific meetings focused on the use of tyrosine kinase inhibitors (TKIs) for the treatment of MTC and other endocrine tumors.  RESULTS:  The elucidation during the past 2 decades of multiple genetic abnormalities in endocrine tumors has provided specific targets for therapy.  The identification of activating mutations of the RET tyrosine kinase receptor in both hereditary and sporadic MTC makes this malignant disease an excellent model for examination of the effect of a group of small organic molecule TKIs for treatment of metastatic MTC.  Clinical trials with several TKIs targeting RET and other tyrosine kinase receptors have shown positive results with generally tolerable toxicity.  Approximately one-third to one-half of patients with MTC have a reduction in tumor size of 0% to 50%, with the longest treatment duration of approximately 4 years.  The most common treatment-related toxic effects are cutaneous effects, nausea, and diarrhea.  Cardiovascular toxicity, such as hypertension, prolongation of the corrected QT interval, or heart failure, is uncommon but may be serious.  CONCLUSION:  Despite promising initial results, these studies are in their early stages, and none of these therapies is currently approved by the US Food and Drug Administration for treatment in the United States.  These studies highlight the potential for targeting endocrine cancer signaling pathways and provide a paradigm for treatment of endocrine cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRQlQm_c49yJkGy1nwu7K2mfW6udTcc2eYgKMzKxmSx7bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1MjhsV2nuw%253D%253D&md5=7a2294c883c223842c9af6d31db65745</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.4158%2FEP09148.RAR&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4158%252FEP09148.RAR%26sid%3Dliteratum%253Aachs%26aulast%3DYe%26aufirst%3DL.%26aulast%3DSantarpia%26aufirst%3DL.%26aulast%3DGagel%26aufirst%3DR.%2BF.%26atitle%3DTargeted%2520therapy%2520for%2520endocrine%2520cancer%253A%2520the%2520medullary%2520thyroid%2520carcinoma%2520paradigm%26jtitle%3DEndocr.%2520Pract.%26date%3D2009%26volume%3D15%26spage%3D597%26epage%3D604" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Gild, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bullock, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, B. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clifton-Bligh, R.</span><span> </span><span class="NLM_article-title">Multikinase inhibitors: a new option for the treatment of thyroid cancer</span> <span class="citation_source-journal">Nat. Rev. Endocrinol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">617</span><span class="NLM_x">–</span> <span class="NLM_lpage">624</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Fjm401358b&amp;key=10.1038%2Fnrendo.2011.141" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Fjm401358b&amp;key=21862995" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Fjm401358b&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1ajsr3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2011&pages=617-624&author=M.+L.+Gildauthor=M.+Bullockauthor=B.+G.+Robinsonauthor=R.+Clifton-Bligh&title=Multikinase+inhibitors%3A+a+new+option+for+the+treatment+of+thyroid+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Multikinase inhibitors: a new option for the treatment of thyroid cancer</span></div><div class="casAuthors">Gild, Matti L.; Bullock, Martyn; Robinson, Bruce G.; Clifton-Bligh, Roderick</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Endocrinology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">617-624</span>CODEN:
                <span class="NLM_cas:coden">NREABD</span>;
        ISSN:<span class="NLM_cas:issn">1759-5029</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Preclin. models have shown that inhibition of kinases in mitogenic and angiogenic signaling pathways can have antitumoral effects.  Starting with a brief synopsis of a malignancy that responds well to kinase inhibition (chronic myeloid leukemia) compared with one with less durable responses as yet (melanoma), this Review highlights challenges that must be overcome in order to successfully translate small-mol. therapies to thyroid cancer in the future.  Thyroid cancer typically has a good outcome following std. treatments, which include surgery, radioactive iodine ablation and treatment with TSH-suppressive levothyroxine.  Thyroid cancers that persist or recur following these therapies have a poorer prognosis.  Activation of mitogenic and angiogenic signaling pathways occurs in these cancers, and preclin. models have shown that inhibition of key kinase steps in these pathways can have antitumoral effects.  Several of these kinase inhibitors have now been tested in phase II and phase III trials, with modestly encouraging results.  Some promising data exist for the use of vandetanib (also known as ZD6474), motesanib, axitinib, cabozantinib (also known as XL184), sorafenib, sunitinib, pazopanib and lenvatinib (also known as E7080) in progressive thyroid cancer of medullary, papillary and follicular subtypes.  These drugs are generally well-tolerated, although dose-limiting toxicities are common, and a few (probable) treatment-related deaths have been reported.  Addnl. phase III trials will be needed to conclusively show that treatment benefit exceeds risk.  Drug resistance can occur via activation of alternate mitogenic signals (pathway switching), as has been reported for the use of kinase inhibitors in other malignancies, such as melanoma.  The hypothesis that combinations of kinase inhibitors targeting different pathways might produce better results is currently being tested in several clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXsZ46UZpqrbVg90H21EOLACvtfcHk0lhKEZVI875KEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1ajsr3F&md5=7ac1c2c3f6693ac567c1c2000eda01c0</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fnrendo.2011.141&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrendo.2011.141%26sid%3Dliteratum%253Aachs%26aulast%3DGild%26aufirst%3DM.%2BL.%26aulast%3DBullock%26aufirst%3DM.%26aulast%3DRobinson%26aufirst%3DB.%2BG.%26aulast%3DClifton-Bligh%26aufirst%3DR.%26atitle%3DMultikinase%2520inhibitors%253A%2520a%2520new%2520option%2520for%2520the%2520treatment%2520of%2520thyroid%2520cancer%26jtitle%3DNat.%2520Rev.%2520Endocrinol.%26date%3D2011%26volume%3D7%26spage%3D617%26epage%3D624" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Wilhelm, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adnane, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newell, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villanueva, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Llovet, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, M.</span><span> </span><span class="NLM_article-title">Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">3129</span><span class="NLM_x">–</span> <span class="NLM_lpage">3140</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Fjm401358b&amp;key=10.1158%2F1535-7163.MCT-08-0013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Fjm401358b&amp;key=18852116" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm401358b&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1ensLfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=3129-3140&author=S.+M.+Wilhelmauthor=L.+Adnaneauthor=P.+Newellauthor=A.+Villanuevaauthor=J.+M.+Llovetauthor=M.+Lynch&title=Preclinical+overview+of+sorafenib%2C+a+multikinase+inhibitor+that+targets+both+Raf+and+VEGF+and+PDGF+receptor+tyrosine+kinase+signaling"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling</span></div><div class="casAuthors">Wilhelm, Scott M.; Adnane, Lila; Newell, Philippa; Villanueva, Augusto; Llovet, Josep M.; Lynch, Mark</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3129-3140</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Although patients with advanced refractory solid tumors have poor prognosis, the clin. development of targeted protein kinase inhibitors offers hope for the future treatment of many cancers.  In vivo and in vitro studies have shown that the oral multikinase inhibitor, sorafenib, inhibits tumor growth and disrupts tumor microvasculature through antiproliferative, antiangiogenic, and/or proapoptotic effects.  Sorafenib has shown antitumor activity in phase II/III trials involving patients with advanced renal cell carcinoma and hepatocellular carcinoma.  The multiple mol. targets of sorafenib (the serine/threonine kinase Raf and receptor tyrosine kinases) may explain its broad preclin. and clin. activity.  This review highlights the antitumor activity of sorafenib across a variety of tumor types, including renal cell, hepatocellular, breast, and colorectal carcinomas in the preclin. setting.  In particular, preclin. evidence that supports the different mechanisms of action of sorafenib is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUzT2_aZFYYLVg90H21EOLACvtfcHk0lil1b6YTYuJvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1ensLfE&md5=5811a502a95fc01db8b44da17e17f590</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-08-0013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-08-0013%26sid%3Dliteratum%253Aachs%26aulast%3DWilhelm%26aufirst%3DS.%2BM.%26aulast%3DAdnane%26aufirst%3DL.%26aulast%3DNewell%26aufirst%3DP.%26aulast%3DVillanueva%26aufirst%3DA.%26aulast%3DLlovet%26aufirst%3DJ.%2BM.%26aulast%3DLynch%26aufirst%3DM.%26atitle%3DPreclinical%2520overview%2520of%2520sorafenib%252C%2520a%2520multikinase%2520inhibitor%2520that%2520targets%2520both%2520Raf%2520and%2520VEGF%2520and%2520PDGF%2520receptor%2520tyrosine%2520kinase%2520signaling%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2008%26volume%3D7%26spage%3D3129%26epage%3D3140" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Gan, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seruga, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knox, J. J.</span><span> </span><span class="NLM_article-title">Sunitinib in solid tumors</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">821</span><span class="NLM_x">–</span> <span class="NLM_lpage">834</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Fjm401358b&amp;key=10.1517%2F13543780902980171" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Fjm401358b&amp;key=19453268" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm401358b&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmtlWqsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2009&pages=821-834&author=H.+K.+Ganauthor=B.+Serugaauthor=J.+J.+Knox&title=Sunitinib+in+solid+tumors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Sunitinib in solid tumors</span></div><div class="casAuthors">Gan, Hui K.; Seruga, Bostjan; Knox, Jennifer J.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">821-834</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Background: Until recently, few treatments were available for renal cell carcinoma (RCC) and gastrointestinal stromal tumors (GIST).  Several targeted agents inhibiting key pathogenetic pathways have since been developed for RCC (sunitinib, sorafenib, bevacizumab, temsirolimus, everolimus) and GIST (imatinib, sunitinib).  Sunitinib is a multi-kinase inhibitor of VEGFR-2, PDGFR (α,β), FLT-3, KIT, CSF-1 and RET.  Objective: To summarize the literature regarding the structure, pharmacokinetics, pharmacodynamics, toxicity and current clin. use of sunitinib.  Other potential roles for this drug in RCC, GIST and other tumor types will be discussed.  Methods: A literature search identified relevant (pre)clin. studies of sunitinib and other relevant agents.  Results/conclusions: Sunitinib revolutionized the management of advanced RCC and GIST.  With the realization that cross-resistance between targeted agents is incomplete, evolving strategies include sequential treatment, concurrent treatment, and biomarker development.  Sunitinib also shows promise in several other tumor types that lack therapeutic options.  What remains less clear is its role in tumors that are not heavily dependent on a central pathogenetic pathway, esp. if effective cytotoxic therapies exist.  Future clin. trials will clarify whether there is a role for sunitinib in these tumors, possibly in combination with cytotoxic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqShpbTMsQw4bVg90H21EOLACvtfcHk0lil1b6YTYuJvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmtlWqsLY%253D&md5=3d6fd5375ce16825e4a02d10b6545392</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1517%2F13543780902980171&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543780902980171%26sid%3Dliteratum%253Aachs%26aulast%3DGan%26aufirst%3DH.%2BK.%26aulast%3DSeruga%26aufirst%3DB.%26aulast%3DKnox%26aufirst%3DJ.%2BJ.%26atitle%3DSunitinib%2520in%2520solid%2520tumors%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2009%26volume%3D18%26spage%3D821%26epage%3D834" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Mologni, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Redaelli, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morandi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plaza-Menacho, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gambacorti-Passerini, C.</span><span> </span><span class="NLM_article-title">Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase</span> <span class="citation_source-journal">Mol. Cell. Endocrinol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">377</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">6</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Fjm401358b&amp;key=10.1016%2Fj.mce.2013.06.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Fjm401358b&amp;key=23811235" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Fjm401358b&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1GmurfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=377&publication_year=2013&pages=1-6&author=L.+Mologniauthor=S.+Redaelliauthor=A.+Morandiauthor=I.+Plaza-Menachoauthor=C.+Gambacorti-Passerini&title=Ponatinib+is+a+potent+inhibitor+of+wild-type+and+drug-resistant+gatekeeper+mutant+RET+kinase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase</span></div><div class="casAuthors">Mologni, Luca; Redaelli, Sara; Morandi, Andrea; Plaza-Menacho, Ivan; Gambacorti-Passerini, Carlo</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Endocrinology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">377</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">1-6</span>CODEN:
                <span class="NLM_cas:coden">MCEND6</span>;
        ISSN:<span class="NLM_cas:issn">0303-7207</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">RET kinase is aberrantly activated in thyroid cancers and in rare cases of lung and colon cancer, and has been validated as a mol. target in these tumors.  Vandetanib was recently approved for the treatment of medullary thyroid cancer.  However, vandetanib is ineffective in vitro against RET mutants carrying bulky aminoacids at position 804, the gatekeeper residue, similarly to drug-resistant BCR-ABL mutants in chronic myeloid leukemia.  Ponatinib is a multi-target kinase inhibitor that was recently approved for treatment-refractory Philadelphia-pos. leukemia.  We show here potent inhibition of oncogenic RET by ponatinib, including the drug-insensitive V804M/L mutants.  Ponatinib inhibited the growth of RET+ and BCR-ABL+ cells with similar potency, while not affecting RET-neg. cells.  Both in biochem. and in cellular assays ponatinib compared favorably with known RET inhibitors, such as vandetanib, cabozantinib, sorafenib, sunitinib and motesanib, used as ref. compds.  We suggest that ponatinib should be considered for the treatment of RET+ tumors, in particular those expressing vandetanib-resistant V804M/L mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrA1KRyhCS6ULVg90H21EOLACvtfcHk0lil1b6YTYuJvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1GmurfP&md5=f08de33f80af574f3ec843d26269ed98</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.mce.2013.06.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mce.2013.06.025%26sid%3Dliteratum%253Aachs%26aulast%3DMologni%26aufirst%3DL.%26aulast%3DRedaelli%26aufirst%3DS.%26aulast%3DMorandi%26aufirst%3DA.%26aulast%3DPlaza-Menacho%26aufirst%3DI.%26aulast%3DGambacorti-Passerini%26aufirst%3DC.%26atitle%3DPonatinib%2520is%2520a%2520potent%2520inhibitor%2520of%2520wild-type%2520and%2520drug-resistant%2520gatekeeper%2520mutant%2520RET%2520kinase%26jtitle%3DMol.%2520Cell.%2520Endocrinol.%26date%3D2013%26volume%3D377%26spage%3D1%26epage%3D6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Santos, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gomez, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raez, L. E.</span> <span class="citation_source-journal">Invest. New Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">1261</span><span class="NLM_x">–</span> <span class="NLM_lpage">1269</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Santos%2C+E.+S.%3B+Gomez%2C+J.+E.%3B+Raez%2C+L.+E.Invest.+New+Drugs+2012%2C+30%2C+1261%E2%80%931269"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSantos%26aufirst%3DE.%2BS.%26aulast%3DGomez%26aufirst%3DJ.%2BE.%26aulast%3DRaez%26aufirst%3DL.%2BE.%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2012%26volume%3D30%26spage%3D1261%26epage%3D1269" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Kelly, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rixe, O.</span><span> </span><span class="NLM_article-title">Axitinib—a selective inhibitor of the vascular endothelial growth factor (VEGF) receptor</span> <span class="citation_source-journal">Target Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">297</span><span class="NLM_x">–</span> <span class="NLM_lpage">305</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Fjm401358b&amp;key=10.1007%2Fs11523-009-0126-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm401358b&amp;key=1%3ACAS%3A280%3ADC%252BC3c%252FjvVemsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2009&pages=297-305&author=R.+J.+Kellyauthor=O.+Rixe&title=Axitinib%E2%80%94a+selective+inhibitor+of+the+vascular+endothelial+growth+factor+%28VEGF%29+receptor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Axitinib--a selective inhibitor of the vascular endothelial growth factor (VEGF) receptor</span></div><div class="casAuthors">Kelly Ronan J; Rixe Olivier</div><div class="citationInfo"><span class="NLM_cas:title">Targeted oncology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">297-305</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">An improved understanding of the molecular biology involved in many solid tumors has led to the development of novel targeted agents.  Axitinib is a potent and selective inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases 1, 2, and 3.  This review presents preclinical and clinical data available for axitinib, including findings from key phase II clinical trials in a wide variety of tumors including melanomas and renal, pancreatic, thyroid, breast, lung, and colorectal carcinomas.  The differences between axitinib and other VEGFR inhibitors are explored and details of the possible use of blood pressure elevation and erythropoietin blood levels as predictive markers of VEGF/VEGFR pathway inhibition are outlined.  Ongoing Phase III studies in pancreatic and metastatic renal cell carcinoma should help to determine the optimum utilization of these agents at the appropriate stage of disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS4hztAWPIRGr5oR8RchjrrfW6udTcc2eZVlYz1Et8C37ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3c%252FjvVemsA%253D%253D&md5=bc0d9cec7c1f2e72dc68001ad4d7a5e0</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1007%2Fs11523-009-0126-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11523-009-0126-9%26sid%3Dliteratum%253Aachs%26aulast%3DKelly%26aufirst%3DR.%2BJ.%26aulast%3DRixe%26aufirst%3DO.%26atitle%3DAxitinib%25E2%2580%2594a%2520selective%2520inhibitor%2520of%2520the%2520vascular%2520endothelial%2520growth%2520factor%2520%2528VEGF%2529%2520receptor%26jtitle%3DTarget%2520Oncol.%26date%3D2009%26volume%3D4%26spage%3D297%26epage%3D305" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Bible, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suman, V. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menefee, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smallridge, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molina, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maples, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karlin, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Traynor, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumar, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goh, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lim, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bossou, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isham, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webster, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kukla, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bieber, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burton, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erlichman, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayo Phase 2 Consortium</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayo Clinic Endocrine Malignances Disease Oriented Group.</span><span> </span><span class="NLM_article-title">A multiinstitutional phase 2 trial of pazopanib monotherapy in advanced anaplastic thyroid cancer</span> <span class="citation_source-journal">J. Clin. Endocrinol. Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">97</span><span class="NLM_x">, </span> <span class="NLM_fpage">3179</span><span class="NLM_x">–</span> <span class="NLM_lpage">3184</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Fjm401358b&amp;key=10.1210%2Fjc.2012-1520" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Fjm401358b&amp;key=22774206" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Fjm401358b&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhtlymu7vM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2012&pages=3179-3184&author=K.+C.+Bibleauthor=V.+J.+Sumanauthor=M.+E.+Menefeeauthor=R.+C.+Smallridgeauthor=J.+R.+Molinaauthor=W.+J.+Maplesauthor=N.+J.+Karlinauthor=A.+M.+Traynorauthor=P.+Kumarauthor=B.+C.+Gohauthor=W.+T.+Limauthor=A.+R.+Bossouauthor=C.+R.+Ishamauthor=K.+P.+Websterauthor=A.+K.+Kuklaauthor=C.+Bieberauthor=J.+K.+Burtonauthor=P.+Harrisauthor=C.+Erlichmanauthor=Mayo+Phase+2+Consortiumauthor=Mayo+Clinic+Endocrine+Malignances+Disease+Oriented+Group.&title=A+multiinstitutional+phase+2+trial+of+pazopanib+monotherapy+in+advanced+anaplastic+thyroid+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">A multiinstitutional phase 2 trial of pazopanib monotherapy in advanced anaplastic thyroid cancer</span></div><div class="casAuthors">Bible, Keith C.; Suman, Vera J.; Menefee, Michael E.; Smallridge, Robert C.; Molina, Julian R.; Maples, William J.; Karlin, Nina J.; Traynor, Anne M.; Kumar, Priya; Goh, Boon Cher; Lim, Wan-Teck; Bossou, Ayoko R.; Isham, Crescent R.; Webster, Kevin P.; Kukla, Andrea K.; Bieber, Carolyn; Burton, Jill K.; Harris, Pamela; Erlichman, Charles</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Endocrinology and Metabolism</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3179-3184</span>CODEN:
                <span class="NLM_cas:coden">JCEMAZ</span>;
        ISSN:<span class="NLM_cas:issn">0021-972X</span>.
    
            (<span class="NLM_cas:orgname">Endocrine Society</span>)
        </div><div class="casAbstract">Context/Objectives: Pazopanib, an inhibitor of kinases including vascular endothelial growth factor receptor, demonstrated impressive activity in progressive metastatic differentiated thyroid cancer, prompting its evaluation in anaplastic thyroid cancer (ATC).  Design/Setting/Patients/Interventions/Outcome Measures: Preclin. studies, followed by a multicenter single arm phase 2 trial of continuously administered 800 mg pazopanib daily by mouth (designed to provide 90% chance of detecting a response rate of >20% at the 0.10 significance level when the true response rate is >5%), were undertaken.  The primary trial end point was Response Evaluation Criteria in Solid Tumors (RECIST) response.  Results: Pazopanib displayed activity in the KTC2 ATC xenograft model, prompting clin. evaluation.  Sixteen trial patients were enrolled; 15 were treated: 66.7% were female, median age was 66 yr (range 45-77 yr), and 11 of 15 had progressed through prior systemic therapy.  Enrollment was halted, triggered by a stopping rule requiring more than one confirmed RECIST response among the first 14 of 33 potential patients.  Four patients required one to two dose redns.; severe toxicities (National Cancer Institute Common Toxicity Criteria-Adverse Events version 3.0 grades >3) were hypertension (13%) and pharyngolaryngeal pain (13%).  Treatment was discontinued because of the following: disease progression (12 patients), death due to a possibly treatment-related tumor hemorrhage (one patient), and intolerability (radiation recall tracheitis and uncontrolled hypertension, one patient each).  Although transient disease regression was obsd. in several patients, there were no confirmed RECIST responses.  Median time to progression was 62 d; median survival time was 111 d.  Two patients are alive with disease 9.9 and 35 mo after the registration; 13 died of disease.  Conclusions: Despite preclin. in vivo activity in ATC, pazopanib has minimal single-agent clin. activity in advanced ATC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGzLGUlkfYkLVg90H21EOLACvtfcHk0lhbxRfR0-9Z5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhtlymu7vM&md5=99a0db07f2d9c2df87915629e9e991bf</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1210%2Fjc.2012-1520&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fjc.2012-1520%26sid%3Dliteratum%253Aachs%26aulast%3DBible%26aufirst%3DK.%2BC.%26aulast%3DSuman%26aufirst%3DV.%2BJ.%26aulast%3DMenefee%26aufirst%3DM.%2BE.%26aulast%3DSmallridge%26aufirst%3DR.%2BC.%26aulast%3DMolina%26aufirst%3DJ.%2BR.%26aulast%3DMaples%26aufirst%3DW.%2BJ.%26aulast%3DKarlin%26aufirst%3DN.%2BJ.%26aulast%3DTraynor%26aufirst%3DA.%2BM.%26aulast%3DKumar%26aufirst%3DP.%26aulast%3DGoh%26aufirst%3DB.%2BC.%26aulast%3DLim%26aufirst%3DW.%2BT.%26aulast%3DBossou%26aufirst%3DA.%2BR.%26aulast%3DIsham%26aufirst%3DC.%2BR.%26aulast%3DWebster%26aufirst%3DK.%2BP.%26aulast%3DKukla%26aufirst%3DA.%2BK.%26aulast%3DBieber%26aufirst%3DC.%26aulast%3DBurton%26aufirst%3DJ.%2BK.%26aulast%3DHarris%26aufirst%3DP.%26aulast%3DErlichman%26aufirst%3DC.%26aulast%3D%26aulast%3D%26atitle%3DA%2520multiinstitutional%2520phase%25202%2520trial%2520of%2520pazopanib%2520monotherapy%2520in%2520advanced%2520anaplastic%2520thyroid%2520cancer%26jtitle%3DJ.%2520Clin.%2520Endocrinol.%2520Metab.%26date%3D2012%26volume%3D97%26spage%3D3179%26epage%3D3184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Durante, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paciaroni, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plasmati, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trulli, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Filetti, S.</span><span> </span><span class="NLM_article-title">Vandetanib: opening a new treatment practice in advanced medullary thyroid carcinoma</span> <span class="citation_source-journal">Endocrine</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">334</span><span class="NLM_x">–</span> <span class="NLM_lpage">342</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2013&pages=334-342&author=C.+Duranteauthor=A.+Paciaroniauthor=K.+Plasmatiauthor=F.+Trulliauthor=S.+Filetti&title=Vandetanib%3A+opening+a+new+treatment+practice+in+advanced+medullary+thyroid+carcinoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDurante%26aufirst%3DC.%26aulast%3DPaciaroni%26aufirst%3DA.%26aulast%3DPlasmati%26aufirst%3DK.%26aulast%3DTrulli%26aufirst%3DF.%26aulast%3DFiletti%26aufirst%3DS.%26atitle%3DVandetanib%253A%2520opening%2520a%2520new%2520treatment%2520practice%2520in%2520advanced%2520medullary%2520thyroid%2520carcinoma%26jtitle%3DEndocrine%26date%3D2013%26volume%3D44%26spage%3D334%26epage%3D342" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Nagilla, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, E. E.</span><span> </span><span class="NLM_article-title">Cabozantinib for the treatment of advanced medullary thyroid cancer</span> <span class="citation_source-journal">Adv Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">925</span><span class="NLM_x">–</span> <span class="NLM_lpage">934</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2012&pages=925-934&author=M.+Nagillaauthor=R.+L.+Brownauthor=E.+E.+Cohen&title=Cabozantinib+for+the+treatment+of+advanced+medullary+thyroid+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNagilla%26aufirst%3DM.%26aulast%3DBrown%26aufirst%3DR.%2BL.%26aulast%3DCohen%26aufirst%3DE.%2BE.%26atitle%3DCabozantinib%2520for%2520the%2520treatment%2520of%2520advanced%2520medullary%2520thyroid%2520cancer%26jtitle%3DAdv%2520Ther.%26date%3D2012%26volume%3D29%26spage%3D925%26epage%3D934" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Chaud, N. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haddad, R. I.</span><span> </span><span class="NLM_article-title">Vandetanib for the treatment of medullary thyroid cancer</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">6</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2012&pages=1-6&author=N.+G.+Chaudauthor=R.+I.+Haddad&title=Vandetanib+for+the+treatment+of+medullary+thyroid+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChaud%26aufirst%3DN.%2BG.%26aulast%3DHaddad%26aufirst%3DR.%2BI.%26atitle%3DVandetanib%2520for%2520the%2520treatment%2520of%2520medullary%2520thyroid%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D19%26spage%3D1%26epage%3D6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Lombardo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baudin, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiefari, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arturi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bardet, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caillou, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conte, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dallapiccola, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giuffrida, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bidart, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlumberger, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Filetti, S.</span><span> </span><span class="NLM_article-title">Familial medullary thyroid carcinoma: clinical variability and low aggressiveness associated with RET mutation at codon 804</span> <span class="citation_source-journal">J. Clin. Endocrinol. Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">87</span><span class="NLM_x">, </span> <span class="NLM_fpage">1674</span><span class="NLM_x">–</span> <span class="NLM_lpage">1680</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Fjm401358b&amp;key=10.1210%2Fjcem.87.4.8403" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Fjm401358b&amp;key=11932300" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Fjm401358b&amp;key=1%3ACAS%3A528%3ADC%252BD38XivFKltb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2002&pages=1674-1680&author=F.+Lombardoauthor=E.+Baudinauthor=E.+Chiefariauthor=F.+Arturiauthor=S.+Bardetauthor=B.+Caillouauthor=C.+Conteauthor=B.+Dallapiccolaauthor=D.+Giuffridaauthor=J.+M.+Bidartauthor=M.+Schlumbergerauthor=S.+Filetti&title=Familial+medullary+thyroid+carcinoma%3A+clinical+variability+and+low+aggressiveness+associated+with+RET+mutation+at+codon+804"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Familial medullary thyroid carcinoma: clinical variability and low aggressiveness associated with RET mutation at codon 804</span></div><div class="casAuthors">Lombardo, Francesca; Baudin, Eric; Chiefari, Eusebio; Arturi, Franco; Bardet, Stephane; Caillou, Bernard; Conte, Chiara; Dallapiccola, Bruno; Giuffrida, Dario; Bidart, Jean-Michel; Schlumberger, Martin; Filetti, Sebastiano</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Endocrinology and Metabolism</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1674-1680</span>CODEN:
                <span class="NLM_cas:coden">JCEMAZ</span>;
        ISSN:<span class="NLM_cas:issn">0021-972X</span>.
    
            (<span class="NLM_cas:orgname">Endocrine Society</span>)
        </div><div class="casAbstract">Sixty-one heterozygotes harboring the germline V804L mutation of the RET protooncogene were identified in five independent families.  A total of 31 subjects underwent surgery.  Histol. identified C cell hyperplasia in 30 cases, isolated in 12 and assocd. with medullary thyroid carcinoma (MTC) in 18.  Six patients with MTC had lymph node metastases.  Among the 14 patients with basal detectable calcitonin (CT) level, 12 had MTC and 2 had isolated C cell hyperplasia.  In most individuals carrying 804 RET mutation, C cell disease displayed late onset and an indolent course; a pentagastrin test was neg. in the majority of heterozygotes during the first 2 decades and was pos. in only half of them during the third and fourth decades of life.  Interestingly, concomitant somatic M918T was detected in a 12-yr-old girl with MTC and was likely to be responsible for both the early clin. appearance and the aggressiveness of the disease.  Our data show that in these gene carriers, surgery may be postponed to the fourth decade of life or until the pentagastrin stimulation test becomes pos.  Indeed, our data should be confirmed on a larger series of V804L carriers, but may offer a balanced strategy to keep under control and prevent development of the full disease phenotype.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGA2T8pRs9YrVg90H21EOLACvtfcHk0lhAfT9aKj8ugg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XivFKltb8%253D&md5=f7b24f6215486b5b35b9164f08ab65b2</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1210%2Fjcem.87.4.8403&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fjcem.87.4.8403%26sid%3Dliteratum%253Aachs%26aulast%3DLombardo%26aufirst%3DF.%26aulast%3DBaudin%26aufirst%3DE.%26aulast%3DChiefari%26aufirst%3DE.%26aulast%3DArturi%26aufirst%3DF.%26aulast%3DBardet%26aufirst%3DS.%26aulast%3DCaillou%26aufirst%3DB.%26aulast%3DConte%26aufirst%3DC.%26aulast%3DDallapiccola%26aufirst%3DB.%26aulast%3DGiuffrida%26aufirst%3DD.%26aulast%3DBidart%26aufirst%3DJ.%2BM.%26aulast%3DSchlumberger%26aufirst%3DM.%26aulast%3DFiletti%26aufirst%3DS.%26atitle%3DFamilial%2520medullary%2520thyroid%2520carcinoma%253A%2520clinical%2520variability%2520and%2520low%2520aggressiveness%2520associated%2520with%2520RET%2520mutation%2520at%2520codon%2520804%26jtitle%3DJ.%2520Clin.%2520Endocrinol.%2520Metab.%26date%3D2002%26volume%3D87%26spage%3D1674%26epage%3D1680" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Radi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tintori, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Musumeci, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brullo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zamperini, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drenassi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fallacara, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vignaioli, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crespan, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zanoli, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laurenzana, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Filippi, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maga, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schenone, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angelucci, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Botta, M.</span><span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of pyrazolo[3,4-<i>d</i>]pyrimidines active in vivo on the Bcr-Abl T315I mutant</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">5382</span><span class="NLM_x">–</span> <span class="NLM_lpage">5394</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm400233w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=5382-5394&author=M.+Radiauthor=C.+Tintoriauthor=F.+Musumeciauthor=C.+Brulloauthor=C.+Zamperiniauthor=E.+Drenassiauthor=A.+Fallacaraauthor=G.+Vignaioliauthor=E.+Crespanauthor=S.+Zanoliauthor=I.+Laurenzanaauthor=I.+Filippiauthor=G.+Magaauthor=S.+Schenoneauthor=A.+Angelucciauthor=M.+Botta&title=Design%2C+synthesis%2C+and+biological+evaluation+of+pyrazolo%5B3%2C4-d%5Dpyrimidines+active+in+vivo+on+the+Bcr-Abl+T315I+mutant"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fjm400233w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400233w%26sid%3Dliteratum%253Aachs%26aulast%3DRadi%26aufirst%3DM.%26aulast%3DTintori%26aufirst%3DC.%26aulast%3DMusumeci%26aufirst%3DF.%26aulast%3DBrullo%26aufirst%3DC.%26aulast%3DZamperini%26aufirst%3DC.%26aulast%3DDrenassi%26aufirst%3DE.%26aulast%3DFallacara%26aufirst%3DA.%26aulast%3DVignaioli%26aufirst%3DG.%26aulast%3DCrespan%26aufirst%3DE.%26aulast%3DZanoli%26aufirst%3DS.%26aulast%3DLaurenzana%26aufirst%3DI.%26aulast%3DFilippi%26aufirst%3DI.%26aulast%3DMaga%26aufirst%3DG.%26aulast%3DSchenone%26aufirst%3DS.%26aulast%3DAngelucci%26aufirst%3DA.%26aulast%3DBotta%26aufirst%3DM.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520pyrazolo%255B3%252C4-d%255Dpyrimidines%2520active%2520in%2520vivo%2520on%2520the%2520Bcr-Abl%2520T315I%2520mutant%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D5382%26epage%3D5394" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Yang, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, G. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, Q. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, S. Y.</span><span> </span><span class="NLM_article-title">Structure–activity relationship studies of pyrazolo[3,4-<i>d</i>]pyrimidine derivatives leading to the discovery of a novel multikinase inhibitor that potently inhibits FLT3 and VEGFR2 and evaluation of its activity against acute myeloid leukemia in vitro and in vivo</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">1641</span><span class="NLM_x">–</span> <span class="NLM_lpage">1655</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm301537p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=1641-1655&author=L.+L.+Yangauthor=G.+B.+Liauthor=S.+Maauthor=C.+Zouauthor=S.+Zhouauthor=Q.+Z.+Sunauthor=C.+Chengauthor=X.+Chenauthor=L.+J.+Wangauthor=S.+Fengauthor=L.+L.+Liauthor=S.+Y.+Yang&title=Structure%E2%80%93activity+relationship+studies+of+pyrazolo%5B3%2C4-d%5Dpyrimidine+derivatives+leading+to+the+discovery+of+a+novel+multikinase+inhibitor+that+potently+inhibits+FLT3+and+VEGFR2+and+evaluation+of+its+activity+against+acute+myeloid+leukemia+in+vitro+and+in+vivo"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fjm301537p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301537p%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DL.%2BL.%26aulast%3DLi%26aufirst%3DG.%2BB.%26aulast%3DMa%26aufirst%3DS.%26aulast%3DZou%26aufirst%3DC.%26aulast%3DZhou%26aufirst%3DS.%26aulast%3DSun%26aufirst%3DQ.%2BZ.%26aulast%3DCheng%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DL.%2BJ.%26aulast%3DFeng%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DL.%2BL.%26aulast%3DYang%26aufirst%3DS.%2BY.%26atitle%3DStructure%25E2%2580%2593activity%2520relationship%2520studies%2520of%2520pyrazolo%255B3%252C4-d%255Dpyrimidine%2520derivatives%2520leading%2520to%2520the%2520discovery%2520of%2520a%2520novel%2520multikinase%2520inhibitor%2520that%2520potently%2520inhibits%2520FLT3%2520and%2520VEGFR2%2520and%2520evaluation%2520of%2520its%2520activity%2520against%2520acute%2520myeloid%2520leukemia%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D1641%26epage%3D1655" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Dinér, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alao, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Söderlund, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sunnerhagen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grøtli, M.</span><span> </span><span class="NLM_article-title">Preparation of 3-substituted-1-isopropyl-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-amines as RET kinase inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">4872</span><span class="NLM_x">–</span> <span class="NLM_lpage">4876</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm3003944" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=4872-4876&author=P.+Din%C3%A9rauthor=J.+P.+Alaoauthor=J.+S%C3%B6derlundauthor=P.+Sunnerhagenauthor=M.+Gr%C3%B8tli&title=Preparation+of+3-substituted-1-isopropyl-1H-pyrazolo%5B3%2C4-d%5Dpyrimidin-4-amines+as+RET+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm3003944&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3003944%26sid%3Dliteratum%253Aachs%26aulast%3DDin%25C3%25A9r%26aufirst%3DP.%26aulast%3DAlao%26aufirst%3DJ.%2BP.%26aulast%3DS%25C3%25B6derlund%26aufirst%3DJ.%26aulast%3DSunnerhagen%26aufirst%3DP.%26aulast%3DGr%25C3%25B8tli%26aufirst%3DM.%26atitle%3DPreparation%2520of%25203-substituted-1-isopropyl-1H-pyrazolo%255B3%252C4-d%255Dpyrimidin-4-amines%2520as%2520RET%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D4872%26epage%3D4876" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Le Brazidec, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pasis, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tam, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boykin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Black, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Claassen, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chong, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silvian, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ling, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teng, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pathan, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taveras, A.</span><span> </span><span class="NLM_article-title">Synthesis, SAR and biological evaluation of 1,6-disubstituted-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidines as dual inhibitors of Aurora kinases and CDK1</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">2070</span><span class="NLM_x">–</span> <span class="NLM_lpage">2074</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=2070-2074&author=J.+Y.+Le+Brazidecauthor=A.+Pasisauthor=B.+Tamauthor=C.+Boykinauthor=C.+Blackauthor=D.+Wangauthor=G.+Claassenauthor=J.+H.+Chongauthor=J.+Chaoauthor=J.+Fanauthor=K.+Nguyenauthor=L.+Silvianauthor=L.+Lingauthor=L.+Zhangauthor=M.+Choiauthor=M.+Tengauthor=N.+Pathanauthor=S.+Zhaoauthor=T.+Liauthor=A.+Taveras&title=Synthesis%2C+SAR+and+biological+evaluation+of+1%2C6-disubstituted-1H-pyrazolo%5B3%2C4-d%5Dpyrimidines+as+dual+inhibitors+of+Aurora+kinases+and+CDK1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLe%2BBrazidec%26aufirst%3DJ.%2BY.%26aulast%3DPasis%26aufirst%3DA.%26aulast%3DTam%26aufirst%3DB.%26aulast%3DBoykin%26aufirst%3DC.%26aulast%3DBlack%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DClaassen%26aufirst%3DG.%26aulast%3DChong%26aufirst%3DJ.%2BH.%26aulast%3DChao%26aufirst%3DJ.%26aulast%3DFan%26aufirst%3DJ.%26aulast%3DNguyen%26aufirst%3DK.%26aulast%3DSilvian%26aufirst%3DL.%26aulast%3DLing%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DChoi%26aufirst%3DM.%26aulast%3DTeng%26aufirst%3DM.%26aulast%3DPathan%26aufirst%3DN.%26aulast%3DZhao%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DT.%26aulast%3DTaveras%26aufirst%3DA.%26atitle%3DSynthesis%252C%2520SAR%2520and%2520biological%2520evaluation%2520of%25201%252C6-disubstituted-1H-pyrazolo%255B3%252C4-d%255Dpyrimidines%2520as%2520dual%2520inhibitors%2520of%2520Aurora%2520kinases%2520and%2520CDK1%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D2070%26epage%3D2074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Antonelli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bocci, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">La Motta, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrari, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fallahi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fioravanti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sartini, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minuto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piaggi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alì, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berti, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fontanini, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Danesi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Da Settimo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miccoli, P.</span><span> </span><span class="NLM_article-title">Novel pyrazolopyrimidine derivatives as tyrosine kinase inhibitors with antitumoral activity in vitro and in vivo in papillary dedifferentiated thyroid cancer</span> <span class="citation_source-journal">J. Clin. Endocrinol. Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">96</span><span class="NLM_x">, </span> <span class="NLM_fpage">E288</span><span class="NLM_x">–</span> <span class="NLM_lpage">E296</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2011&pages=E288-E296&author=A.+Antonelliauthor=G.+Bocciauthor=C.+La+Mottaauthor=S.+M.+Ferrariauthor=P.+Fallahiauthor=A.+Fioravantiauthor=S.+Sartiniauthor=M.+Minutoauthor=S.+Piaggiauthor=A.+Cortiauthor=G.+Al%C3%ACauthor=P.+Bertiauthor=G.+Fontaniniauthor=R.+Danesiauthor=F.+Da+Settimoauthor=P.+Miccoli&title=Novel+pyrazolopyrimidine+derivatives+as+tyrosine+kinase+inhibitors+with+antitumoral+activity+in+vitro+and+in+vivo+in+papillary+dedifferentiated+thyroid+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAntonelli%26aufirst%3DA.%26aulast%3DBocci%26aufirst%3DG.%26aulast%3DLa%2BMotta%26aufirst%3DC.%26aulast%3DFerrari%26aufirst%3DS.%2BM.%26aulast%3DFallahi%26aufirst%3DP.%26aulast%3DFioravanti%26aufirst%3DA.%26aulast%3DSartini%26aufirst%3DS.%26aulast%3DMinuto%26aufirst%3DM.%26aulast%3DPiaggi%26aufirst%3DS.%26aulast%3DCorti%26aufirst%3DA.%26aulast%3DAl%25C3%25AC%26aufirst%3DG.%26aulast%3DBerti%26aufirst%3DP.%26aulast%3DFontanini%26aufirst%3DG.%26aulast%3DDanesi%26aufirst%3DR.%26aulast%3DDa%2BSettimo%26aufirst%3DF.%26aulast%3DMiccoli%26aufirst%3DP.%26atitle%3DNovel%2520pyrazolopyrimidine%2520derivatives%2520as%2520tyrosine%2520kinase%2520inhibitors%2520with%2520antitumoral%2520activity%2520in%2520vitro%2520and%2520in%2520vivo%2520in%2520papillary%2520dedifferentiated%2520thyroid%2520cancer%26jtitle%3DJ.%2520Clin.%2520Endocrinol.%2520Metab.%26date%3D2011%26volume%3D96%26spage%3DE288%26epage%3DE296" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Bocci, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fioravanti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">La Motta, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orlandi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Canu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Desidero, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mugnaini, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sartini, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cosconati, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frati, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Antonelli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berti, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miccoli, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Da Settimo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Danesi, R.</span><span> </span><span class="NLM_article-title">Antiproliferative and proapoptotic activity of CLM3, a novel multiple tyrosine kinase inhibitor, alone and in combination with SN-38 on endothelial and cancer cells</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">81</span><span class="NLM_x">, </span> <span class="NLM_fpage">1309</span><span class="NLM_x">–</span> <span class="NLM_lpage">1316</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2011&pages=1309-1316&author=G.+Bocciauthor=A.+Fioravantiauthor=C.+La+Mottaauthor=P.+Orlandiauthor=B.+Canuauthor=T.+Di+Desideroauthor=L.+Mugnainiauthor=S.+Sartiniauthor=S.+Cosconatiauthor=R.+Fratiauthor=A.+Antonelliauthor=P.+Bertiauthor=P.+Miccoliauthor=F.+Da+Settimoauthor=R.+Danesi&title=Antiproliferative+and+proapoptotic+activity+of+CLM3%2C+a+novel+multiple+tyrosine+kinase+inhibitor%2C+alone+and+in+combination+with+SN-38+on+endothelial+and+cancer+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBocci%26aufirst%3DG.%26aulast%3DFioravanti%26aufirst%3DA.%26aulast%3DLa%2BMotta%26aufirst%3DC.%26aulast%3DOrlandi%26aufirst%3DP.%26aulast%3DCanu%26aufirst%3DB.%26aulast%3DDi%2BDesidero%26aufirst%3DT.%26aulast%3DMugnaini%26aufirst%3DL.%26aulast%3DSartini%26aufirst%3DS.%26aulast%3DCosconati%26aufirst%3DS.%26aulast%3DFrati%26aufirst%3DR.%26aulast%3DAntonelli%26aufirst%3DA.%26aulast%3DBerti%26aufirst%3DP.%26aulast%3DMiccoli%26aufirst%3DP.%26aulast%3DDa%2BSettimo%26aufirst%3DF.%26aulast%3DDanesi%26aufirst%3DR.%26atitle%3DAntiproliferative%2520and%2520proapoptotic%2520activity%2520of%2520CLM3%252C%2520a%2520novel%2520multiple%2520tyrosine%2520kinase%2520inhibitor%252C%2520alone%2520and%2520in%2520combination%2520with%2520SN-38%2520on%2520endothelial%2520and%2520cancer%2520cells%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2011%26volume%3D81%26spage%3D1309%26epage%3D1316" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yin, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leonard, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sioson, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lapo, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, S.</span><span> </span><span class="NLM_article-title">A variation of the Fischer indolization involving condensation of quinone monoketals and aliphatic hydrazines</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">1753</span><span class="NLM_x">–</span> <span class="NLM_lpage">1757</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Fjm401358b&amp;key=10.1002%2Fanie.201207533" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Fjm401358b&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjtV2ntg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2013&pages=1753-1757&author=J.+Zhangauthor=Z.+Yinauthor=P.+Leonardauthor=J.+Wuauthor=K.+Siosonauthor=C.+Liuauthor=R.+Lapoauthor=S.+Zheng&title=A+variation+of+the+Fischer+indolization+involving+condensation+of+quinone+monoketals+and+aliphatic+hydrazines"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">A Variation of the Fischer Indolization Involving Condensation of Quinone Monoketals and Aliphatic Hydrazines</span></div><div class="casAuthors">Zhang, Jinzhu; Yin, Zhiwei; Leonard, Patrick; Wu, Jing; Sioson, Kate; Liu, Che; Lapo, Robert; Zheng, Shengping</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1753-1757</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A variation of the the Fischer indole synthesis was developed.  Reaction of quinone monoketals with aliph. hydrazines afforded the indoles, via alkylaryldiazenes, in a one-pot method.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPkRZHEdUS67Vg90H21EOLACvtfcHk0lhfUAlrDA9clA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjtV2ntg%253D%253D&md5=066ab4287f9756ddf33c13e6aa3eb40d</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1002%2Fanie.201207533&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201207533%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DYin%26aufirst%3DZ.%26aulast%3DLeonard%26aufirst%3DP.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DSioson%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DLapo%26aufirst%3DR.%26aulast%3DZheng%26aufirst%3DS.%26atitle%3DA%2520variation%2520of%2520the%2520Fischer%2520indolization%2520involving%2520condensation%2520of%2520quinone%2520monoketals%2520and%2520aliphatic%2520hydrazines%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2013%26volume%3D52%26spage%3D1753%26epage%3D1757" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span> <span class="citation_source-book">Glide</span>, version <span class="NLM_edition">5.5</span>; <span class="NLM_publisher-name">Schrodinger, LLC</span>: <span class="NLM_publisher-loc">New York</span>,<span class="NLM_x"> </span><span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Glide%2C+version+5.5%3B+Schrodinger%2C+LLC%3A+New+York%2C+2009."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26btitle%3DGlide%26pub%3DSchrodinger%252C%2520LLC%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">McTigue, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solowiej, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kania, R. S.</span><span> </span><span class="NLM_article-title">Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">109</span><span class="NLM_x">, </span> <span class="NLM_fpage">18281</span><span class="NLM_x">–</span> <span class="NLM_lpage">18289</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Fjm401358b&amp;key=10.1073%2Fpnas.1207759109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Fjm401358b&amp;key=22988103" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Fjm401358b&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhslymtb3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2012&pages=18281-18289&author=M.+McTigueauthor=B.+W.+Murrayauthor=J.+H.+Chenauthor=Y.+L.+Dengauthor=J.+Solowiejauthor=R.+S.+Kania&title=Molecular+conformations%2C+interactions%2C+and+properties+associated+with+drug+efficiency+and+clinical+performance+among+VEGFR+TK+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors</span></div><div class="casAuthors">McTigue, Michele; Murray, Brion William; Chen, Jeffrey H.; Deng, Ya-Li; Solowiej, James; Kania, Robert S.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">45</span>),
    <span class="NLM_cas:pages">18281-18289, S18281/1-S18281/7</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Analyses of compds. in clin. development have shown that ligand efficient-mols. with privileged phys. properties and low dose are less likely to fail in the various stages of clin. testing, have fewer postapproval withdrawals, and are less likely to receive black box safety warnings.  However, detailed side-by-side examn. of mol. interactions and properties within single drug classes are lacking.  As a class, VEGF receptor tyrosine kinase inhibitors (VEGFR TKIs) have changed the landscape of how cancer is treated, particularly in clear cell renal cell carcinoma, which is molecularly linked to the VEGF signaling axis.  Despite the clear role of the mol. target, member mols. of this validated drug class exhibit distinct clin. efficacy and safety profiles in comparable renal cell carcinoma clin. studies.  The first head-to-head randomized phase III comparative study between active VEGFR TKIs has confirmed significant differences in clin. performance.  To elucidate how fundamental drug potency-efficiency is achieved and impacts differentiation within the VEGFR TKI class, we detd. potencies, time dependence, selectivities, and X-ray structures of the drug-kinase complexes using a VEGFR2 TK construct inclusive of the important juxtamembrane domain.  Collectively, the studies elucidate unique drug-kinase interactions that are dependent on distinct juxtamembrane domain conformations, resulting in significant potency and ligand efficiency differences.  The identified structural trends are consistent with in vitro measurements, which translate well to clin. performance, underscoring a principle that may be broadly applicable to prospective drug design for optimal in vivo performance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsIUWiD4sXtbVg90H21EOLACvtfcHk0ljq0wg6bGQOjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhslymtb3I&md5=4a5ec677298a8c924c0f9557ca688a79</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1207759109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1207759109%26sid%3Dliteratum%253Aachs%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DMurray%26aufirst%3DB.%2BW.%26aulast%3DChen%26aufirst%3DJ.%2BH.%26aulast%3DDeng%26aufirst%3DY.%2BL.%26aulast%3DSolowiej%26aufirst%3DJ.%26aulast%3DKania%26aufirst%3DR.%2BS.%26atitle%3DMolecular%2520conformations%252C%2520interactions%252C%2520and%2520properties%2520associated%2520with%2520drug%2520efficiency%2520and%2520clinical%2520performance%2520among%2520VEGFR%2520TK%2520inhibitors%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2012%26volume%3D109%26spage%3D18281%26epage%3D18289" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Knowles, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray-Rust, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kjaer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanrahan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santoro, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ibáñez, C. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonald, N. Q.</span><span> </span><span class="NLM_article-title">Structure and chemical inhibition of the RET tyrosine kinase domain</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">281</span><span class="NLM_x">, </span> <span class="NLM_fpage">33577</span><span class="NLM_x">–</span> <span class="NLM_lpage">33587</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Fjm401358b&amp;key=10.1074%2Fjbc.M605604200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Fjm401358b&amp;key=16928683" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Fjm401358b&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFegsb3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=281&publication_year=2006&pages=33577-33587&author=P.+P.+Knowlesauthor=J.+Murray-Rustauthor=S.+Kjaerauthor=R.+P.+Scottauthor=S.+Hanrahanauthor=M.+Santoroauthor=C.+F.+Ib%C3%A1%C3%B1ezauthor=N.+Q.+McDonald&title=Structure+and+chemical+inhibition+of+the+RET+tyrosine+kinase+domain"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Structure and Chemical Inhibition of the RET Tyrosine Kinase Domain</span></div><div class="casAuthors">Knowles, Phillip P.; Murray-Rust, Judith; Kjaer, Svend; Scott, Rizaldy P.; Hanrahan, Sarah; Santoro, Massimo; Ibanez, Carlos F.; McDonald, Neil Q.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">281</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">33577-33587</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The RET proto-oncogene encodes a receptor tyrosine kinase for the glial cell line-derived neurotrophic factor family of ligands.  Loss-of-function mutations in RET are implicated in Hirschsprung disease, whereas activating mutations in RET are found in human cancers, including familial medullar thyroid carcinoma and multiple endocrine neoplasias 2A and 2B.  We report here the biochem. characterization of the human RET tyrosine kinase domain and the structure detn. of the non-phosphorylated and phosphorylated forms.  Both structures adopt the same active kinase conformation competent to bind ATP and substrate and have a pre-organized activation loop conformation that is independent of phosphorylation status.  In agreement with the structural data, enzyme kinetic data show that autophosphorylation produces only a modest increase in activity.  Longer forms of RET contg. the juxtamembrane domain and C-terminal tail exhibited similar kinetic behavior, implying that there is no cis-inhibitory mechanism within the RET intracellular domain.  Our results suggest the existence of alternative inhibitory mechanisms, possibly in trans, for the autoregulation of RET kinase activity.  We also present the structures of the RET tyrosine kinase domain bound to two inhibitors, the pyrazolopyrimidine PP1 and the clin. relevant 4-anilinoquinazoline ZD6474.  These structures explain why certain multiple endocrine neoplasia 2-assocd. RET mutants found in patients are resistant to inhibition and form the basis for design of more effective inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2p2bSJFNWxbVg90H21EOLACvtfcHk0ljq0wg6bGQOjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFegsb3K&md5=005ddc426f2c1a0a48bf7dc6c6083c88</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M605604200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M605604200%26sid%3Dliteratum%253Aachs%26aulast%3DKnowles%26aufirst%3DP.%2BP.%26aulast%3DMurray-Rust%26aufirst%3DJ.%26aulast%3DKjaer%26aufirst%3DS.%26aulast%3DScott%26aufirst%3DR.%2BP.%26aulast%3DHanrahan%26aufirst%3DS.%26aulast%3DSantoro%26aufirst%3DM.%26aulast%3DIb%25C3%25A1%25C3%25B1ez%26aufirst%3DC.%2BF.%26aulast%3DMcDonald%26aufirst%3DN.%2BQ.%26atitle%3DStructure%2520and%2520chemical%2520inhibition%2520of%2520the%2520RET%2520tyrosine%2520kinase%2520domain%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2006%26volume%3D281%26spage%3D33577%26epage%3D33587" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">McTigue, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, Y.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solowiej, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kania, R. S.</span><span> </span><span class="NLM_article-title">Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">109</span><span class="NLM_x">, </span> <span class="NLM_fpage">18281</span><span class="NLM_x">–</span> <span class="NLM_lpage">18289</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Fjm401358b&amp;key=10.1073%2Fpnas.1207759109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Fjm401358b&amp;key=22988103" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Fjm401358b&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhslymtb3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2012&pages=18281-18289&author=M.+McTigueauthor=B.+W.+Murrayauthor=J.+H.+Chenauthor=Y.-L.+Dengauthor=J.+Solowiejauthor=R.+S.+Kania&title=Molecular+conformations%2C+interactions%2C+and+properties+associated+with+drug+efficiency+and+clinical+performance+among+VEGFR+TK+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors</span></div><div class="casAuthors">McTigue, Michele; Murray, Brion William; Chen, Jeffrey H.; Deng, Ya-Li; Solowiej, James; Kania, Robert S.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">45</span>),
    <span class="NLM_cas:pages">18281-18289, S18281/1-S18281/7</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Analyses of compds. in clin. development have shown that ligand efficient-mols. with privileged phys. properties and low dose are less likely to fail in the various stages of clin. testing, have fewer postapproval withdrawals, and are less likely to receive black box safety warnings.  However, detailed side-by-side examn. of mol. interactions and properties within single drug classes are lacking.  As a class, VEGF receptor tyrosine kinase inhibitors (VEGFR TKIs) have changed the landscape of how cancer is treated, particularly in clear cell renal cell carcinoma, which is molecularly linked to the VEGF signaling axis.  Despite the clear role of the mol. target, member mols. of this validated drug class exhibit distinct clin. efficacy and safety profiles in comparable renal cell carcinoma clin. studies.  The first head-to-head randomized phase III comparative study between active VEGFR TKIs has confirmed significant differences in clin. performance.  To elucidate how fundamental drug potency-efficiency is achieved and impacts differentiation within the VEGFR TKI class, we detd. potencies, time dependence, selectivities, and X-ray structures of the drug-kinase complexes using a VEGFR2 TK construct inclusive of the important juxtamembrane domain.  Collectively, the studies elucidate unique drug-kinase interactions that are dependent on distinct juxtamembrane domain conformations, resulting in significant potency and ligand efficiency differences.  The identified structural trends are consistent with in vitro measurements, which translate well to clin. performance, underscoring a principle that may be broadly applicable to prospective drug design for optimal in vivo performance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsIUWiD4sXtbVg90H21EOLACvtfcHk0lhcuWzeY_WF1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhslymtb3I&md5=4a5ec677298a8c924c0f9557ca688a79</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1207759109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1207759109%26sid%3Dliteratum%253Aachs%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DMurray%26aufirst%3DB.%2BW.%26aulast%3DChen%26aufirst%3DJ.%2BH.%26aulast%3DDeng%26aufirst%3DY.-L.%26aulast%3DSolowiej%26aufirst%3DJ.%26aulast%3DKania%26aufirst%3DR.%2BS.%26atitle%3DMolecular%2520conformations%252C%2520interactions%252C%2520and%2520properties%2520associated%2520with%2520drug%2520efficiency%2520and%2520clinical%2520performance%2520among%2520VEGFR%2520TK%2520inhibitors%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2012%26volume%3D109%26spage%3D18281%26epage%3D18289" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Kubo, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimizu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohyama, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murooka, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwai, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakamura, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hasegawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobayashi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takahashi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takahashi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kato, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Izawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isoe, T.</span><span> </span><span class="NLM_article-title">Novel potent orally active selective VEGFR-2 tyrosine kinase inhibitors: synthesis, structure–activity relationships, and antitumor activities of <i>N</i>-phenyl-<i>N</i>′-{4-(4-quinolyloxy)phenyl}ureas</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">1359</span><span class="NLM_x">–</span> <span class="NLM_lpage">1366</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm030427r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=1359-1366&author=K.+Kuboauthor=T.+Shimizuauthor=S.+Ohyamaauthor=H.+Murookaauthor=A.+Iwaiauthor=K.+Nakamuraauthor=K.+Hasegawaauthor=Y.+Kobayashiauthor=N.+Takahashiauthor=K.+Takahashiauthor=S.+Katoauthor=T.+Izawaauthor=T.+Isoe&title=Novel+potent+orally+active+selective+VEGFR-2+tyrosine+kinase+inhibitors%3A+synthesis%2C+structure%E2%80%93activity+relationships%2C+and+antitumor+activities+of+N-phenyl-N%E2%80%B2-%7B4-%284-quinolyloxy%29phenyl%7Dureas"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Fjm030427r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm030427r%26sid%3Dliteratum%253Aachs%26aulast%3DKubo%26aufirst%3DK.%26aulast%3DShimizu%26aufirst%3DT.%26aulast%3DOhyama%26aufirst%3DS.%26aulast%3DMurooka%26aufirst%3DH.%26aulast%3DIwai%26aufirst%3DA.%26aulast%3DNakamura%26aufirst%3DK.%26aulast%3DHasegawa%26aufirst%3DK.%26aulast%3DKobayashi%26aufirst%3DY.%26aulast%3DTakahashi%26aufirst%3DN.%26aulast%3DTakahashi%26aufirst%3DK.%26aulast%3DKato%26aufirst%3DS.%26aulast%3DIzawa%26aufirst%3DT.%26aulast%3DIsoe%26aufirst%3DT.%26atitle%3DNovel%2520potent%2520orally%2520active%2520selective%2520VEGFR-2%2520tyrosine%2520kinase%2520inhibitors%253A%2520synthesis%252C%2520structure%25E2%2580%2593activity%2520relationships%252C%2520and%2520antitumor%2520activities%2520of%2520N-phenyl-N%25E2%2580%25B2-%257B4-%25284-quinolyloxy%2529phenyl%257Dureas%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D1359%26epage%3D1366" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Verbeek, H. H. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alves, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Groot, J.-V. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osinga, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plukker, J. T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Links, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hofstra, R. M. W.</span><span> </span><span class="NLM_article-title">The effects of four different tyrosine kinase inhibitors on medullary and papillary thyroid cancer cells</span> <span class="citation_source-journal">J. Clin. Endocrinol. Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">96</span><span class="NLM_x">, </span> <span class="NLM_fpage">E991</span><span class="NLM_x">–</span> <span class="NLM_lpage">E995</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2011&pages=E991-E995&author=H.+H.+G.+Verbeekauthor=M.+M.+Alvesauthor=J.-V.+B.+de+Grootauthor=J.+Osingaauthor=J.+T.+M.+Plukkerauthor=T.+P.+Linksauthor=R.+M.+W.+Hofstra&title=The+effects+of+four+different+tyrosine+kinase+inhibitors+on+medullary+and+papillary+thyroid+cancer+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVerbeek%26aufirst%3DH.%2BH.%2BG.%26aulast%3DAlves%26aufirst%3DM.%2BM.%26aulast%3Dde%2BGroot%26aufirst%3DJ.-V.%2BB.%26aulast%3DOsinga%26aufirst%3DJ.%26aulast%3DPlukker%26aufirst%3DJ.%2BT.%2BM.%26aulast%3DLinks%26aufirst%3DT.%2BP.%26aulast%3DHofstra%26aufirst%3DR.%2BM.%2BW.%26atitle%3DThe%2520effects%2520of%2520four%2520different%2520tyrosine%2520kinase%2520inhibitors%2520on%2520medullary%2520and%2520papillary%2520thyroid%2520cancer%2520cells%26jtitle%3DJ.%2520Clin.%2520Endocrinol.%2520Metab.%26date%3D2011%26volume%3D96%26spage%3DE991%26epage%3DE995" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Perspicace, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jouan-Hureaux, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ragno, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballante, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sartini, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">La Motta, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Da Settimo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirsch, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schneider, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faivre, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hesse, S.</span><span> </span><span class="NLM_article-title">Design, synthesis and biological evaluation of new classes of thieno[3,2-<i>d</i>]pyrimidinone and thieno[1,2,3]triazine as inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2)</span> <span class="citation_source-journal">Eur. J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">765</span><span class="NLM_x">–</span> <span class="NLM_lpage">781</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2013&pages=765-781&author=E.+Perspicaceauthor=V.+Jouan-Hureauxauthor=R.+Ragnoauthor=F.+Ballanteauthor=S.+Sartiniauthor=C.+La+Mottaauthor=F.+Da+Settimoauthor=B.+Chenauthor=G.+Kirschauthor=S.+Schneiderauthor=B.+Faivreauthor=S.+Hesse&title=Design%2C+synthesis+and+biological+evaluation+of+new+classes+of+thieno%5B3%2C2-d%5Dpyrimidinone+and+thieno%5B1%2C2%2C3%5Dtriazine+as+inhibitor+of+vascular+endothelial+growth+factor+receptor-2+%28VEGFR-2%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPerspicace%26aufirst%3DE.%26aulast%3DJouan-Hureaux%26aufirst%3DV.%26aulast%3DRagno%26aufirst%3DR.%26aulast%3DBallante%26aufirst%3DF.%26aulast%3DSartini%26aufirst%3DS.%26aulast%3DLa%2BMotta%26aufirst%3DC.%26aulast%3DDa%2BSettimo%26aufirst%3DF.%26aulast%3DChen%26aufirst%3DB.%26aulast%3DKirsch%26aufirst%3DG.%26aulast%3DSchneider%26aufirst%3DS.%26aulast%3DFaivre%26aufirst%3DB.%26aulast%3DHesse%26aufirst%3DS.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520new%2520classes%2520of%2520thieno%255B3%252C2-d%255Dpyrimidinone%2520and%2520thieno%255B1%252C2%252C3%255Dtriazine%2520as%2520inhibitor%2520of%2520vascular%2520endothelial%2520growth%2520factor%2520receptor-2%2520%2528VEGFR-2%2529%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2013%26volume%3D63%26spage%3D765%26epage%3D781" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">La Motta, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sartini, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tuccinardi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nerini, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Da Settimo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinelli, A.</span><span> </span><span class="NLM_article-title">Computational studies of epidermal growth factor receptor: docking reliability, three-dimensional quantitative structure–activity relationship analysis, and virtual screening studies</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">964</span><span class="NLM_x">–</span> <span class="NLM_lpage">975</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2007&pages=964-975&author=C.+La+Mottaauthor=S.+Sartiniauthor=T.+Tuccinardiauthor=E.+Neriniauthor=F.+Da+Settimoauthor=A.+Martinelli&title=Computational+studies+of+epidermal+growth+factor+receptor%3A+docking+reliability%2C+three-dimensional+quantitative+structure%E2%80%93activity+relationship+analysis%2C+and+virtual+screening+studies"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLa%2BMotta%26aufirst%3DC.%26aulast%3DSartini%26aufirst%3DS.%26aulast%3DTuccinardi%26aufirst%3DT.%26aulast%3DNerini%26aufirst%3DE.%26aulast%3DDa%2BSettimo%26aufirst%3DF.%26aulast%3DMartinelli%26aufirst%3DA.%26atitle%3DComputational%2520studies%2520of%2520epidermal%2520growth%2520factor%2520receptor%253A%2520docking%2520reliability%252C%2520three-dimensional%2520quantitative%2520structure%25E2%2580%2593activity%2520relationship%2520analysis%252C%2520and%2520virtual%2520screening%2520studies%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D52%26spage%3D964%26epage%3D975" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Mologni, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rostagno, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brussolo, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knowles, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kjaer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray-Rust, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosso, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zambon, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scapozza, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mcdonald, N. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucchini, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gambacorti-Passerini, C.</span><span> </span><span class="NLM_article-title">Synthesis, structure–activity relationship and crystallographic studies of 3-substituted indolin-2-one RET inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">1482</span><span class="NLM_x">–</span> <span class="NLM_lpage">1496</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2010&pages=1482-1496&author=L.+Mologniauthor=R.+Rostagnoauthor=S.+Brussoloauthor=P.+P.+Knowlesauthor=S.+Kjaerauthor=J.+Murray-Rustauthor=E.+Rossoauthor=A.+Zambonauthor=L.+Scapozzaauthor=N.+Q.+Mcdonaldauthor=V.+Lucchiniauthor=C.+Gambacorti-Passerini&title=Synthesis%2C+structure%E2%80%93activity+relationship+and+crystallographic+studies+of+3-substituted+indolin-2-one+RET+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMologni%26aufirst%3DL.%26aulast%3DRostagno%26aufirst%3DR.%26aulast%3DBrussolo%26aufirst%3DS.%26aulast%3DKnowles%26aufirst%3DP.%2BP.%26aulast%3DKjaer%26aufirst%3DS.%26aulast%3DMurray-Rust%26aufirst%3DJ.%26aulast%3DRosso%26aufirst%3DE.%26aulast%3DZambon%26aufirst%3DA.%26aulast%3DScapozza%26aufirst%3DL.%26aulast%3DMcdonald%26aufirst%3DN.%2BQ.%26aulast%3DLucchini%26aufirst%3DV.%26aulast%3DGambacorti-Passerini%26aufirst%3DC.%26atitle%3DSynthesis%252C%2520structure%25E2%2580%2593activity%2520relationship%2520and%2520crystallographic%2520studies%2520of%25203-substituted%2520indolin-2-one%2520RET%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2010%26volume%3D18%26spage%3D1482%26epage%3D1496" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span> <span class="citation_source-book">Maestro</span>, version <span class="NLM_edition">9.1</span>; <span class="NLM_publisher-name">Schrödinger, LLC</span>: <span class="NLM_publisher-loc">New York</span>,<span class="NLM_x"> </span><span class="NLM_year">2009</span><span class="NLM_x">; </span><a href="http://www.schrodinger.com/" class="extLink">http://www.schrodinger.com/</a> (accessed May 15,<span class="NLM_x"> </span><span class="NLM_year">2011</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Maestro%2C+version+9.1%3B+Schr%C3%B6dinger%2C+LLC%3A+New+York%2C+2009%3B+http%3A%2F%2Fwww.schrodinger.com%2F+%28accessed+May+15%2C+2011%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26btitle%3DMaestro%26pub%3DSchr%25C3%25B6dinger%252C%2520LLC%26date%3D2009%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Pettersen, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goddard, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Couch, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greenblatt, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meng, E. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrin, T. E.</span><span> </span><span class="NLM_article-title">UCSF chimera: a visualization system for exploratory research and analysis</span> <span class="citation_source-journal">J. Comput. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">1605</span><span class="NLM_x">–</span> <span class="NLM_lpage">1612</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Fjm401358b&amp;key=10.1002%2Fjcc.20084" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Fjm401358b&amp;key=15264254" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Fjm401358b&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmvVOhsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2004&pages=1605-1612&author=E.+F.+Pettersenauthor=T.+D.+Goddardauthor=C.+C.+Huangauthor=G.+S.+Couchauthor=D.+M.+Greenblattauthor=E.+C.+Mengauthor=T.+E.+Ferrin&title=UCSF+chimera%3A+a+visualization+system+for+exploratory+research+and+analysis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">UCSF Chimera-A visualization system for exploratory research and analysis</span></div><div class="casAuthors">Pettersen, Eric F.; Goddard, Thomas D.; Huang, Conrad C.; Couch, Gregory S.; Greenblatt, Daniel M.; Meng, Elaine C.; Ferrin, Thomas E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Computational Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1605-1612</span>CODEN:
                <span class="NLM_cas:coden">JCCHDD</span>;
        ISSN:<span class="NLM_cas:issn">0192-8651</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">The design, implementation, and capabilities of an extensible visualization system, UCSF Chimera, are discussed.  Chimera is segmented into a core that provides basic services and visualization, and extensions that provide most higher level functionality.  This architecture ensures that the extension mechanism satisfies the demands of outside developers who wish to incorporate new features.  Two unusual extensions are presented: Multiscale, which adds the ability to visualize large-scale mol. assemblies such as viral coats, and Collab., which allows researchers to share a Chimera session interactively despite being at sep. locales.  Other extensions include Multalign Viewer, for showing multiple sequence alignments and assocd. structures; ViewDock, for screening docked ligand orientations; Movie, for replaying mol. dynamics trajectories; and Vol. Viewer, for display and anal. of volumetric data.  A discussion of the usage of Chimera in real-world situations is given, along with anticipated future directions.  Chimera includes full user documentation, is free to academic and nonprofit users, and is available for Microsoft Windows, Linux, Apple Mac OS X, SGI IRIX, and HP Tru64 Unix from http://www.cgl.ucsf.edu/chimera/.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFmD4M5S0cPbVg90H21EOLACvtfcHk0lg-FR17g-5QGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmvVOhsbs%253D&md5=944b175f440c1ff323705987cf937ee7</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1002%2Fjcc.20084&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcc.20084%26sid%3Dliteratum%253Aachs%26aulast%3DPettersen%26aufirst%3DE.%2BF.%26aulast%3DGoddard%26aufirst%3DT.%2BD.%26aulast%3DHuang%26aufirst%3DC.%2BC.%26aulast%3DCouch%26aufirst%3DG.%2BS.%26aulast%3DGreenblatt%26aufirst%3DD.%2BM.%26aulast%3DMeng%26aufirst%3DE.%2BC.%26aulast%3DFerrin%26aufirst%3DT.%2BE.%26atitle%3DUCSF%2520chimera%253A%2520a%2520visualization%2520system%2520for%2520exploratory%2520research%2520and%2520analysis%26jtitle%3DJ.%2520Comput.%2520Chem.%26date%3D2004%26volume%3D25%26spage%3D1605%26epage%3D1612" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4AG8" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4AG8','PDB','4AG8'); return false;">PDB: 4AG8</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2IVV" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2IVV','PDB','2IVV'); return false;">PDB: 2IVV</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2IVT" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2IVT','PDB','2IVT'); return false;">PDB: 2IVT</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1YWN" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1YWN','PDB','1YWN'); return false;">PDB: 1YWN</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3VHE" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3VHE','PDB','3VHE'); return false;">PDB: 3VHE</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ASE" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ASE','PDB','4ASE'); return false;">PDB: 4ASE</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4AGC" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4AGC','PDB','4AGC'); return false;">PDB: 4AGC</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ASD" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ASD','PDB','4ASD'); return false;">PDB: 4ASD</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4AGD" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4AGD','PDB','4AGD'); return false;">PDB: 4AGD</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2X2L" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2X2L','PDB','2X2L'); return false;">PDB: 2X2L</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i33"><a href="/doi/suppl/10.1021/jm401358b">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_81657"></div></div></div></div></div><hr /></hr><p class="last">Tables 1-SI to 9-SI, including physical, spectral, computational, and purity data of compounds described, and Figure 1-SI, including putative binding poses of <b>8b</b> and <b>9c</b> in the active site of VEGFR-2. This material is available free of charge via the Internet at <a class="extLink" href="http://pubs.acs.org">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm401358b/suppl_file/jm401358b_si_001.pdf">jm401358b_si_001.pdf (198.94 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm401358b&amp;pbContext=%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2014.57.issue-4%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Barticle%3Aarticle%3A10.1021%2Fjm401358b" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm401358b" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677ae68ccb263cbe","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
